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SUNNARY 
This study analyzes the economic, political and social forces 
which shape minor tranquillizer use in contemporary Western 
industrialised societies, with particular reference to Australia. 
It exposes fundamental contradictions and weaknesses in medical 
knowledge and practice and the unresolved conflicts revolving around the 
medical profession's strong attachment to a biomedical model and its 
neglect of the socio-economic dimensions of illness. These and other 
factors are discussed which continually challenge, as well as support, 
the power of the medical profession and the nature of the doctor-patient 
relationship. It is argued that the patient, or health consumer, whose 
health is directly affected by this technology, has a vital role to play 
in its control, especially in the valuable contribution made by the 
women's movement. 
The difficulties in confronting and curbing the excess profits and 
global power of the drug industry in maintaining tranquillizer sales, 
are outlined. Finally, some examples are given of how state 
intervention in Britain and Australia has shaped the increasing 
bureaucratization of medicine and the drug industry, and played an 
important role in a shifting balance of power between the interested 
groups. 
INTRODUCTION 
The prototype benzodiazepines, chlordiazepoxide (Librium) and 
diazepam (Valium), were introduced and marketed in the early 1960s by 
the Swiss-based transnational pharmaceutical company, Hoffmann-La Roche. 
They were hailed as a significant technological innovation within the 
group of pharmaceutical drugs known as 'minor' tranquillizers and were 
promoted as 'wonder drugs' of remarkable safety and efficacy, able to 
"make even fierce wildcats turn as tame and playful as kittens"'' when 
tested at the zoo. 
Since then the benzodiazepines have had a chequered history. 
Their widespread and uncritical promotion and acceptance peaked during 
the 1970s when Valium became the single most-prescribed drug in the 
United States (closely followed by Librium). In Australia, Valium was 
the most prescribed single item under the Pharmaceutical Benefits Scheme 
(PBS) in the first half of the 1970s, dropping to second place in 1976-
1977. Meanwhile, Roche's inflationary and transfer-pricing tactics in 
relation to these two best-sellers (considered to be the most profitable 
pharmaceuticals ever produced) were exposed by a number of international 
enquiries. At the same time, concern mounted over their over-
prescribing and addiction potential (even at normal dosage levels), and 
their efficacy in relieving anxiety was called into question. Valium 
was targeted by various consumer action and women's movement groups, and 
a concerted campaign was mounted against its use (especially by women, 
who have been consistently shown to be the major consumers of 
benzodiazepines). 
In the 1980s, its increasing notoriety has led to a decline in 
Valium sales, but benzodiazepine sales have continued to escalate. 
Surveys and prescription audits have demonstrated that although Valium 
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is no longer the drug of choice, a plethora of other 'me too' 
benzodiazepines are taking its place. In Australia, benzodiazepines now 
lead the cases of reported drug poisonings, with double the number of 
mentions compared with alcohol. 
This study is an attempt to explain the phenomenon of the 
benzodiazepi nes through an examination of their promotion and use in the 
context of the economic, social and political forces located in the 
interactions between the four major interested parties: the medical 
profession, the consumers, the drug industry, and the state. 
Chapter 1 presents a brief history of the development of 
banzodiazepines and describes their pharmacological action and 
relationship with other tranquillizers and mood-changing drugs. By 
reference to the two major methods of data collection, surveys and 
prescription audits, the changing patterns of benzodiazepine use are 
presented. 
Chapter 2 summarizes the debate in the medical-scientific 
literature over the efficacy and safety of benzodiazepines. The range 
of medical opinion on their recommended use is summarized. Conflict 
over their efficacy has centred on their alleged anti-anxiety activity. 
This has been exacerbated by problems surrounding the medical definition 
and measurement of anxiety, which is outlined. The long-held claim of a 
low mortality rate for the benzodiazepines is the first safety issue 
examined, followed by depression of the central nervous system (an 
expected side-effect associated with tranquillizers) and the debate on 
other unwanted effects on the foetus, the newborn and the elderly. The 
primary area of conflict over safety of the benzodiazepines is their 
addiction potential. An outline is given of medicine's efforts to 
define addiction and the withdrawal symptoms of benzodiazepine 
addiction. This includes a summary of the debate on dosage, length of 
time of use and different pharmacokinetic properties of benzodiazepines 
as well as psychological and other non-technological factors. The 
debate on addiction concludes with an examination of methods used for 
detecting benzodiazepine addiction. The chapter ends with a brief 
reference to other safety issues. 
The next two chapters (3 and 4) examine the intersections amongst 
the four major interested parties. Chapter 3 focuses on the medical 
profession and the health consumer; whereas Chapter 4 examines the drug 
industry and the state. This has been done for ease of analysis rather 
than to imply any separation of effects between the four groups. 
Chapter 3 develops the analysis of the medical-scientific debate 
in the previous chapter. The conflict over benzodiazepine safety and 
efficacy serves to identify medicine's difficulties with its biomedical 
model of illness and this is exacerbated in the area of addiction. A 
comprehensive description is then provided of the major consumers of 
minor tranquillizers according to gender, age, health status and 
institutional environment. This concentrates on women's greater use of 
benzodiazepines and includes an analysis of the five most commonly used 
explanatory models. The role of the doctor in prescribing 
benzodiazepines is then examined, with reference to the influential 
factors of medical education and the professionalization process. The 
chapter ends with a description of the important role of the consumer 
health movement in shaping tranquillizer use. 
Chapter 4 introduces the drug industry, with an overview of its 
global nature and high profitability. Both domestic and international 
factors important to the outstanding financial performance of the drug 
industry and its manufacture of the benzodiazepines are then outlined. 
and include patent protection, research and development and promotion of 
their products. This is followed by an outline of the role of the state 
in enforcing controls over the drug industry on drug safety and 
efficacy, and the resultant effect of drug lag as well as some important 
issues concerning generics. Finally, two case studies are presented to 
illustrate the preceding discussions. Both are historical accounts 
concerning the benzodiazepines. The first outlines the British attempt 
to introduce a limited drug list in 1985 which highlights the various 
economic and political forces shaping the availability of 
benzodiazepines in that country. The second case study describes 
Roche's controversial use of transfer pricing strategies to increase its 
already unprecedented financial returns from the benzodiazepines and the 
largely ineffectual attempt by the British state to regulate the 
company's activities in the 1970s. Some theoretical implications of the 
relationship between the drug industry and the state are discussed in 
the conclusion. 
Chapter 5 is an historical outline of socio-economic factors 
important to minor tranquillizer use in Australia and builds on the 
analysis developed in the previous chapters. The chapter opens with 
details of early post-war initiatives by the state which later were 
crucial to benzodiazepine use, including the establishment and 
development of the Prescription Benefits Scheme (PBS), as well as the 
introduction and strengthening of other important state controls on drug 
sal es in Australia. The outstanding sales record of Valium following 
its release and listing on the PBS in 1972 is described, followed by the 
attempt by the Whitlam government to curb the drug Industry in 
Australia. The conflict between between the state and Roche (and the 
rest of the drug industry) is detailed, especially during 1973. The 
changing pattern of benzodiazepine sales during the late 1970s is then 
described, followed by an outline of the Ralph Report's investigation 
into the Australian drug industry and the important role of the PBS. 
Various developments in the early 1980s are listed, including the 
continuing development of benzodiazepines by the drug industry and their 
changing* patterns of use in the community, the drug industry's 
continuing call for state support and the consumer movement's campaign 
against drug advertising. 
The Hawke government's response to the Australian drug industry is 
described, beginning with its efforts to curb the rising state drug 
bill. The other strategy of the Hawke government is then examined - the 
National Campaign Against Drug Abuse - a small part of which has been 
directed against women's use of minor tranquillizers. The erosion of 
doctors' professional power, both within the state and the community, is 
next discussed, followed by an account of the strengthening health 
consumer movement (especially the contribution of the women's movement) 
and the implications of these developments for minor tranquillizer use. 
The final section summarises the shifting power balance in Australia 
between the state, the drug industry, the medical profession and the 
consumer interest groups and their relevance to minor tranquillizer use. 
Some important contemporary critiques of the medical profession and the 
role of the state in health and medicine relevant to minor tranquillizer 
use, are then discussed. 
Chapter 6 reviews and summarises the key economic, social, and 
political elements discussed in this study which have contributed to the 
changing pattern of benzodiazepine use, both in Australia and 
internationally. It concludes with some suggested strategies for change 
and emphasizes the crucial importance of gender issues. 
FOOTMOTE: 
1. Robert Ball, "The Secret Life of Hoffmann-La Roche", Fortune, August 
1971, p.134 
1 BENZODIAZEPINES: A DESCRIPTION AND HISTORY OF THEIR USE 
1.1 Historical Introduction 
The use of tranquillizers as a treatment for anxiety has a long 
history; alcohol is, perhaps, the best known and most widely used in 
the Western world. Table 1.1 lists examples of commonly used mood-
changing drugs, including the tranquillizers. During the first half of 
this century, medical intervention in the treatment of anxiety consisted 
mainly of prescribing sedatives such as bromides and barbiturates.'' The 
first barbiturate was introduced in about 1902 (barbitone, marketed as 
Veronal by Fischer and von Mering) and other barbiturates began to 
compete on the market in the following years: for example, 
phenobarbitone (Luminal) in 1912 and amylobarbitone (Amytal) in 1923.2 
As the dangers of overdose and dependence associated with barbiturates 
became more widely recognised, alternative pharmacological treatments 
were sought such as the propanediols introduced in the 1950s, the best 
known being meprobamate (Miltown).^ 
The first commercially available benzodiazepine was 
chlordiazepoxide (Librium) which was approved for marketing in 1960 in 
the United States by the Food and Drug Administration (FDA).^ 
Originally known as methaminodiazepoxide (or Ro 5-0690), 
chlordiazepoxide was first synthesised in 1955 by the chemist, Leo H. 
Sternbach, and his associates at the Roche laboratories. However, 
because it had been mistakenly assumed to be inert, its development by 
Roche was delayed until 1957 when their pharmacologist, Lowell 0. 
Randall, found it had sedative and anti-convulsant activity in animals.^ 
According to Randall, chlordiazepoxide was: 
2 to 10 times more potent than meprobamate ... Unlike 
meprobamate, it is more effective by the oral than by the 
subcutaneous route. An outstanding feature of the 
behavioral action of (chlordiazepoxide) is the wide dose 
Table 1.1: Examples of commonly used mood changing prescribed drugs 
Group Generic Name Example of Brand Name 













































































Source: G. Chesher, "The pschotropic drugs. Part 1: pharmacological 
aspects", in M. Diesendorf (ed). The Magic Bullet, (Canberra, 
Society for Social Responsibility in Science, 1977), pp.42-43 
7a 
range over which it is effective without producing ataxia or 
other side effects.^ 
After screening hundreds of other benzodiazepines, diazepam 
(synthesised in 1959) was marketed by Roche in 1963. In tests published 
the following year, diazepam was said to be more effective than 
chlordiazepoxide,7 and since then diazepam has become probably the most 
commonly used drug in the Western world. Other benzodiazepines soon 
came on the market from different pharmaceutical manufacturers: for 
example, oxazepam (Serax/Serapax) in 1965 by Wyeth Pharmaceuticals and 
clorazepate dipotassium (Tranxene) in 1972 by Abbott Laboratories.^ 
During the 1970s many more benzodiazepines became available. 
There was an increase in the number both of new benzodiazepine 
derivatives and of similar generic compounds manufactured by different 
drug companies under their own brand names. The former may be 
categorized as 'me too' drugs as they are of similar structure and 
function to diazepam, although slightly modified to circumvent patenting 
restrictions held by Roche. The latter are identical drugs manufactured 
after a patent has expired or, sometimes, made under licence from the 
patent holder. By 1983 there were at least twenty-five different 
benzodiazepines marketed world-wide.^ 
Roche enjoyed a monopoly on diazepam sales in Australia until 1978 
(although in 1976 another brand (Ducene) was marketed by Sauter 
Laboratories, a subsidiary of Roche). All competitors were forced to 
wait until after the patent lapsed in December 1978.^0 in Australia, 
there are currently fourteen benzodiazepines available, marketed under 
twenty-seven different brand names by twelve different pharmaceutical 
companies (Table 1.2). Roche manufactures the largest number of 
benzodiazepines (8), then Alphapharm (5), Wyeth (3) and Protea (2). Not 
Table 1.2: Benzodiazepines available in Australia in July 1988 
Generic Name Most Commonly 
Prescribed As 
Brand Name Manufacturer 
alprazolam anti-anxiety Xanax Upjohn 
bromazepam anti-anxiety Lexotan Roche 
clobazam anti-anxiety Frisium Hoechst 
clonazepam anti-convulsant Rivotril Roche 
clorazepate 
dipotassium 
anti-anxiety Tranxene Glaxo 
chlordiaz-



















flurazepam sedative/hypnotic Dalmane Roche 

























Source: Intercontinental Medical Statistics (Australasia) Pty Ltd, 
MIMS. No.4, June/July 1988 
Ba 
all of these companies are independent of each other. As well as Sauter 
Laboratories being a subsidiary of Roche, Ayerst and Wyeth are 
subsidiaries of American Home Products J'' Sixteen brands are available 
on both the Pharmaceutical Benefits Scheme (PBS) and the Repatriation 
Pharmaceutical Benefits Scheme (RPBS) whilst seven are available only on 
the RPBS and three are not subsidised by the state under either scheme. 
A comparison of the benzodiazepines available in Australia with those 
available in other countries shows that the number of different kinds of 
benzodiazepines is at a minimum in both Australia (14) and the United 
States (12), in contrast to Britain (20) or other countries such as 
Japan (21) (Table 1.3). 
Because they were believed to be selective as anti-anxiety agents 
and sedatives without severe effects on the central nervous system, 
benzodiazepines were separated out as 'minor' tranquillizers, or 
sedatives, in contrast to the anti-psychotics, or 'major' tranquillizers 
(Table 1.1). A new term, 'anxiolytic', was coined in order to stress 
the selectivity of the minor tranquillizers.''^ 
1.2 Phamacological Description of Benzodiazepines 
Benzodiazepines are chemically related compounds which can be 
generally characterised by their rate of elimination from the 
bloodstream: that is, whether they have a short, intermediate or long 
half-life (Table 1.4). Their differences become even less marked when 
their metabolic relationship, following ingestion, is examined, as many 
of them are broken down into the same metabolite (for example, 
desmethyldiazepam, which has a long half-life) (Figure 1.1). 
Twenty-five years after their introduction on the market, the 
mechanism of action of the benzodiazepines is still not fully 
understood. During the 1970s they were found to affect almost every 
Table 1.3: Benzodiazepines available in Australia and other selected 
industrialized countries (1984) 
Generic Australia 
Name 
USA UK Germany Italy Japan France 
Alprazolam Yes Yes Yes Yes ... . . . Yes 
Bromazepam Yes — Yes Yes Yes Yes Yes 
Camazepam — — — Yes Yes — — 
Chlordiaz-
epoxide Yes Yes Yes Yes Yes Yes Yes 
Clobazepam Yes — Yes Yes Yes — Yes 
Clonazepam Yes YEs Yes Yes Yes Yes Yes 
Clorazepate Yes Yes Yes Yes Yes Yes Yes 
Clotiazepam — — — Yes — Yes — 
Cloxazolam — — — — Yes — — 
Delorazepam — — — — Yes — — 
Diazepam Yes Yes Yes Yes Yes Yes Yes 
Estazolam — — — — Yes Yes Yes 
Ethyl lofla-
zepate — — — — — — Yes 
Fludiazepam — — — — — Yes — 
Flunitrazepam Yes — Yes Yes Yes Yes Yes 
Flurazepam Yes Yes Yes Yes Yes Yes — 
Flutazolam — — — — — Yes — 
Halazepam — Yes — — — — — 
Haloxazolam — — — — — Yes — 
Ketazolam — — Yes Yes — — . . . 
Loprazolam — — Yes — — . — — 
Lorazepam Yes Yes Yes Yes Yes Yes Yes 
Lormetazepam — — Yes Yes Yes — — 
Medazepam — — Yes Yes Yes Yes Yes 
Midazolam — — Yes — — — — 
Nimetazepam — — — — — Yes — 
Nitrazepam Yes — Yes Yes Yes Yes Yes 
Nordiazepam — — — — Yes — — 
Oxazepam Yes Yes Yes Yes Yes Yes Yes 
Oxazolam — — — Yes — Yes — 
Pinazepam — — — — Yes — — 
Prazepam — Yes Yes Yes Yes Yes Yes 
Temazepam Yes Yes Yes Yes Yes — Yes 
Tetrazepam — — — Yes — — Yes 
Tofisopam — — — — — — Yes 
Triazolam ~ — Yes Yes Yes Yes Yes Yes 
13 12 20 22 21 21 19 
Source: J. Marks, The Benzodiazepines. Use, Overuse, Misuse, Abuse. 
(Lancaster,. MTP Press, 1978), p.63; Intercontinental Medical 
Statistics, MIMS Annual 1984. (Crows Nest, IMS, 1985) 
9a 
Table 1.4: Elimination half-life of selected benzodiazepines 





(long > 50 hours) 
(intermediate 10-50 hours) 
(short < 10 hours) 
Chlordiazepoxide Yes Long 
Diazepam Yes Long 
Clorazepate Yes Long 
Flurazepam Yes Long 
Clonazepam No Intermediate 
Clobazam Yes Intermediate 
Flunitrazepam Yes Intermediate 
Nitrazepam Yes Intermediate 
Bromazepam Yes Short-1ntermed i ate 
Lorazepam No Short-1ntermed i ate 
Alprazolam Yes Short-Intermedi ate 
Oxazepam No Short 
Temazepam No Short 
Midazolam No Ultra-Short 
Triazolam Ultra-Short 
Source: G.D. Burrows et al, "Benzodiazepines - clinical applications", 
Aust Prescriber, 8, No.2, 1985, p.27; J.B. Cohn, "Long- and 
short-acting benzodiazepines - a review of the role of 
benzodiazepines", in M.R. Trimble (ed). Benzodiazepines 
Divided. (Chichester, John Wiley & Sons, 1983), p.231 
9b 

















* pharmacologically active metabolite 
Source: G.D. Burrows et al, "Benzodiazepines 
Aust Prescriber, 8. No.2, 1985, p.27 
- clinical applications". 
9c 
known neurotransmitter, including the catecholamines (acetylcholine, 
glycine and serotonin)J3 More recently, medical opinion appears to 
favour the theory that benzodiazepines bind to specific receptor sites 
in the central nervous system, particularly in certain areas of the 
brain where they enhance the action of the inhibitory neurotransmitter, 
gamma-ami no butyric acid (GABA)J4 jhe discovery in the late 1970s of 
specific binding sites in the brain, and other tissues, has led to the 
belief that there may be natural compounds made in the body similar to 
benzodiazepines, although these have not been i d e n t i f i e d . 1 5 
The complexity of the human body and its emotional and physical 
interactions create problems in gaining an understanding of the 
mechanism of action of benzodiazepines. The widespread use of 
benzodiazepines without any clear understanding of how these drugs work, 
confirms the accepted practice which Chesher has pointed out: 
despite the enormous number of potent drugs now available to 
the physician and in constant use, in only a few cases can it 
be said that we know how the drug is w o r k i n g . 
1.3 Patterns of Benzodiazepine Use 
The two common methods for measuring tranquillizer or 
benzodiazepine use focus either on the consumer (population surveys) or 
the prescription (prescription audits). As well as the usual 
methodological problems, care must be taken in analysing such data 
because of the confusing diversity in nomenclature of mood-changing 
drugs as well as the inclusion of both benzodiazepines and barbiturates 
within the minor tranquillizer group and the separate listing of 
benzodiazepines as tranquillizers or sedatives. 
1.3.1 Survejrs 
American researchers carried out surveys in the early 1970s in 
Europe and the United States to find that between 10% and 17% of people 
reported using anti-anxiety and/or sedative drugs in the past year 
(12.5% to 21.5% women and 7% to 12% men) (Figure 1.2). In the European 
study, between 3.5% to 9% reported regular use (daily use for one month 
or more) and of these, 5% to 12% were women and 2% to 6.5% were men.''^ 
When the American survey was repeated in 1979, reported minor 
tranquillizer use for the previous year had fallen from 15% to 11%18. 
However, none of the data separated out benzodiazepines from other minor 
tranquillizers. Marks estimated that approximately 60% of the drugs 
were benzodiazepines in the earlier surveys compared with about 84% in 
the later American survey19 (that is, whilst reported use of minor 
tranquillizers had dropped, the proportion of benzodiazepines had 
increased - this was not measured). 
Survey data collected in Australia during the 1970s give variable 
results and are also difficult to compare because of differences such as 
in methodology, survey population, class of drug examined, definition on 
rate of usage of drug. For example, a small survey carried out in 1971 
by George in "a beach-side suburb of the North Shore of Sydney" found 
one-third of respondents reported having ever used tranquillizers and/or 
sedatives, whilst 5% said they used them daily.20 Her later 1973 survey 
carried out in a Western Suburb of Sydney gave a similar result21 as did 
the 1971 Canberra Mental Health Survey, which found 5% of women used 
tranquillizers daily.22 However, higher estimates have been found in 
other surveys. For example, a 1975 survey of Sydney members of a union 
found that 13% of women and 6% of men were daily users of tranquillizers 
or sedatives23 whilst a survey of Medicheck patients in Sydney in 1975 
Figure 1.2; Comparison between men and women of use of anti-
anxiety/sedative drug during previous year (used 
at least once) 
Source: M.B. Baiter et al (1974) and 
H.J. Parry et al (1973) 
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found ^9% of women and 7% of men were daily users of sedatives, 
tranquillizers or antidepressants.24 Both these were non-random 
population samples. A small-scale but random survey of Sydney women in 
1976 found that 12% were daily users of tranquillizers and sedatives.^^ 
The 1983 Australian Health Survey, using a larger sample but omitting 
populations in hospitals and other institutions, found that 7% of those 
surveyed reported taking a tranquillizer and/or sleeping pill in the 
previous two weeks (9% women and 5% men).^^ 
1.3.2 Prescription Audits 
In 1972 in the United States, Valium was the most frequently 
prescribed drug^^ whilst sales of all benzodiazepines peaked in 1975, 
with approximately 65 million prescriptions of Valium and 90 million 
prescriptions of all benzodiazepines.^^ Benzodiazepine prescription 
sales in Europe (measured by the method preferred by the World Health 
Organisation which expresses drug sales in terms of 'defined daily 
dose') levelled out or fell slightly in the late 1 9 7 0 s . S i m i l a r l y , 
an estimate of the number of NHS non-hospital prescriptions in England 
found only a slight decline of sedatives and tranquillizers (from 
approximately 20 million in 1976 to 18 million in 1982) whilst sedatives 
remained relatively static.^^ 
However, a Canadian prescription audit in Saskatchewan found a 
greater than 50% drop in Valium prescriptions between 1977 and 1982 
(from 213,549 in 1977 to 96,372 in 1982) whilst sedative prescriptions 
of benzodiazepines, although less in quantity, had more than doubled 
(from 39,619 in 1977 to 96,473 in 1982) - due mainly to the marketing of 
a new drug, t r i a z o l a m . A u s t r a l i a n data support the Saskatchewan 
report. 
It should firstly be noted that Australian prescription audit 
figures all understate quantities, since they do not include 
prescriptions in hospitals nor Repatriation, defence and private (non-
PBS) prescriptions. Furthermore, numbers of prescriptions do not 
specify quantities of the drug prescribed. For example, 2mg and 5mg 
diazepam tablets can be prescribed in lots of 50's on the PBS whereas 
15mg and 30mg oxazepam tablets are available in 25's. Therefore, a 
prescription of 50 x 5mg Valium tablets, at a conservative dosage of 
2.5mg three times per day with two repeats, gives about five months 
supply; a higher, but not unusual, dosage of 30mg per day yields just 
under one month's supply. On the other hand, a prescription of 25 x 
30mg Serepax tablets, at a conservative dosage of 15mg three times per 
day with one repeat, gives about two weeks' supply; the maximum 
recommended dosage of 30mg four times per day yields just under one 
week's supply.^^ Prescription regulations have been revised by the 
state from time to time so that prescription numbers do not represent 
equivalent dosage units from one year to another, nor do those made 
under the PBS represent a constant ratio of all prescriptions.^^ 
Despite these qualifications to Australian prescription audits, a 
definite trend in benzodiazepine prescribing can be discerned. 
Of the top fifty most prescribed items in Australia in 1984/85, 
there were four benzodiazepines. In descending order of prescription 
volume, they were: oxazepam, nitrazepam, diazepam and temazepam.^^ 
Diazepam, prescribed mainly as an anti-anxiety agent, was the most 
prescribed single item in Australia under the Pharmaceutical Benefit 
Scheme from the year it was introduced on to the PBS in 1972/73 up to 
1975/76. The following year it dropped to second place.^^ 
Prescription sales for the 1970s of the minor tranquillizers 
available under the PBS in Australia have closely followed overseas 
patterns, although the Australian sales volume was significantly lower 
than in the United S t a t e s . j h e number of PBS prescriptions for minor 
tranquillizers (mainly diazepam and oxazepam) peaked in 1974/75 at 
almost 5 million prescriptions (approximately 4.5 million of these were 
for diazepam). However, sales of diazepam and oxazepam bottomed out 
around 1980 and, since then, have slowly increased to approximately 4 
million in 1984/85.37 This has been due to the fact that, whilst 
prescriptions for diazepam dropped to 1.5 million in 1984/85, those for 
oxazepam increased from 0.98 million to 2.5 million, making oxazepam the 
seventh most prescribed PBS item for 1984/85 (Figure 1.3). 
Nitrazepam, the second best selling benzodiazepine in Australia, 
is prescribed mainly as a sedative. PBS prescription sales for 
nitrazepam (listed on the PBS in December 1970)3^ peaked in 1977/78 at 
just over 2 million, and have fallen since then to about 1.6 million in 
1984/85. However, this has been offset by prescription sales of the new 
benzodiazepine, temazepam, also marketed as a sedative, which have 
rapidly increased since its introduction in Australia in 1980/81. As a 
result, total sales of benzodiazepines sold as sedatives have steadily 
continued to increase to just over 2.5 million prescriptions in 1984/85 
(Figure 1.4). 
Prescription sales of the four major-selling benzodiazepines 
(sold as both minor tranquillizers and sedatives) have increased 
gradually in the past ten years. After a drop in the late 1970s, 
prescription volumes in 1984/85 have returned to a level similar to that 
in 1975/76, at just over 6.5 million (Figure 1.5). 
1.4 Conclusion 
A cross-cultural gender bias in benzodiazepine use has been 
consistently found in the industrialized countries, with twice as many 
Figure 1.3: PBS prescription volume of benzodiazepinesrxonimonly prescribed as 
sedative/hypnotics (nitrazepam and temazepam) in Australia from 
1972-73 to 198A-85 
Source: Commonwealth Department of Health (personal communication) (1986) 
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Figure 1.4: PBS prescription volume of benzodiazepines commonly prescribed as 
minor tranquillizers (diazepam and oxazepam) in Australia from 
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Figure 1.5; PBS prescription volume of four most commonly prescribed benzodiazepines 
(diazepam, oxazepam, nitrazepam and temazepam) and expressed as a percentage 
of total PBS prescription volume in Australia from 1972-73 to 1984-85 
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women as men reporting their use. Other trends in use, or prescribing 
patterns, are less consistent. Generally, tranquillizer sales soared in 
the early 1970s, mainly due to Roche's Valium but also to 'me too' 
products marketed by other companies. Australia ranks with the United 
States as having a relatively small number of benzodiazepines available, 
compared with other countries such as Britain and Japan. During the 
1970s, about 15% of the population reported having used a minor 
tranquillizer in the preceding twelve months, whilst regular daily users 
averaged from 3.5% to 9%. Such averages conceal the gender-based 
differences, as women's use would be higher and men's use lower than 
these averages. 
Many believe that as Valium sales declined later in the 1970s, 
benzodiazepine use generally decreased and is no longer a cause for 
concern. However, Australian figures (as elsewhere) show that whilst 
sales of diazepam (mainly Valium) under the Prescription Benefits Scheme 
(PBS) dropped sharply from the mid-1970s, sales of other benzodiazepines 
have increased significantly so that, overall, benzodiazepine 
prescriptions have increased steadily since the mid-1970s (although 
remaining relatively constant with respect to the total prescription 
volume). Sales of benzodiazepines classified as sedatives have 
increased at a faster rate than for the minor tranquillizer category. 
Some of the factors influencing the changing trends in 
benzodiazepine sales are discussed in the next section, which traces the 
shifting scientific-medical debate as it has informed doctors and 
influenced their prescribing habits. 
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2 NEDICAL-SCIENTIFIC DEBATE ON BENZODIAZEPINES 
2.1 Introduction 
Benzodiazepines have been a focus of conflicting knowledge claims 
amongst medical-scientific 'experts' over evidence of their efficacy and 
safety. A doctor's decision to prescribe a benzodiazepine draws on her 
or his interpretation of this knowledge. The following review of 
literature written largely by and for a medical audience captures the 
process of conflict arising from divided expert opinion. It describes 
the shift in consensus over almost thirty years from the early 
widespread acceptance and promotion of benzodiazepines to contemporary 
medical opinion that they are effective and safe, if prescribed 
cautiously. However, consensus is no longer so widely established and 
there are many who hold strongly opposing views. 
2.2 Efficacy of Benzodiazepines 
2.2.1 RecoHBended Uses of Benzodiazepines 
Over the past few decades, benzodiazepines have been prescribed or 
recommended to be prescribed for: anxiety, phobic anxiety and panic 
attacks, insomnia, seizures, musculoskeletal disorders, alcohol 
withdrawal, anaesthesia and premedication for endoscopy and surgery,'' 
night terrors or somnambulism in children,2 pathologic anxiety and 
anxiety associated with medical disease, depression, insomnia not 
associated with medical or psychiatric disease, anxiety and agitation 
associated with musculoskeletal disorders,3 depression with associated 
anxiety, cerebral palsy, sleep disorders including somnambulism and 
enuresis, childbirth,^ tinnitus, dizziness, postoperative shock, 
backache, neck pain, recovery from influenza, sleep disturbances for the 
parent of a hyperactive child,5 death or illness of a family member, 
marriage or relationship problems, rape, incest, problems with parents. 
stressful house moving,6 and disorders in the Third World, such as 
tetanus, cerebral malaria and eclampsia.7 On the other hand, 
benzodiazepine use has been questioned or specifically not recommended 
for the following: situational anxiety,^ low levels of anxiety and 
muscle tension,9 anxiety associated with depression,10 psychosomatic 
illnesses, tension headache, nocturnal enuresis, organic brain disease, 
dysmenorrhoea, behaviour disorders, cerebral palsy, psychotic diseases 
or depression, pregnancy, and labourJ1 
Clearly, conflict surrounds the application of minor tranquillizer 
technology, and within the medical literature resolution of the 
controversy depends upon the standard model and methodological 
procedures of scientific medicine. Yet far from resolving it, these 
have served only to polarize the debate, from appeals to ban 
benzodiazepines because they are so dangerous,12 to calls for them to be 
available without prescription because they are so safe13. 
Lennane, a leading medical expert in Australia in the addiction 
area, has recommended benzodiazepines only for short-term treatment of 
extreme insomnia difficulties and for long-term treatment of epilepsy. 
She has proposed that personality characteristics associated with 
anxiety and insomnia problems are also strongly linked with dependence 
on benzodiazepines.!^ Consequently, she has not recommended their use 
for anxiety. Most controversy surrounds the use of benzodiazepines for 
anxiety and other disorders of a non-physical nature; although their 
use for physical problems has been far less questioned, this is also 
problematic. 
2.2.2 Anti-anxiety or Sedative? 
The drug manufacturers categorize different benzodiazepines 
exclusively as either anti-anxiety agents or sedatives (except for a 
small number listed as anti-convulsants, and, in Australia, diazepam is 
an exception as it is listed as an anti-anxiety agent, and for the 
relief of muscle spasm as well as an anti-convulsant). A recent issue 
of a commonly used Australian drug compendium designated the following 
as anti-anxiety agents: alprazolam, bromazepam, chlordiazepoxide, 
clobazam, clorazepate, diazepam, lorazepam, and oxazepam. For the 
treatment of muscular spasm, chlordiazepoxide and diazepam were 
recommended; as hypnotics, it recommended flunitrazepam, flurazepam and 
nitrazepam; and for epilepsy it recommended clonazepam or, for status 
epilepticus, parenteral diazepam (See also Table 1.2) 
Despite more recent medical criticism of the artificial nature of 
this differentiation17, especially as many are metabolised to the same 
compounds, doctors continue to prescribe selectively. The contemporary 
view is that benzodiazepines with a longer half-life are more 
appropriate for anxiety whilst the shorter acting variants are more 
appropriate as sedatives as they cause less trouble with unwanted 
residual effects the following day. The nitrazepams were the early 
available alternative to diazepam as sedatives, and continue to be the 
most prescribed 'sedative' benzodiazepine although a considerable body 
of expert opinion favours the much shorter acting variants such as 
temazepam.18 
2.2.3 Anxiety 
However, the key to understanding the forces behind arguments 
about the efficacy of benzodiazepines is found in their use for anxiety. 
Here, appeals to rigorously designed scientific study have not solved 
basic problems defined by the agenda set by scientific medicine of 
simply identifying and measuring anxiety. 
(a) Definition of anxiety 
Usdin has described difficulties experienced by the medical 
profession in clearly defining the term anxiety. He found three 
different definitions in one volume concerning anxiolytics and more than 
six different definitions from various sources.19 
In the United States, Greenblatt and his colleagues have published 
extensively in the New England Journal of Medicine, strongly promoting 
the efficacy and safety of benzodiazepines. However, in their first 
review of the benzodiazepines in 1974, Greenblatt and Shader admitted: 
Anxiety is an elusive clinical syndrome. It describes a 
psychophysiologic response resembling fear but inappropriate 
to the reality of the perceived threat. Manifestations can 
include psychic symptoms (irritability, tension, excessive 
worry, and inappropriate apprehension) somatic symptoms 
(palpitations, breathlessness, diaphoresis, urinary 
frequency, fatigue, restlessness, or disordered sleep), or 
combinations of both. Anxiety characteristically is a 
phasic or episodic disorder with multiple remissions and 
exacerbations.20 
Ten years later, in their next major review, Greenblatt and his 
colleagues addressed the definitional problems of anxiety by sub-
dividing anxiety into various categories: situational, pathologic, 
chronic, associated with physical diseases, mixed anxiety depression, 
and anticipatory anxiety associated with panic disorders.21 The 
difficulties they experienced are evident; for example, when they 
differentiate between situational and pathologic anxiety: 
Situational anxiety that is not disproportionately intense 
may improve performance and stimulate adaptive and coping 
behaviour; such anxiety is generally non-pathologic and 
probably better left untreated. Pathologic anxiety, on the 
other hand, is maladaptive and impairs rather than improves 
functioning in occupation and family. ... When symptoms last 
more than one month and are not distinguished by a pattern 
of panic attacks and avoidance behavior on the one hand or 
of obsessive-compulsive thinking and ritualistic behavior on 
the other, or both, a diagnosis of generalised anxiety 
disorder is usually warranted.22 
They concluded by appealing to an "individualised common-sense approach" 
and "individually tailored clinical judgement".23 Hence, value 
judgements rather than clearly identifiable symptoms, prevail in 
assessing the intensity of anxiety. 
Not only the intensity of anxiety but also the time course is 
considered relevant in diagnosis. Two systems of classification of 
anxiety are in concurrent use: the World Health Organisation's 
International Classification of Disease, Ninth Revision {ICD-9), revised 
in 1977, and the American Psychiatric Association's Diagnostic and 
Statistical Manual of Mental Disorders (DSM-III), revised in 1980. The 
DSM-III uses a multi-axial diagnostic system to classify four different 
categories in which anxiety is listed as the primary feature, containing 
sixteen different disorders. A distinction is made between panic 
disorders and generalised anxiety disorder. They are classified as two 
separate disorders because of the observed time scale: generalised 
anxiety disorder being persistent; panic disorder being episodic.24 
The British psychiatrist, Tyrer, and his colleagues, who favour a more 
conservative approach to prescribing benzodiazepines, have recommended 
short-term use of benzodiazepines only for periods of acute stress and 
not for generalised anxiety disorders such as described in ICD-9 and 
DSM-III.25 Difficulties in defining anxiety have moved the American 
psychiatrists in recent years to revise the DSM-III, partly to emphasise 
externally apparent symptoms of anxiety associated with a disorder, 
rather than on assumed underlying psychological symptoms.26 
(b) Neasurenent of anxiety 
Numerous attempts have been made to measure emotional states, such 
as anxiety. For example, the battery of tests used by Shapiro and his 
colleagues included the: Hopkins Symptom Check List (HSCL-62), 
Psychiatric Outpatients Mood Scale (POMS), Minnesota Multiphasic 
Personality Inventory (MMPI), Hamilton Anxiety Scale (HAS), Hamilton 
Depressive Scale (HDS), a fifteen-item Diagnostic and Background 
Information Scale, and a seven-point Likert Scale for anxiety, 
depression, psychopathology, prognosis and the predominance of anxiety 
over depression.27 They pointed out, however, that there is a lack of 
correlation between individual types of tests for measurement of 
anxiety, levels of anxiety and depression vary between patients so that 
it is difficult to separately classify these conditions, and levels of 
anxiety and depression vary for each patient with time. As a result, 
they were forced to resort to additional measurements of anxiety using 
clinical evaluations by psychiatrists. They reported that this provided 
more statistically reliable measurement of anxiety and depression.28 
Thus, like Greenblatt and his colleagues, they found individualised 
value judgements necessary for the 'reliable' measure of anxiety. 
Nevertheless, tests such as those listed above have been important 
legitimating tools for asserting the scientific accuracy of medical 
studies on anxiety. For example, Mellinger and his colleagues earlier 
analysed data collected from an American national household survey of 
approximately 2,500 adults, to conclude that psychotherapeutic drugs 
were used generally by respondents who needed them; that is, by those 
who reported suffering at least medium levels of 'psychic distress'.29 
This conclusion means that the researchers assumed first, that because 
the majority of regular drug users report high psychic distress and or 
life crisis, the drug use was a result of their living difficulties 
(that is, a way of coping); secondly, and more importantly, that these 
difficulties - more likely for those who were women, or in lower 
socioeconomic groups, black, male and never married, or female and 
married - are a medical problem; thirdly, because these problems are 
experienced as severe, that they are severe medical problems and not 
minor everyday problems of living; fourthly, these severe medical 
problems require a medical solution based on an: 
objective account of [drug therapy's] costs, risks, and 
benefits relative to those of available options.30 
Finally, they claimed objectivity for their analysis because they used 
the measuring devices such as the HSCL and this had long-term expert 
approval.31 
However, as we have seen, other researchers such as Shapiro have 
expressed a less naive faith in such objective tests of anxiety and have 
resorted to using subjective personal assessments. 
2.2.4 Sunmary of Efficacy 
The previous discussion points up some of the difficulties in 
determining the efficacy of benzodiazepines. Most conflict has 
surrounded their use for the treatment of anxiety. Whilst their use for 
physical disorders such as muscular tension has not been so 
controversial, there is similar potential for doubts over their efficacy 
in this area. Scientific medicine has classified anxiety as an illness, 
or disease, and has encouraged a technical fix for its treatment with 
benzodiazepines. However, medicine's ability to define and measure the 
disease state of anxiety and treat it appropriately has been shown to be 
problematic. 
Despite considerable evidence casting doubt on the efficacy of 
benzodiazepines, particularly for the treatment of non-physiological 
problems, the general consensus of medical opinion appears to be that 
benzodiazepines are effective for the short-term treatment of acute 
anxiety and insomnia, as well as treatment of muscle tension, convulsive 
disorders (such as epilepsy) neuromuscular disorders (such as 
spasticity) and for anaesthesia. With respect to anxiety and sleep 
disorders, there have been some concessions towards accommodating 
alternative therapies which may even be non-medical, such as 
psychotherapy, occupational therapy, relaxation methods or community 
care. However, these are usually seen as adjuncts to drug therapy, 
thereby maintaining the role of the doctor in the treatment p r o g r a m . 3 2 
2.3 Safety of Benzodiazepines 
2.3.1 Introduction 
The alleged safety of benzodiazepines was another strong reason 
for the preference for the benzodiazepines over the barbiturates and 
meprobamate, as the minor tranquillizer of choice. It was widely 
believed that benzodiazepines had fewer and less severe unwanted 
effects, were much safer in overdosage, interacted very little with 
other drugs and were less addictive.33 strong doubt has been cast on 
all four of these safety aspects and some, such as the addiction 
potential and withdrawal effects of benzodiazepines at clinically 
prescribed doses, have become highly controversial. Like the efficacy 
issue, the medical-scientific debate has become polarised between those 
who advocate cautious use (such as the British psychiatrists, Lader, 
Petursson, Tyrer, Catalan and Gath)34 and those who continue to voice 
the long-held views on their extreme safety (such as the American 
doctors, Greenblatt and Shader): 
Probably the least controversial aspect of the pharmacology 
of benzodiazepines is their tremendous index of safety. The 
replacement of barbiturates by benzodiazepines as the 
primary agents for the treatment of anxiety and insomnia has 
greatly reduced the morbidity and mortality associated with 
overdosage of sedative-hypnotic d r u g s . 3 5 
The major issues in the safety debate are summarized as follows. 
2.3.2 Low Mortality Rate 
The low mortality rate associated with overdose of 
benzodiazepines, compared with the barbiturates, is often referred to in 
the literature as a strong rationale for their use.36 Marks (a doctor 
who had previously worked for Roche during the development and marketing 
of the benzodiazepines) has summarised a number of studies which found 
only two deaths directly attributable to benzodiazepines alone, out of a 
total of 9,500 drug overdose cases and 1,500 drug fatalaties examined.37 
Nevertheless, it is well accepted that benzodiazepines are 
dangerous if taken with alcohol, or other CNS depressants.38 
Australian mortality data reveal the extent of problems from these drug 
combinations. Accidental drug related deaths reported by the Coroners 
Courts for New South Wales show that, of a total of 127 deaths in 1984, 
two deaths involved benzodiazepines alone while twenty-five deaths were 
associated with a mixture of benzodiazepines and one or more other drug 
(including alcohol) and can be compared with ninety-one deaths 
associated with heroin on its own or associated with other drugs.39 a 
Melbourne study of road deaths found that two-thirds of the victims had 
drugs other than alcohol in their blood and 46% of the drugs were 
prescribed by doctors. Altogether, of those who were in any way 
responsible for the fatalaties, 82% had used alcohol or other drugs at 
the time of the accident.40 Although some have acknowledged that 
alcohol consumption is high throughout society,41 problems with 
accurately assessing a patient's alcohol consumption are conspicuously 
absent from the medical-scientific debate. Morbidity data also reveal 
benzodiazepines have become a problem. In Australia, they now lead the 
cases of reported drug poisonings, with double the number of mentions 
compared with alcohol.42 
Occasional reports are found of deaths linked with benzodiazepine 
use, other than overdosage. A recent case was the death of a healthy 
volunteer medical student who was participating in British clinical 
trials of a new preparation of the benzodiazepine, midazolam. Although 
evidence at the inquest supported the view that the drug possibly 
contributed to his death from aplastic anaemia, an open verdict was 
returned so that the manufacturers, Roche, were able to pay compensation 
to the family without admitting negligence.43 jhe Australian drug 
compendia provide information on life-threatening disorders such as 
blood discrasias and liver abnormalities, which are listed as possible 
adverse reactions.44 
2.3.3 Depression of the Central Nervous System 
Because of their sedative effects, the most common unwanted effect 
of benzodiazepines is excessive depression of the central nervous system 
(CNS). This can be manifested, even at low doses, as: drowsiness, 
impaired memory and recall, reduced co-ordination, fatigue, muscle 
weakness, impaired speech, loss of concentration and speech defects.45 
Disadvantages in collecting information on unwanted effects are 
that they may be considered too trivial to report, voluntary reporting 
systems are not heavily supported, and reports in the literature are 
often drawn from test conditions quite removed from every-day situations 
and from observations of people who would not be characteristically 
prescribed benzodiazepine medication. For example, healthy young adults 
may be recruited46 or simulated driving experiments carried out in a 
laboratory setting.47 
It can be argued that more relevant data could be collected from 
large-scale epidemiological studies. However, the problems are 
considerable. For example, the first attempt to study the effects of 
benzodiazepine use on traffic accidents in natural conditions, carried 
out in Britain by Skegg and his col leagues,48 was criticised because the 
design of the study did not allow measurement of the contribution of 
alcohol consumption.49 it is also difficult to distinguish between 
contributory effects of the medication and the condition for which it is 
being treated.50 Greenblatt has also criticised this study, stating 
that: 
such studies suggest but certainly do not prove that 
benzodiazepines cause automobile accidents.51 
Besides implying that benzodiazepines were not as effective as he had 
stated elsewhere, in that he questioned the emotional state of the 
drivers taking tranquillizers, Greenblatt opportunistically adopted a 
simplistic model of science's ability to prove any drug as a causative 
agent. Contemporary practice, drawing on epidemiological methods, is 
to examine the association of drug use with particular events, where the 
contribution of the drug(s) is part of a continuum of the effect, 
ranging from probably insignificant to highly probable that it is a 
contributory agent. 'Proof is rarely obtained yet it is certainly 
possible to draw conclusions concerning strongly linked factors. For 
example. Drew in the Commonwealth Department of Health has estimated 
that tobacco is involved in the largest number of drug-related deaths. 
This data was calculated from 'death indices' associated with particular 
drugs derived from a study of Australian and international literature.52 
2.3.4 Effects on the foetus, newborn and elderly 
Considering the delay in discovering the hidden dangers of another 
sedative, thalidomide, also prescribed in the early 1960s, surprisingly 
little attention has been given to the possible dangers of teratogenic 
and other effects on the foetus by benzodiazepines. About fifteen years 
after their introduction, epidemiological studies in the United States 
and Finland found a link between birth defects and benzodiazepines when 
taken during the first trimester of pregnancy.53 However, conflicting 
evidence published at the same time,54 possibly together with the fact 
that the birth defects (cleft lip and/or cleft palate) were not as 
severe as in the thalidomide case, has resulted in this safety aspect 
being pursued no further. Occasional warnings are given, such as by the 
British Committee on the Review of Medicines in their revised guidelines 
for data sheets of benzodiazepines which stated: 
do not use during preqnancy, especially durinq the first and g g
, unless there are compelling r e a s o n s . 5 5 last trimesters 
In addition, warnings provided by the drug companies are inconsistent. 
In Australia, the MI MS bi-monthly drug compendium mentioned 
benzodiazepine use during pregnancy fifteen times as requiring special 
precautions, four times as contraindicated whilst for eight different 
benzodiazepines there was no reference at all to use during pregnancy. 
For full information supplied by the drug companies, the MIMS Annual for 
the preceeding year included entries for five different benzodiazepines 
which referred to possible foetal effects whilst the majority made 
general warnings on drug use during pregnancy. The variety of 
instructions for the six different brands of diazepam are of interest: 
* Antenex: no information 
* Astra Pharmaceuticals Diazepam Injection: 
Diazepam should not be administered during pregnancy 
unless the expected benefits outweigh any potential 
risks. Placental transfer of diazepam does o c c u r . 5 b 
* David Bull Diazepam Injection: 
Diazepam readily passes the placental barrier, with 
the concentration of the drug in the fetal 
circulation approaching or similar to that in the 
maternal circulation. Epidemiological studies have 
shown an association between diazepam use during 
pregnancy and cleft palate in the offspring. 
Diazepam is therefore not recommended during the 
first trimester of pregnancy.57 
* Ducene: 
The established practice of not prescribing drugs in 
early pregnant^ unless absolutely necessary should 
be adhered to.So 
* Pro-Paiii: no information 
* Yaliia: 
The established practice of not prescribing drugs in 
early pregnancy unless absolutely necessary should 
be adhered to. 
Contemporary reviews of the benzodiazepines generally refer to the 
studies on possible foetal effects as well as repeating general warnings 
on drug use in pregnancy.60 However, these and any other warnings 
concerning use in pregnancy were completely omitted in Greenblatt's up-
dated 1983 review of the benzodiazepines.61 
As well as being possibly dangerous in the early stages of 
pregnancy, it is now accepted that benzodiazepines can harm the newborn. 
A number of reports since 1972 have pointed out that high doses (30mg or 
more) of diazepam given to the mother during labour can cause in the 
newborn, multiple breathing difficulties, low temperature, poor sucking 
and "floppiness".62 These potential dangers were recognised by the 
British Committee on the Review of Medicines in their 1980 guidelines 
for data sheets.63 Nevertheless, a British survey found that 
obstetricians favoured use of benzodiazepines in treatment of pre-
eclamptic toxaemia.64 
Whilst British medical opinion had turned against the use of 
benzodiazepines during labour by 1980, in Australia they were still 
being promoted to doctors for use in labour as late as 1984. Moreover, 
they were promoted quite clearly more for the doctor's convenience than 
for the patient, when suggested for: 
the facilitation of labour, [as] 'Valium' Roche renders the 
parturient more calm and cooperative.65 
Despite the known dangers to the foetus, for use during pregnancy it was 
recommended that "treatment must be continued consistently until the 
foetus reaches maturity".66 
It is commonly accepted that the elderly are more sensitive to 
minor tranquillizers and recommended dosages are usually half those for 
adults,67 although the special requirements of the elderly are often 
ignored in the literature.68 
2.3.5 Addiction and Withdrawal 
The question of addiction to, or dependence on, benzodiazepines is 
the most emotive issue surrounding their use. For approximately twenty 
years the general consensus of medical opinion has been that normal 
dosages of benzodiazepines were relatively free of problems of 
addiction. Withdrawal reactions had been noted from the time of their 
introduction.69 
However, there have been two waves of concern over benzodiazepine 
dependence in the medical-scientific debate. The first wave peaked in 
the late 1960s and early 1 9 7 0 s , 7 0 when it was resolved that their 
addiction potential was low. Large-scale population surveys such as the 
Boston Collaborative Drug Surveillance Program of the early 1970s could 
detect no signs of benzodiazepine dependence.71 When found, 
benzodiazepine dependence at normal dosage was established to occur 
after three to four months continual use.72 Reports in the literature 
declined, despite use increasing to a maximum, until the second wave in 
the late 1970s when addiction again became an issue but this time 
prompting stronger calls for more cautious use of benzodiazepines.73 
Greenblatt and his colleagues provide excellent examples of the 
conservative medical reaction to the second wave of concern over 
addiction to benzodiazepines. Moral arguments were used to minimise the 
addiction effects, such as accusing the "lay media" of "sensationalistic 
and terrifying depictions of benzodiazepine abuse and addiction", and to 
exonerate the doctor's role at the expense of "substance-abusing 
populations".74 Appeals to a more rational scientific knowledge base 
were also used: 
whenever this problem has been evaluated in systematic 
scientific studies, the results have not confirmed the 
implications of journalistic reports.75 
Nevertheless, a considerable body of contemporary medical opinion has 
become more concerned about benzodiazepine addiction. The addiction 
controversy has centred on the following issues: the definition of 
dependence and of benzodiazepine withdrawal symptoms; the dose and 
length of time of benzodiazepine use; the different pharmacokinetic 
properties of the benzodiazepines; and design of research and the data 
used. 
(a) Definition of addiction and benzodiazepine withdrawal synptoms 
Drug dependence, or addiction, has been interpreted in a variety 
of ways. Indeed, definitional confusion has resulted in confusion with 
terminology. 
Although there has been, and is, no commonly accepted definition 
of addiction, the World Health Organisation's (WHO) struggle with this 
concept reflects the continuing conflict of differing views of the 
medical-scientific community and in the public mind generally. In 1957, 
the WHO Expert Committee on Addiction-Producing Drugs gave the following 
definition: 
Drug addiction is a state of periodic or chronic 
intoxication produced by repeated consumption of a drug 
(natural or synthetic). Its characteristics include: (1) 
an overpowering desire or need (compulsion) to continue 
taking the drug and to obtain it by any means; (2) a 
tendency to increase the dose; (3) a psychic 
(psychological) and generally a physical dependence on the 
effects of the drug; (4) detrimental effect on the 
individual and society.76 
This view of the drug having addictive properties was replaced in their 
1964 definition, when they also replaced the term "drug addiction" with 
"drug dependence" in order to shift the focus on to the behavioural 
aspects. The current definition of drug dependence most commonly 
referred to is that put forward by the WHO in 1974, where drug 
dependence was defined as: 
A state, psychic and sometimes also physical, resulting from 
the interaction between a living organism and a drug, 
characterized by behavioral and other responses that always 
include a compulsion to take the drug on a continuous or 
periodic basis in order to experience its psychic effects 
and sometimes to avoid the discomfort of its absence.77 
Drug dependence is divided between physical and emotional effects. For 
example, the WHO described the two different states of dependence as: 
Physical dependence. An adaptive state that manifests 
itself by intense physical disturbances when the 
administration of the drug is suspended. 
Psychic dependence. A condition in which a drug produces a 
feeling of satisfaction and a psychic drive that requires 
periodic or continuous administration of the drug to produce 
pleasure or to avoid discomfort.78 
The medical-scientific debate contains many examples of doctors 
maintaining the 'addictive drug' concept and the stereotyped picture of 
tranqui11izer addiction based on barbiturates (tolerance, with 
subsequent escalation of dosage and gross drug seeking behaviour). The 
competing picture of benzodiazepine addiction, on the other hand, is 
much more subtle, behaviourally-based and can include neither drug 
seeking behaviour nor tolerance. 
The British contribution to the medical-scientific debate was to 
establish a benzodiazepine withdrawal syndrome.79 Some of the barriers 
to this discovery were revealed in an editorial in the Lancet in 1979 
which stated that: 
many of the mild withdrawal symptoms are indistinguishable 
from the symptoms of anxiety states ... the condition should 
be suspect when a patient repeatedly tries to wean himself 
from a benzodiazepine and restarts ... because of headache 
.. or symptoms unrelated to the initial anxiety syndrome.^^ 
The dilemma had been revealed, if not resolved. If it was 
difficult to identify and measure anxiety states in order to determine 
whether to prescribe benzodiazepines (let alone determine their 
efficacy), how much more difficult was it to be certain that anxiety 
which occurred after withdrawal was due to re-emergence of the original 
'syndrome' and not a a withdrawal effect of the drug? Contradictory 
views of anxiety were further expressed in the Lancet editorial, which 
referred to anxiety as a "mild withdrawal symptom" but also considered 
it a serious illness suitable for treatment with benzodiazepines. 
As a result, there are continuing attempts within the medical-
scientific debate to differentiate anxiety states. It is generally 
accepted that a differential diagnosis can be done according to the time 
sequence of appearance of anxiety after withdrawal. The original 
anxiety symptoms are believed to appear more slowly and plateau out 
about two to three weeks after withdrawal whereas anxiety associated 
with withdrawal is said to appear two to three days after the drug is 
withdrawn, and to peak after about seven to eight days.81 However, some 
withdrawal symptoms have been reported four to six months after 
medication has stopped.82 
(b) Dose and length of tine of benzodiazepine use and method of 
withdrawal 
The consensus of opinion within the medical-scientific debate is 
that the higher the dose and the longer the length of time of 
benzodiazepine use, the more likely is dependence. However, the second 
wave of debate about dependence from the late 1970s has produced 
divergent views on dosage and recommended time of use as well as method 
of withdrawal from benzodiazepines. 
Withdrawal effects have been documented since the time of 
introduction of benzodiazepines. The best-known early study is one by 
Hoi lister and his colleagues which detailed unwanted effects observed in 
psychiatric in-patients given massive doses of Librium (300-600 mg. 
Librium per day - that is, six to forty times more than usual 
therapeutic dosages), and then abruptly withdrawn after five to six 
months of use.83 Occasional case reports of withdrawal effects from 
normal dosages of benzodiazepines also appeared at that time. 
Despite the extreme nature of Hoi lister's study, it did appear to 
raise some general concern against benzodiazepines. Roche reacted by 
supporting staff members from their American laboratories to publish a 
literature review of clinical studies on Librium published from 1960 to 
1966 in the United States.84 To support their arguments on the safety 
of benzodiazepines, they pointed to only twelve reported cases of 
withdrawal effects, ten of which were from the study by Hoi lister and 
his associates using extraordinarily large doses. Another literature 
survey on diazepam dependence up to 1965 also found few reports on 
withdrawal but these authors were critical of the inadequate 
experimental methodology.85 
The first wave of debate over dependence culminated in 1973 with a 
report on the first controlled study of withdrawal effects after normal 
dosages (actually at the top of the range of recommended dosages, at 
45mg per day).86 it was stated that withdrawal effects could be avoided 
for up to a maximum of four months of benzodiazepine use. There has 
been widespread acceptance of this finding despite problems in the 
design of their study. 
In the second wave of the debate, Tyrer's group87 examined 
dependence in long-term moderate users of benzodiazepines who were 
suddenly withdrawn in a double blind study. They found between 21% and 
45% of the people who completed the study had withdrawal symptoms. 
There were also methodological problems with this study, relating to 
non-completing participants, which would have significantly reduced the 
estimate of withdrawal incidence. Another British study carried out at 
about the same time by Petursson and Lader88 found a 100% withdrawal 
reaction rate following normal doses of long-term benzodiazepine use. 
The methodology of this study has been criticised because of the small 
sample of self-selected participants.89 
(c) Different pharvacokinetic properties of benzodiazepines 
In the late 1970's Kales and his colleagues described their 
discovery of 'rebound insomnia', consisting of: 
a marked worsening of sleep following the abrupt withdrawal 
of certain benzodiazepine drugs administered in only single 
doses nightly for short periods.90 
Rebound insomnia was linked with withdrawal from the shorter acting 
benzodiazepines (such as triazolam, flunitrazepam and nitrazepam)but not 
with flurazepam and diazepam which have metabolites with longer half-
lives. The short-acting benzodiazepines were also implicated in an 
analogous syndrome of 'rebound anxiety'.91 
In 1981, the British team led by Tyrer reported on withdrawal 
studies after long-term use of diazepam (which breaks down to a 
metabolite with a long half-life) and lorazepam (which has a much 
shorter half-life and tends not to accumulate in the body, mostly being 
eliminated after each dose). They found that the shorter acting 
benzodiazepine produced a more severe withdrawal reaction. They 
therefore recommended that withdrawal from benzodiazepines should 
commence with a withdrawal regime on a longer acting benzodiazepine, 
such as diazepam, with a gradual reduction in the dosage to follow.92 
However, others have revealed that it may be too simplistic to 
assume a direct link between rate of elimination from the bloodstream 
and withdrawal symptoms. Drugs with comparable half-lives do not 
produce similar effects93 and possible complicating factors could be the 
speed of absorption of benzodiazepines, such as its effects (or of a 
metabolite) in the free state versus bound to protein, or differences in 
levels in blood versus brain and other sites of the body.94 
(d) Psychological and other factors 
Most of the medical-scientific debate on benzodiazepine addiction 
has emphasised the technical aspects of the drug use (dosage, length of 
time of use and method of withdrawal). Psychological aspects have 
received less attention and usually in terms of predisposing personality 
disorders. Often, a judgemental attitude serves to place blame on the 
person addicted to benzodiazepines. For example, Greenblatt has split 
those who are addicted into two groups. On the one hand, there are 
those who are willing to place themselves under medical supervision and 
are rewarded by being cared for by a responsible and knowledgeable 
doctor. On the other hand, there is the deviant group who are 
denigrated as "substance-abusing populations".95 
Tyrer's group has stated that personality is an important factor 
in benzodiazepine dependence and that "patients with passive and 
dependent personality characteristics are more liable to develop 
symptoms".96 They concluded that this "explains why almost all the 
reports of pharmacological dependence have come from patients being 
treated with benzodiazepines for psychiatric reasons".97 However, an 
alternative explanation is that doctors would be less likely to look for 
dependence in people with 'normal personalities' who are using 
benzodiazepines for physical conditions such as spasticity. Other 
evidence contradicts their findings. For example, although working with 
only a small sample, Ashton recently found only two patients with 
psychiatric problems out of twelve referred to her by their general 
practitioners for help in withdrawal from long-term benzodiazepine 
use.98 More importantly, Tyrer has not distinguished between 
prospective and retrospective studies: the majority of dependence 
studies are of the latter type and could not differentiate between 
personality disorders resulting from drug use and pre-existing 
conditions. 
(e) Methods for detection of benzodiazepine dependence 
The early literature review by the Roche workers can be criticized 
as methodologically weak, as they did not state how many of the 287 
clinical studies surveyed, covering 17,935 patients, even attempted to 
investigate withdrawal effects, let alone discontinued use of the drug, 
except for the Hoi lister study.99 
The literature review published by Marks about ten years later has 
often been used to support the view that the incidence of benzodiazepine 
dependence was insignificant. Marks found only twenty-eight cases of 
dependence recorded in Britain over the period 1960 to mid-1977, giving 
a risk of dependence from normal therapeutic dosages of one case per 
fifty million patient-months. He concluded that there were fewer than 
five hundred cases of dependence world-wide.100 However, this can be 
contrasted with a much higher incidence of benzodiazepine dependence 
found over a three-year period (1977-1980) in only one clinic in 
Gottingen than Marks had found in his literature survey covering 18 
years for the entire Federal Republic of Germany, A more recent 
estimate (only five years after Marks' literature survey) using evidence 
from clinical studies, has suggested that benzodiazepine dependence may 
affect two to three million people worldwide.102 
The Drug Abuse Warning Network (DAWN) in the United States has 
also been criticised for its poor data collection methods.103 
2.3.6 Other Safety Issues 
Apart from excessive depression of the CNS (causing oversedation, 
reduced physical coordination and impaired memory), other unwanted 
effects from benzodiazepines are considered to be rare and include 
'paradoxical' aggression, brain scan abnormalities,104 respiratory 
problems, rashes and other skin problems105, and blood dyscrasias such 
as aplastic anemia.106 
2.3.7 Sumnary of Safety 
Safety issues concerning the benzodiazepine minor tranquillizers 
have been focussed on addiction problems, where two distinct waves of 
opinion have prevailed: the first came to a peak in the early 1970s 
when prescribing of benzodiazepines was also reaching a maximum, and the 
second became prominent about ten years later when a much more cautious 
attitude became prevalent. The debate over addiction problems has 
centred around problems of definition of addiction and solutions which 
are largely technical such as altering the prescribed dose or the length 
of time of use. Safety issues concerning foetal effects and effects on 
the newborn and elderly have emerged from time to time but have not 
engendered the same controversy. 
2.4 Conclusion 
The early enthusiastic optimism for benzodiazepines can be seen 
as a reaction against the high death rates from barbiturate overdoses. 
The contemporary reaction against benzodiazepines has shifted focus to 
morbidity rather than mortality issues, that is quality rather than 
quantity of life. The different American and British attitudes possibly 
reveal cultural influences within the debate. 
The medical-scientific debate has played a part in shaping the 
meaning of minor tranquilliser technology. An examination of the debate 
has captured the problematic nature of the positivist claims of 
medicine's scientific knowledge base. These mirror fundamental problems 
within the model of scientific medicine which promotes a mind-body split 
reflected in the physical and mental separation of disease states, an 
essentialist view of disease favouring the concept of specific etiology, 
and the overarching Cartesian influence of the body viewed as a machine. 
The contemporary medical-scientific debate has, above all, sought 
to define problems with tranquillizer use in technical terms which have, 
nevertheless, failed to yield satisfactory solutions. Minor 
tranquillizers continue to be used at very high levels. Technical 
solutions continue to be sought. Already, alternative drugs such as 
propanolol, low doses of major tranquillizers and anti-depressants are 
being promoted.107 Behind the technical barriers lie the social forces 
which have shaped the course of the debate and the use of minor 
tranquillizers. A more rational use of benzodiazepines must start with 
the extension of the debate into the social context, which continues in 
the next chapter dealing with factors influencing prescribing and 
consumption patterns. 
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3 THE MEDICAL PROFESSION AND CONSUMERS 
3.1 Introduction 
The previous chapter demonstrated that the debate over efficacy 
and safety of minor tranquillizers in the medical literature has been 
largely structured in terms of scientific and technological problems and 
solutions. Despite the positive role of stress as an aid in adaptation 
to, or protection from, the environment, anxiety and other stress-
related problems often have been interpreted as discrete medical 
diseases amenable to technological solutions such as a prescription. 
People who consult doctors often expect a technological cure 
(prescription) for their ills, although it seems that doctors may 
reinforce these expectations.'' Similarly, solutions to the addictive 
potential of the minor tranquillizers have been sought in terms of a 
technologically deterministic and futile pursuit of the non-addictive 
minor tranquillizer, or in an anti-technological stance such as 
advocating total withdrawal of the benzodiazepines from the market. 
This chapter opens with a discussion of the inadequacy of the 
biomedical model of disease in light of the social forces which shape 
health and illness. These are examined with respect to the prescribing 
of benzodiazepines for the four groups most at risk: women, the 
elderly, the chronically ill and the institutionalized. The influence 
of the medical profession and the health consumer movement on the 
application of this particular drug technology is examined. 
3.2 Illness - More Than a Technological Problem 
3.2.1 The Limits of the Biomedical Model 
The search for better and safer tranquillizers has been based on 
an ideology of scientific and technological progress. This ideology has 
been crucial to the legitimation of medical science. For example. 
improvements in the health of industrial societies were interpreted as 
the result of the medical control of infectious agents, such as vaccines 
and the sulphonamides and antibiotics introduced earlier this century. 
More recently, the work of McKeown and other have shown instead that 
improved nutrition, housing, hygiene and general public health measures 
(often fought against by doctors themselves) were the major factors 
responsible for the marked decline in mortality in Britain after 
industrialisation in the 19th century.2 Nevertheless, this myth of 
medical and scientific progress continues to underpin the contemporary 
drug industry and medical prescribing practices which support the 
widespread manufacture and use of minor tranquillizers and other drugs. 
Social attitudes to health and illness and the conflicts between 
and within medical and general community definitions of health are 
important to this analysis. For example, health can be viewed 
negatively or positively, functionally or as an ideal, such as: 
"freedom from disease or a i l m e n t " " n o t the mere absence of disease, 
but total physical, mental and social well-being";^ and "a state of 
optimum capacity for the effective performance of valued tasks".^ The 
latter two definitions acknowledge the social component surrounding 
judgements on 'well-being', 'optimum capacity', 'effective performance' 
and 'valued tasks'. 
Western medicine has been criticised for its mechanistic and 
reductionist view of illness as a mechanical failure obeying scientific 
principles. It implies a deviation from the 'normal' state of a 
perfectly functioning machine; that is, a state of health which can be 
objectively assessed, or measured, and differentiated from other disease 
states. Kennedy, for example, has stated: 
Illness, a central concept of medicine, is not a matter of 
objective scientific fact. Instead, it is a term used to 
describe deviation from a notional norm. So, a choice exists 
whether to call someone ill. The choice depends upon the 
norm chosen and this is a matter of social and political 
judgement.6 
As an example of the social meaning behind the medical judgement of 
normal health, Kennedy has pointed out that when a doctor decides a 
woman is anxious or depressed because she is not coping with an 
unfulfilling and stressful lifestyle as a housewife, the doctor has made 
a judgement that not being able to cope (that is, being anxious) is an 
abnormal state requiring medication with tranquillizers or anti-
depressants.7 
The previous chapter showed the difficulties for the medical 
profession in establishing a norm for measuring anxiety using a medical 
model which assumes that there is a normal anxiety-free state of health. 
In Western medicine, the mind-body split and the subdivision of medicine 
into specialities has established that there are abnormal diseases of 
the mind which can be objectively assessed and treated medically such as 
within psychiatry. Efforts to explore the social meaning of illness 
have been hampered by the acceptance of medical definitions of illness 
within the social sciences. For example, sociological texts commonly 
distinguish between disease, illness and sickness, accepting a 
positivist definition of disease such as "organic malfunctioning, to 
objectively measurable disorders".8 The distinction between mental and 
physical illness is contradicted by other sociological reports on the 
holistic manner in which people tend to report illness.9 
The contemporary critique of Western medicine has shown how the 
medicalization of common social problems rests on assumptions about 
'normal' emotional health and what Dubos has called a 'mirage of 
health'.10 Numerous sociological studies have confirmed the pervasive 
nature of illness generally as well as problems such as anxiety which 
could be classed as mental d i s o r d e r s O t h e r studies have explored the 
social processes in establishing a norm for psychiatric diagnosis, such 
as Temerlin's classic experiment. An actor portraying 'normal' behavior 
was diagnosed as normal by only 50% of one group of psychiatrists and 
clinical psychologists whilst for two other groups diagnoses were 
polarised between a unanimous decision or a minority opinion that he was 
normal, depending on an accompanying expert opinion on the absence or 
presence of mental illness respectively. 
Some critics such as S z a s z , 1 3 have chosen to reject the concept of 
mental illness. Others have sought to more firmly establish medical 
psychiatry, such as Engel, an American professor of psychiatric 
medicine, who has proposed the expansion of the biomedical model of 
disease to that of a 'biopsychosocial' model, in order to incorporate 
'disease' states such as grief. Engel's call for educational reforms of 
the medical profession "soundly based on scientific principles"1^ and 
his assertion that: 
it is the doctor's, not the patient's, responsibility to 
establish the nature of the problem and to decide whether or 
not it is best handled in a medical f r a m e w o r k , 1 5 
expose his goal of reinforcing the power of a scientific medical elite 
by expanding its jurisdiction over both body and mind into a wider 
social arena. Within the social sciences, an alternative to Engels' 
biopsychosocial model has been an ethnomedical model, based more on the 
Parsonian concept of disease in terms of social functioning and set 
within a cultural context.16 
The ascendancy of the scientific psychomedical expert as arbiter 
of health-related decisions has been linked with the exclusion of women 
from the healing professions, a long-term process which some historians 
trace back to the elimination of female lay healers during the time of 
the European witch h u n t s . B y the beginning of this century the 
medical expert had become male, white and a member of the upper socio-
economic class, unlike the majority of his patientsJ8 This imbalance 
has been identified as a major force in the use of minor tranquillizers 
and is explored later in this chapter. 
3.2.2 Addiction 
The limits of the dominant biomedical model of disease are vividly 
illustrated in the area of addiction which has emerged as a major safety 
issue with respect to the benzodiazepines. An historical outline was 
given in Chapter 2 of changes to WHO definitions of addiction over the 
past thirty years. By the 1970s the term 'dependence' had been put 
forward to replace 'addiction', as its use had been limited to describe 
a purely physiological process and primarily focussed on the opiates.''^ 
This model of addiction has been described by Moss and Nicholson as: 
a model that included the inherent overpowering nature of the 
drugs .... the two key indicators of addiction became the 
development of physical tolerance to the drug and the 
appearance of physical withdrawal symptoms once the drug was 
removed from the person's system.20 
Within a space of only twenty years since the formation of its 
Expert Committee on Addiction-Producing Drugs,21 the interpretation by 
WHO has undergone considerable change; from one which attached 
addictive properties to certain drugs, with the primary effect being 
physical addiction, to a more recent emphasis on addictive behaviour, in 
which physical effects may or may not be present. This shift toward a 
behavioural view of drug addiction reflects a contemporary view that 
physical effects are not a necessary part of drug dependence. However, 
the WHO definition is still problematic in that it perpetuates a 
dichotomy between the mind and body. We are still viewing two sides of 
the same coin; our attention is merely being focused on to the other 
side of that same coin. Nevertheless, contemporary debate on 
benzodiazepines reveals that some medical 'experts' continue to hold the 
view that the danger is in the drug. For example, Marks recently 
differentiated between a "psychoactive substance" (one which "influences 
mental processes") and a "psychotropic substance" (which "influences 
mental processes and on which dependence o c c u r s " ) . 2 2 
Furthermore, the term 'addiction' has not been wholly replaced by 
the term 'dependence'; both coexist amongst health professionals and in 
popular usage. There are a growing number of health professionals, 
other than doctors, working in the field of addiction. During the 
1970's, the concept of addiction as a behavioural phenomenon had 
broadened beyond the use of drugs. For example, changed community 
attitudes were reflected in the concept of addiction put forward in 1975 
by the American social psychologist, Stanton Peele, in terms of any 
object, including relationships between people.23 Soon after, he 
proposed the following definition: 
addiction is any compulsive activity or involvement which 
decreases a person's ability to deal with other aspects of 
his life to the point where that activity or involvement 
comprises the dominant source of emotional reinforcement and 
identity for the person.24 
Nicholson and Moss have proposed that this contemporary view of 
addiction corresponds to that which was widely held prior to the 
Industrial Revolution. Industrialisation was accompanied by a sense of 
personal powerlessness at the widespread and fundamental changes in the 
structure of society. Alcohol and, later, opiates and other drugs were 
seen to be able to take control of the individual. This view of the 
'dangerous drug' profited the medical profession, who could appoint 
themselves to the control of such substances, thereby enhancing their 
power as well as medicalizing problems that people encountered with 
drugs.25 
Levine has traced the history of the emergence of the disease 
concept of alcoholism (loss of control over drinking behaviour, curable 
only by abstinence). He states that around the turn of the 19th century 
a new paradigm, or model, was created which: 
defined addiction as a central problem in drug use and 
diagnosed it as a disease, or disease-like. ... During the 
17th century, and for most of the 18th, the assumption was 
that people drank and got drunk because they wanted to, and 
not because they 'had' to. ... alcohol did not permanently 
disable the will; it was not addicting, and habitual 
drunkenness was not regarded as a d i s e a s e . 2 6 
Levine depicts the emergence of the disease concept of addiction 
at that time as a paradigm shift from the Old World view, where a 
person's behaviour was believed to be based on choice (not compulsion), 
to a New World view, which embraced: 
Locke's argument that it is possible to differentiate between 
'Desire' and 'Will'. This distinction is ... at the heart of 
the concept of addiction.27 
The two paradigms can be represented by two conflicting views of 
individual behaviour: 'voluntary' (active choice) and involuntary (loss 
of control). Despite its apparent attempts to move away from some of 
the aspects of the disease theory of addiction, through replacement of 
terms such as 'alcoholism' with 'alcohol dependence syndrome', the WHO 
clearly still uses an "involuntary" model, for example when they 
recently described alcohol dependence syndrome as: 
characterised by behavioural and other responses that always 
include a compulsion to take alcohol.28 
The contemporary re-emergence of the 'voluntary' model of 
addiction has accompanied a rejection of use of terminology such as the 
'disease' of addiction, which was so long associated with the 
'involuntary' model.29 in her review of contemporary views of 
addiction, Krivanek captures the prevailing sentiment amongst health 
workers in the field of addiction when she rejects a disease model, 
preferring to describe addiction as the extreme of a 'drug misuse-
addiction continuum'. Like others, she resists rejecting the term 
'addiction'; instead, it has been redefined in behavioural terms, 
describing drug addiction as: 
a behaviour pattern characterised by an ongoing and 
overwhelming preoccupation with the use of a drug and the 
securing of its supply.30 
The challenges to the concept of addiction within different health 
professions mirror a corresponding tension within community concepts of 
disease. A 'voluntary' model of disease, coming out of 'marketplace' 
psychology is competing for acceptance.31 Some medical practitioners 
have also adopted these new concepts.32 The struggle over concepts and 
terminology concerning addiction hinge on the role of different health 
professions and their struggle for legitimacy with respect to the 
medical profession. Moss and Nicholson point out the crucial role of 
the medical profession in the last century in promoting the 
'involuntary' concept and, thus, that addiction was a disease.33 
3.3 The Consiaers of Tranquillizers 
It was shown in Chapter 1 that women are twice as likely as men 
to be prescribed benzodiazepines. Cooperstock and Hi 1134 have 
identified three other groups at risk: the elderly, chronically ill and 
the institutionalized. Because these groups are not mutually exclusive, 
elderly women are most at risk. Another study on elderly women's high 
use of psychoactive drugs has described the phenomenon as the 
medicalization of poverty.35 whilst relevant, this view does not 
recognize sufficiently that the medicalization process also includes 
being female and aged. 
A Canadian study has examined high consumers of mood-changing 
drugs, including minor tranquillizers (that is, those more likely to be 
addicted to these drugs). High consumers were found to: be women; be 
in the older age groups; report relatively poor health and a higher 
degree of unhappiness; have difficulty defining their problems to their 
doctors; have a low level of education; be married; be unemployed 
outside the home; and more likely to be heavy smokers yet abstain from 
alcohol.36 By contrast, men are more likely to be high consumers of 
alcohol and less likely to visit the doctor for help with emotional and 
other life-style problems.37 An American survey found that women who 
are long-term users of minor tranquillizers and/or sedatives are more 
likely to be poorly educated and of lower socio-economic status38, in 
Australia, it was found that the highest users of prescribed mood-
changing drugs were pensioners or housewives.39 
Gender-based differences in tranquillizer use have been most 
extensively examined, undoubtedly as a direct result of the strong 
resurgence of interest in women's health issues coming out of the second 
wave of feminism.Class-based differences in tranquillizer use have 
been more difficult to identify^'' and reflect the problematic 
relationship between illness and c l a s s ^ 2 as well as gender and class.^^ 
Differences based on ethnicity or aboriginality have received minimal 
attention in Australia, as elsewhere. 
3.3.1 Women 
There is a marked gender imbalance between doctors and patients: 
in Western societies about 80% to 90% of doctors are male44 (in 
Australia the figure is about whereas twice as many women as men 
are prescribed benzodiazepines. Clarke's review of gender and illness^^ 
should be borne in mind with respect to medical and sociological 
research on gender-based illness presented in this section. 
The following five models^^ summarise the reasons most often used 
to explain prescribing patterns of benzodiazepines: they are the 
morbidity, consulting, reporting, stereotyping and social control 
models. 
(a) Morbidity Model 
According to this model, more women than men suffer from 
psychiatric and other emotional illness. 
This can be a biologically determinist argument claiming innate 
differences between men and women in susceptibility to mental or 
emotional disturbances (such as hormonal influences) and draws on 
medical definitions of disease as discussed above. Medical evidence is 
usually sought by attempts to "measure" psychiatric illness, using 
information obtained either in the clinical situation, from the patient 
or the doctor, or from health surveys, as shown in Chapter 2. Under the 
guise of 'scientific' questionnaires, these are basically either self-
reports or 'expert' judgements masked by the subsequent conversion to 
numerical data useful for statistical analysis and a positivist belief 
in a value-free science. It was shown in Chapter 2 that such data are 
restricted by the limits of the measuring device, which make it 
impossible to measure psychiatric illness free from bias of the observer 
or the observed, and thus social and political norms. 
Alternatively, women's higher morbidity can be linked with their 
different social roles. Common reasons put forward include women's 
social roles being more stressful, the sick role being more compatible 
with other role responsibilities, or women's over-socialisation and 
adoption of a feminine role.^S For example, married women in Britain 
and the United States are more likely than single women to be treated 
for depression and anxiety, whilst for married men the reverse is 
t r u e . W o m e n in paid work outside the home have been reported to use 
fewer benzodiazepines^O and to be less liable to depression^! compared 
with women who stay at home. Often these 'social role' arguments are 
placed within a social control model. A positivist attitude towards 
identification and measurement of anxiety and other social problems is 
also important to this model, 
(b) Consulting Model 
There is a general consensus that women consult doctors more often 
than men.52 However, gender differences are relatively minor. For 
example, the 1983 Australian Health Survey found 57% of people who 
reported consulting a doctor were women.53 And a recent survey in Perth 
found no significant gender differences in use of health services, 
including consulting a doctor. These results may be confounded by 
factors discussed in the reporting model. 
There are two common explanations of the consulting model. One is 
medical dominance over women's fertility cycle (contraception, 
pregnancy, child-birth, menopause). For example, in the field of 
surgery medical dominance over women's fertility resulted in 
hysterectomy becoming the most frequent operation in the United States 
by 1980, replacing the tonsillectomy and the a p p e n d e c t o m y . T h e other 
is that social structures assign greater responsibility to women for 
childcare so that children are brought to the doctor more often by 
women, who may therefore also consult the doctor. Moreover, data 
collection often does not allow for variations in the ratio of men to 
women in a population, especially amongst the aged who more often 
consult a doctor and are more often women. 
(c) Reporting Hödel 
Surveys both in Australia and other Western industrialised 
societies agree that women, more often than men, report illness as well 
as emotional difficulties such as stress and d e p r e s s i o n . 5 6 A Canadian 
study of long-term use of tranquillizers reported that men were less 
able than women to express emotions g e n e r a l l y . 5 7 
Surveys can be criticised for using medical definitions of 
disease. For example, illness groupings in the Australian Health 
S u r v e y s 5 8 place "nerves, tension and depression" within the "mental 
disorders" category whilst migraine, hypertension, asthma, diarrhea and 
other stomach disorders, skin rashes, allergies, insomnia, breathing 
difficulties, chest pain, heartburn, dizziness, and headaches are 
grouped under other categories according to the international code 
number of medically defined diseases. Yet all of these complaints 
would be likely to have a stress-related component; whilst the medical 
model has split the mental from the physical and then into various 
categories consonant with specialisation within the profession, the 
common lay interpretation of stress-related illness could include many 
of the above. 
Another problem lies with the exclusion of illness groupings. For 
example, in the Australian Health Surveys, whilst "hangover" is a 
category included, the frequency of drinking is not, and withdrawal from 
tranquillizers or other prescribed drugs was not included yet frequency 
of use of prescribed drugs was included. Similarly, cigarette smoking 
is not included in these health surveys despite the high incidence of 
tobacco use in drug-induced deaths (81% in 1984)59 and therefore 
morbidity. Alcohol and tobacco use have, instead, been segregated as 
"drug problems" rather than "health problems". Mechanic has described 
alcohol and tobacco use as "acting out" behavioral symptoms of stress-
related illness, more likely to be expressed by men and, moreover, he 
has extended the symptoms to include violent crimes. That is, gender 
differences in reporting are not due to numerical differences in 
symptoms but rather to differences in the type of symptoms.^^ 
The gender of the person to whom a woman is reporting is also 
important. Cooperstock has found that women alter the content of their 
reporting when a man is present to agree more with the male view.^'' The 
gender of the doctor also influences the doctor's attitudes. Male 
doctors have been reported to complain that female patients report vague 
emotional complaints which are trivial.62 This can also be considered 
within the stereotyping model, 
(d) Stereotyping Model 
According to this model, doctors are more prone to look for, and 
therefore diagnose, neurotic disorders in women because this is seen to 
be normal for women. The etymological roots of hysteria as a disease of 
the womb and the history of medicine's change of view of hysteria from a 
physical to a mental disorder have been described by Ehrenreich and 
Englishes. This stereotypical view of women as emotionally unbalanced 
and ruled by her biology permeates our society and is reinforced in 
medical education and by drug advertising as well as by women themselves 
who are not immune to social pressures. 
Although there is no doubt that female stereotypes are used in 
describing patterns of illness in educational texts and in drug 
advertisements promoting minor tranquillizers for women,64 it is 
difficult to directly assess the effects on the doctor. However, the 
power of drug promotion is indirectly confirmed by the drug industry's 
continuing high expenditure on promotion, and by doctors' changing 
prescribing habits away from generics towards brand name products when 
moving from hospital practice to general practice.^^ 
Doctors' consistent reports of 'trivial' complaints from patients 
may also be gender biased when a male norm for health is chosen by the 
doctor and when a female patient is unable to describe her symptoms in 
terms clear to the doctor (that is, consistent with the medical model). 
Mant and her colleagues have proposed that doctors do not so much over-
diagnose psychiatric disease for their female patients as that they 
under-diagnose among men.^^ 
(e) Social Control Hödel 
Many criticisms of Western medicine and technology have viewed 
medicine as an agent of social control, a concept first suggested in 
1951 by Parsons.Feminists have used this model with respect to the 
social control of women.68 Women's high rate of benzodiazepine use has 
been explained in terms of this model69 although a wave of publications 
on this subject in the mid-1980s have adopted an individualistic 
approach aimed more at the psychological problems of tranquillizer 
addiction and methods of self-help for withdrawal.70 
3.3.2 The Elderly 
The extent of prescribing of minor tranquillizers to the elderly 
is under-stated. The elderly comprise a significant proportion of 
patients in general hospitals, veterans' hospitals, nursing homes and 
other institutions, and yet these same institutions are usually not 
included in data collections (for example, Australian figures on 
prescription sales and the Federal Government Health Surveys of 1978-79 
and 1983). Nevertheless, surveys repeatedly show that elderly women are 
prescribed more psychoactive drugs than any other group according to age 
and sex. 
An American survey done in 1970/71 found that minor tranquillizers 
and hypnotics were taken in the previous year by 33% women and 18% men, 
of the population surveyed aged 60-74. In Canada, it has been reported 
that twice the number of prescriptions for psychotropics are given to 
the elderly as for younger people.71 The 1983 Australian Health 
Survey found that the incidence of use of tranquillizers and sleeping 
pills for people 65 years and over (24%)was almost double that of those 
between 45 and 64 years of age (14%)- similar to the Canadian findings. 
However, methodological differences make it difficult to compare the 
various surveys. 
Poly-drug use is another frequent problem for the elderly, creating 
iatrogenic illnesses. An English study has found that 75% of people 
over 75 years of age receive a drug and that two-thirds of these receive 
up to three drugs simultaneously.A Canadian study found that the 
average number of prescriptions dispensed in 1978-79 to those aged 65 
and over in a regional drug benefit plan was 16 prescriptions per person 
per annum.73 This is particularly disturbing in view of the generally-
held medical opinion that the elderly have less ability to metabolise 
and eliminate drugs.^^ 
Reasons put forward for the disproportionately high use of 
psychotropics by elderly people include the following. The morbidity 
and consulting models point to elderly people's poorer health and more 
frequent contact with doctors. For example, the 1983 Australian Health 
Survey found that the highest incidence of consultation with a doctor in 
the two weeks prior to the survey was for people aged 65 years and over 
(approximately 28% followed by children under 5 years (22% and then in 
decreasing order from 64 years down.^^ By contrast, the consulting and 
social control models have also been applied to the high rate of 
prescribing of benzodiazepines to elderly people in terms of 
medicalization of social and other problems which are more often 
presented to the doctor.^^ 
3.3.3 The Chronically 111 
Chronic, rather than acute, disease has become increasingly 
important in Western medicine. Australian estimates of chronic health 
problems vary between 14% and 45% of the population, with the ten most 
often reported conditions being arthritis, hay fever, hypertensive 
disease, eczema and dermatitis, migraine, bronchitis, asthma, deafness, 
varicose veins and heart d i s e a s e . A l t h o u g h many of these could be 
interpreted as strongly social in origin, they are commonly viewed as 
part of the changing pattern of modern disease within a medical 
framework. For example, Cooperstock has adopted this concept within a 
biopsychosocial model of illness but has criticized the widespread 
prescribing of mood-changing drugs such as the benzodiazepines to the 
chronically ill (such as for acute myocardial infarction, migraine and 
gastrointestinal d i s o r d e r s ) . 7 8 An American study in the early 1970s 
found that 70% of cases in which diazepam was prescribed were for 
conditions other than "mental disorders"; they included 
musculoskeletal, circulatory, medical/surgical aftercare, 
gastrointestinal and other mainly physiological disorders (as well as 
"senility and geriatric care").^^ This has been confirmed elsewhere.®^ 
The usual medical purpose stated for prescribing tranquillizers to the 
chronically ill is to either 'protect' the person from stress which 
could exacerbate their illness or from emotional reactions to the 
illness itselfSI although this could also be expressed in terms of a 
social control model. 
3.3.4 The Institutionalized 
Information is much more difficult to gather concerning 
institutionalized people. Institutions such as hospitals, nursing homes 
and prisons appear to have considerable autonomy and to not be required 
to participate in government organised data collection on patterns of 
drug use. This is also true for Australia. 
However, there is some evidence that these populations may be 
those most prescribed psychotropics. An American survey of mainly 
nursing homes in the early 1970s concluded that their high rate of use 
of tranquillizers indicated that benzodiazepines were also used as a 
tool for institutional control. Cultural or social differences in rates 
of use do exist, however. It was recently reported by a Sydney 
behavioural scientist that a nursing home he visited in Holland was 
supplying drugs to only two of the 240 people in the home, whereas the 
reverse trend is common in Australia.®^ 
3.4 The Medical Profession 
Two important factors concerning the medical profession which have 
shaped benzodiazepine prescribing are medical education and the 
professionalization of medicine (a third - drug promotion - is discussed 
in Chapter 4). 
3.4.t Medical Education 
The biomedical model of disease has dominated contemporary Western 
medical education. For example, a British medical student in the late 
1960s, commenting on medical education, stated: 
It is ridiculous that the study of venereal disease is 
compulsory when the study of sexual relations is ignored.^^ 
A considerable body of evidence on sexism within medical education 
has been documented.84 a common belief amongst doctors is that most 
women are neurotic and it has been proposed that this has arisen from a 
conjunction of medicine's ideological emphasis on the physical over the 
psychological with the belief in the inferiority of women. Examples are 
given of ignorance or misinformation concerning female sexuality in 
American and British gynaecology textbooks as well as trivializing 
physiological problems such as menstrual disorders, vaginal infections 
and pain during labour. 
It is only in recent years that medical education has begun to 
change a long-term practice of excluding women, from the early European 
university-trained physicians of the Middle Ages through to the 
establishment of obstetrics and gynaecology with the exclusion of 
midwives in America a little more than fifty years ago.^^ whilst women 
are increasingly studying medicine (and graduating more successfully 
than men), in Australia they are practising in lower status fields such 
as community medicine or specialised areas such as psychiatry. This 
trend has been blamed on educational constraints linked with the sexual 
division of domestic labour (female doctors carry most of the burden of 
domestic work). Medicine and obstetrics and gynaecology are perceived 
to have higher social status which is reinforced by rigorous 
postgraduate education requirements. This effectively excludes women, 
whereas in psychiatry it is possible to qualify more quickly.Similar 
patterns have also been observed overseas.87 jhe high prevalence of a 
traditional sexual division of domestic labour amongst male and female 
doctors also strongly indicates that medical education has done little 
to correct (and may even reinforce) sexist stereotypes and these must 
flow on to affect attitudes to patients and prescribing patterns. 
Current medical education in Australia appears to promote 
conservative attitudes to prescription of benzodiazepines^S. it has 
also been stated that Australian medical students are encouraged to 
prescribe generically during their hospital training. However, this 
practice changes dramatically once they enter private practice^^ and 
appears to be strongly influenced by drug industry promotional 
activities (see Chapter 4). 
For the specialisation of psychiatry, several studies in the late 
1960s and early 1970s exposed differences in psychiatric diagnoses 
between and within Britain and the United States which could be traced 
to educational differences. London psychiatrists were ten times more 
likely to diagnose 'manic-depressive psychosis' than their New York 
colleagues who tended to diagnose 'schizophrenia' more often. British 
psychiatrists generally diagnosed mental illness less often although 
regional differences within Britain indicated that those trained at 
Glasgow more often diagnosed 'affective illnesses' (such as manic-
depressive psychosis) than 'schizophrenia', while those trained at 
Maudsley Hospital in London diagnosed mental illness less often (as also 
did younger compared with older psychiatrists).^^ 
3.4.2 Professionalization 
Turner has described the important role of professionalization as 
a strategy of occupational control by doctors. He has identified three 
key factors in the process of professionalization: the production and 
maintenance of 'esoteric' knowledge, the cultivation and maintenance of 
a large base of clients, and the maintenance of autonomy and the 
relationship with the clients. In addition, for the medical profession 
he has stressed the importance of medical dominance over other health-
related occupations such as midwifery (subordination), optometry 
(limitation) and chiropractic (exclusion) as described by Will is.91 
Medical education and professionalization are strongly 
interdependent. The hospital has been identified as the primary 
influence on medical professional power.92 For example, the 
introduction of the British National Health Scheme (NHS) perpetuated the 
control of the teaching hospital sector by the specialists. Teaching 
hospitals operated with government funding whilst the specialists 
determined priorities for research and education within them. At the 
same time, the specialists also benefited financially from consultancy 
fees and from private practice.93 in America, the alliance of medicine 
with science and the accompanying educational changes introduced with 
the Flexner Report in the early twentieth century all consolidated power 
within a medical elite and facilitated greater professional controls 
over the practice of medicine, which has been categorized as activist, 
heroic and masculinist.94 
Willis95 has provided a Marxist analysis of the power relations of 
the medical profession in Western industrialised societies. In tracing 
the history of the rise of medical power in Australia, he has stressed 
the importance of professionalization in his analysis of the division of 
labour in health care. He has shown that the social relations of class 
and gender have shaped "which technology is used, how and when it is 
used and who controls its u s e " 9 6 within a hierarchically organized 
health care system where the medical profession is in the most powerful 
position. The significance of the medical profession in shaping minor 
tranquillizer use is illustrated in a Canadian survey which found that 
nurse practitioners prescribed far less use of tranquillizers and 
sedatives than d o c t o r s . 9 7 Freidson and Johnson have been acknowledged 
as key figures in the development of structuralist theories on 
professionalism around issues of power: F r e i d s o n 9 8 in emphasising a 
profession's organised autonomy over control of its own work, permitting 
it to form a monopoly unlike many other occupations; J o h n s o n 9 9 for 
rejecting trait theory and functionalist interpretations of professions 
in favour of a theory of different institutionalized forms of 
professional control, whether collegiate, by patronage or state 
m e d i a t i o n . 1 0 0 
By examining the division of labour in health care, Willis has 
concluded that state patronage underpins medical dominance and its 
reproduction of class structure, but he goes further to stress the 
importance of the ideology of professionalism in legitimating autonomy 
of doctors and therefore strengthening their position of power through 
s e l f - r é g u l â t i o n . 1 0 1 Willis also attempts to incorporate the effects of 
gender, race and other factors in his discussions on power relations 
within medicine. When he examines gender issues within the division of 
labour, mainly through a section dealing with the subordination of 
midwifery, he concedes that: "in this instance gender struggle takes 
precedence (over c l a s s ) " 1 0 2 and "in some historical instances, such as 
the subordination of midwives ... the gender of the historical actions 
must also be c o n s i d e r e d " . 1 0 3 However, with respect to the other two 
sections on optometry and chiropractic within the division of labour 
(both male dominated fields), he has concluded that gender is not 
important to the history of medical dominance. His assertion denies the 
historical antecedents to the exclusion of women from optometry and 
chiropractic and, above all, from medicine itself (for example, the 
emergence of male medical dominance in the United States arising from 
the early conflict between the irregular and regular doctors)J04 
Many writers on the power of the medical profession, such as those 
discussed above, omit to include the importance of medical prescribing 
power. This has been important in maintaining medical dominance such as 
over the profession of pharmacy and with respect to drug industry sales 
where two distinct markets have been created: 'ethical' and 'over-the-
counter' (OTC) drugs. American pharmacists, for example, have been 
given a greater role in prescribing since the early 1970s with the 
repeal of the anti-substitution laws.105 Pressures to introduce similar 
practices in Australia have been unsuccessful so far. Medical dominance 
with respect to other health practitioners has also reinforced high 
prescribing rates since non-medical practitioners are excluded from the 
Medicare system, or not permitted to prescribe drugs, or practice non-
drug therapies (such as counselling, meditation, acupuncture, and 
massage). The medical profession zealously guards its 'freedom to 
prescribe' and generally resists state auditing or regulation of 
this.106 
Most importantly, the Marxist focus on the division of labour in 
medicine has led writers such as Willis to neglect the power relations 
in the doctor-patient relationship and therefore to virtually deny the 
important role of the patient. This has been addressed by Freidson in 
his discussion of the ways in which bureaucratic or professional 
medicine treat the client as an object.107 This has important 
implications for prescribing practices, in that the objectification of 
the patient linked with the profit motive, has shaped the structure of 
medical practice so that consultations are brief and pressures increase 
on the doctor to prescribe in order to be seen to be effective. It has 
been estimated that 75% of consultations with a general practitioner, 
family practitioner or internist result in the use of at least one 
drugJ08 
However, prescribing patterns of benzodiazepines are not constant 
within the medical profession and indicate marked divisions between 
different sections of the profession. Psychiatrists and neurologists 
have accounted for only 17% of prescriptions for mood-changing drugs and 
even less for the two major benzodiazepines, diazepam and 
chlordiazepoxide. By contrast, general practitioners produce 40% of 
prescriptions for mood-changing d r u g s . D r u g promotion is often 
blamed for high prescribing rates but it is clear that an important 
factor is also the doctor's susceptibility to the drug industry message. 
This would be shaped by educational differences which, in turn, depend 
on the professional organization and strength of the different medical 
groups and the way they determine their own educational processes. 
Postgraduate education has the potential to educate doctors in a more 
conservative approach to drug therapy. As psychiatrists would tend to 
see people with severe anxiety or other emotional problems, they may 
tend to prescribe major rather than minor tranquillizers (although in 
Chapter 2, evidence was cited for benzodiazepine efficacy only against 
medium to high levels of anxiety). This tendency has not been evaluated 
in the literature. Most importantly, the retreat from professional 
unity by specialisation within the medical profession has diluted 
medical political p o w e r . 1 1 0 
The economic and political benefits enjoyed by doctors closely 
involved in drug and other health-related industries have been described 
as contributing to a medical-industrial complexJ'''' These can arise 
from doctors' entrepreneurial activities in profit-making health care 
industries, such as private hospitals or non-hospital based diagnostic 
laboratories1''2 or from their position as employees within the drug 
industry. In the latter case, doctors are attempting to improve their 
image and legitimate their activities within the process of 
professionalization. In the 1970s a new medical specialty -
pharmaceutical medicine - was created and reinforced by promotion of 
appropriate certification and publication of specific textbooks 
3.5 Health Consiner Novenent 
Health consumers have played a crucial role in changing attitudes 
to tranquillizers. In the late 1970s and early 1980s, critical reports 
of benzodiazepines - mainly Valium - became widespread. 
In the United States, the public attack against Valium intensified 
with the release in 1979 of Barbara Gordon's autobiography, I'm Dancing 
As Fast As I Can, detailing her addiction to Valium''''^ and which 
underwent eleven printings in 1979 (its year of release) and was 
serialized in the Ladies' Home J o u r n a l . M o s t importantly, political 
pressure from Ralph Nader's consumer group - the Public Citizen Health 
Research Group - provoked a strong public and industry response with the 
release in 1982 of their book. Stopping Valium (publication coincided 
with the release of the film version of V m Dancing M Fast ^ I Can). 
Roche reacted to the adverse publicity surrounding their best-selling 
product, vital to their profitability, by initiating legal proceedings 
against the book's allegedly inappropriate use of a trade name and 
demanding the pulping of all copies.''''^ 
The groundswell of change in public attitudes to minor 
tranquillizers in the United States during the 1970s, led by women's 
groups as well as other health and consumer organizations, forced the 
government to respond in 1979 with an enquiry by the House Select 
Committee on Narcotics Abuse and Control on the use of these drugs 
amongst women. The drug industry responded by intensifying the focus of 
their advertisements on other markets, such as old people (that is, by 
medicalizing a normal process of aging into a disease state) and people 
having difficulties coping with physical illness. After repeated 
warnings from the Food and Drug Administration (FDA) to the drug 
industry to improve its self regulation with respect to promoting 
unnecessary use of tranquillizers, in 1980 the FDA itself finally 
imposed tighter regulations on advertising of benzodiazepines, by 
requiring the following warning in the product labelling: 
(name of anxiolytic) is indicated for the management of 
anxiety disorders or for the short term relief of the 
symptoms of anxiety. Anxiety or tension associated with the 
stress of everyday life usually does not require treatment 
with an anxiolytic. 
Concurrently, the FDA tried to enforce compulsory inclusion of drug 
information for the consumer whenever a prescription for a 
benzodiazepine was filled. But, after a year of lobbying by the drug 
industry, trade groups and the AMA, the government suspended the 
regulation.118 
The second wave of increased debate within the medical community 
over benzodiazepine safety, outlined in Chapter 2, which began in the 
late 1970s is clearly a reaction to the consumer movement's actions over 
benzodiazepine addiction. Whilst the debate still flourishes within the 
medical-scientific literature and in the community at large, prescribing 
practices have only been slightly modified in that prescription rates 
have not continued to increase (see Chapter 1). A substantial number of 
these prescriptions may represent users who have become addicted to 
benzodiazepines. An unknown quantity of these prescriptions may never 
be filled or, once filled, not used completely. Whilst difficult to 
measure as well as carried out on an individualistic basis, non-
compliance also represents consumer action against benzodiazepines and 
cannot be ignored. Patient non-compliance was estimated in 1980 to cost 
119 
more than 300 million pounds per year. 
Consumer power is also exercised through the litigation process. 
Recent legal actions over health related problems have been initiated by 
consumers overseas^^^ and in Australia^^^ against the giant tobacco 
companies (one case had cost the industry about $25 million in legal 122 
defence costs). Doctors' prescribing of benzodiazepines in Australia 
may be curtailed by fear of legal and economic costs, following the 
first successful prosecution in 1986 of a West Australian psychiatrist 123 
by a former patient who had become addicted to Lexotan. 
The current strengthening of conservative forces within Western 
industrialized societies threatens the continued effectiveness of 
movements for social change, such as the health consumer and women's 
movements. The dangers of neo-Romanticism to the women's movement and 
the professionalization of consumer representatives on official 125 
organising bodies dealing with health issues are just some of the 
potential traps. Nevertheless, the political power of the health 
consumer movement continues to challenge medical dominance and, in 
Australia, has undergone remarkable growth in the past few years (see 
Chapter 5). 
3.6 Conclusion 
The changing meaning of benzodiazepine use has been explained in 
terms of changing concepts of health and illness. The biomedical model 
of scientific medicine is being challenged by medicine's extension into 
the social sphere. The disease concept of addiction was used to explore 
some of the conflicting forces in the struggle for a dominant paradigm 
within medicine. The social forces shaping the use of benzodiazepines 
were firstly elaborated by turning to the major users of minor 
tranquillizer (women, the elderly, the chronically ill and the 
institutionalized) and examining five different models commonly used to 
explain their behaviour. The role of the medical profession was then 
examined for their direct effects on the consumer (structure of the 
consultation process, sexist stereotypes) and indirectly through 
education and continuing education (including drug industry advertising) 
and the professionalization process of the doctor. 
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4 THE DRUG INDUSTRY AND REGULATION BY THE STATE 
4.1 Introduction 
The economic successes and political and ethical problems 
experienced by the drug industry have attracted considerable attention 
from both Marxist and other analysts. This work, as for many others, 
makes use of Silverman's extensive research of the industry, in both the 
United States and the developing countries, gained from his background 
as a trained scientist, academic and science writer with many years' 
experience in the United States as a consultant to the state on health 
issues J 
Whilst including the important role of the medical profession and 
consumer, this chapter concentrates on the drug industry and its 
interactions with the state. Firstly, factors significant to the 
development and marketing of minor tranquillizers and other ethical 
drugs are discussed, including industry profits, patent protection and 
its importance to profitability, different avenues for research and 
development, the complexity of drug promotion, and interventions by the 
state on drug safety and efficacy. Secondly, two case studies conclude 
the chapter: one describing the British attempt to curb the numbers of 
benzodiazepines available on the NHS and at the same time to introduce a 
limited drug formulary, and the other describing the confrontation 
between the British state and Roche over the company's transfer pricing 
policies with respect to Valium and Librium. Both studies provide 
valuable insight into past attempts at and potential future state 
controls on the drug industry in Australia, which will be examined in 
Chapter 5. 
The chapter concludes with a discussion of various neo-Marxist 
analyses of the state and medicine and their application to the minor 
tranquillizer drug industry. Whilst none of these theoretical 
approaches has been adopted, a broad summary has been provided of the 
economic, political and social forces shaping minor tranquillizer use 
through the drug industry and the state. 
4.2 Profitability of the Drug Industry 
The pharmaceutical drug industry has the reputation of being the 
most powerful and profitable in the world. It is dominated by a small 
number of transnational companies established in Germany, Switzerland, 
France, Britain and the United States but with subsidiaries world wide, 
as shown in Table 4.1 (which lists the top fifty drug companies in 1977 
ranked by value of pharmaceutical sales). 
In Australia, there are about 140 companies which manufacture 
and/or supply pharmaceutical drugs, and about 110 of these supply items 
for the Pharmaceutical Benefits Scheme (PBS). In 1985 the largest 
market shares (in descending order of market share) were held by five 
subsidiaries of overseas transnationals: Merck, Sharp and Dohme; Ciba-
Geigy; Wellcome Australia; Roche; and Glaxo. The top four companies 
held about 40% of the PBS market and about 20% of the overall drug 
market.2 Only a small number of drug companies supplying the Australian 
market manufacture locally and most of these established facilities in 
Australia during the 1950s and 1960s, when profits were high and 
Australia was attractive as a regional base for exporting to the South-
East Asian region.3 
There are about ten thousand drug manufacturers around the world. 
Of these, only about one hundred operate at an international level, 
accounting for about 90% of world shipments of all drugs for human use 
(valued at $(US)50 billion in 1976) whilst the top fifty drug companies 
account for two-thirds of this total. Australia's small contribution to 
Table 4.1: Top Fifty Transnational Pharmaceutical Companies, 1977 














1 Hoechst-Roussel FRG 1,573 16 1 
2 Merck & Co USA 1,446 84 1, 3, 4 
3 Bayer FRG 1,273 13 1, 3, 
i. 7 
5, 
4 Ciba-Geigy SWI 1,150 28 
6i / 
1, 3, 7 
5 Hoffmann-La Roche SWI 1,145 51 1. 4 
6 American Home 
Products USA 1,116 39 1, 3, 5 
7 Warner-Lambert USA 1,025 40 1. 2, 7 
8 Pfizer USA 1,016 50 1, 7 
9 Sandoz SWI 935 48 1 
10 Eli Lilly USA 911 53 1 
11 Upjohn USA 744 66 1, 2 
12 Boehringer 
Ingelheim FRG 735 77 1 
13 Squibb USA 668 50 1. 3, 7 
14 Bristol-Myers USA 666 30 1, 7 
15 Takeda JPN 646 65 1 
16 Rhone Poulenc FRA 614 13 1,3 
17 Schering-Plough USA 606 63 1 
18 Glaxo UK 594 72 1, 2, 3, 
4, 6, 7 
19 Abbott Laboratories USA 581 47 1, 4, 5 
20 Beecham UK 524 36 1. 3, 5 
21 Johnson & Johnson USA 518 18 1, 3 
22 Montedison ITA 487 8 n 3 
23 Cyanamid USA 484 20 1. 4 
24 Schering FRG 456 51 1.4 
25 AKZO NLD 442 10 1 
26 ICI UK 414 5 1 
27 Smith Kline USA 411 53 1 
28 Wellcome UK 385 65 1 
29 G.D. Searle USA 382 51 1 
30 Baxter Travenol USA 355 42 1, 7 
31 Boehringer Mannheim FRG 353 78 1 
32 RevIon USA 334 29 n 2, 7 
33 Dow USA 333 5 1, 2, 6 
34 Astra SWE 307 73 1, 2 
35 Shionogi JPN 286 78 1 
36 Fujisawa JPN 285 80 1 
37 E. Merck FRG 275 44 1 
38 3M USA 266 7 1 
39 Sankyo JPN 245 79 1 
40 Richardson-Merrel1 USA 235 28 1 
41 Sterling Drug USA 232 14 1. 3 
42 Penwalt USA 217 26 1. 2, 7 
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43 Syntex PAN 216 69 1, 4, 5 
44 A.H. Robins USA 212 69 1, 2, 4. 
& 5 
45 BASF FRG 210 2 1 
46 Meiji Seika JPN 175 32 1 
47 CM Industries FRA 165 62 1, 2, 3 
48 Altana (Varta) FRG 158 47 1 
49 Miles Laboratories USA 158 33 1, 7 
50 Tanabe Seiyaku JPN 154 51 1, 5 
Ethical drugs; 2. Proprietary drugs; 3. Veterinary products; 
4. Vitamins and fine chemicals; 5. Nutritional products; 
6. Agrochemicals; 7. Hospital and laboratory supplies and equipment. 
Source: Gary Gereffi, The Pharmaceutical Industry and Dependency in the 
Third World, "TFrinceton, N.J., Princeton University Press, 
1983T, pp.170-172 
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world sales is shown in a 1986 geographic breakdown of world sales (by 
value): European Economic Community (EEC) 25%; USA 20%; Eastern 
Europe 15%; Japan 15%; Australia 2%; Other 23%.^ 
The level of 'foreign' sales of the top fifty drug companies 
varies widely, from a low of 7% (or less) of output for the Japanese 
companies (which manufacture mainly for a large domestic market) to a 
high of more than 90% for the Swiss companies. Only three countries 
(the United States, the Federal Republic of Germany and Japan) produce 
half of the world's output of pharmaceutical products.5 Table 4.2 
illustrates how Australia (and Canada) is in a similar position to Third 
World and developing nations in its low level of support of a domestic 
pharmaceutical drug industry, and its corresponding reliance on imports 
from overseas-based transnationals. 
Profits in the pharmaceutical industry generally far exceed those 
for other manufacturing industries.6 World-wide sales (human and 
veterinary products, dosage and bulk forms) of American drug companies 
from 1950 to 1960 approximately doubled in value, and in the subsequent 
decade improved even further by almost trebling in value (from $1.4 
billion in 1950 to $6.8 billion in 1970). The profitability of the drug 
industry was estimated to generally average about double the rest of 
manufacturing industry. Net profits (as a percentage of sales) for the 
American drug industry averaged 9% from 1960 to 1972, with some 
companies showing profits far above this average (for example, in 1972 
profits of the twenty-six major drug companies in the United States 
varied from 2.1% to 21.9% of sales; at other times, net profits have 
been reported of up to 54% and even during the depression years of 1930 
to 1935, Upjohn reported minimum profits of 30%). In contrast, profits 
on sales for all other American manufacturing industry have usually been 
Table 4.2: Pharmaceutical Market Shares Held by Domestic and Foreign 









Saudi Arabia 0 100 
Nigeria 3 97 
Belgium 10 90 
Venezuela 12 88 
Canada 15 85 
Australia 15 85 
Brazil 15 85 
Indonesia 15 85 
Mexico 18 82 
India 25 75 
Iran 25 75 
Argentina 30 70 
Philippines 35 65 
Italya 40 60 
Netherlands^ 40 60 
South Africa 40 60 
United Kingdom^ 40 60 
Sweden^ 50 50 
France^ 55 45 
Spain 55 45 
Germany, Federal Republic ofa 65 35 
Switzerland^ 72 28 
United States^ 85 15 
Japan® 87 13 
USSR 100 0 
aThe home country of at least one of the major pharmaceutical 
transnational corporations 
Source: Gary Gereffi, The Pharmaceutical Industry and Dependency in the 
Third World, (Princeton, J.J., Princeton University Press, 
T 9 W , p.186. 
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arçund 6%. Similarly, annual after-tax profits based on investment 
averaged 18% in contrast with only 11% for all major American 
manufacturing industry. Profits on prescription drugs would be even 
higher, since these figures include other pharmaceutical products, 
subject to much greater price competition.7 A similar pattern of high 
profitability compared with the manufacturing sector as a whole has been 
demonstrated in the British drug industry.8 
Table 4.3 illustrates the differential effects on profits by 
various manufacturing items in the drug industry. Because profits are 
so much more sensitive to price changes compared with sales volume, drug 
companies will set prices as high as the market will bear and will 
defend those prices, sometimes at great cost in the short term, with a 
view to protecting their profits over the longer term. 
4.3 Patents 
Patents have been crucial to the ability of drug companies to 
monopolise an innovative drug treatment and therefore to charge high 
prices. In the case of Roche's Valium and Librium, this has been 
clearly documented in Section 4.9.2. Historically, the patented 
medicine business was an important forerunner of the modern drug 
industry. The high profits possible from patented drugs were realised 
at an early date and examples can be found dating back to at least 
seventeenth century Britain.^ 
Contemporary drug companies tend to specialize in a restricted 
range of patented products (for example, ICI's heart pills, Beecham's 
antibiotics and Roche's tranquillizers), effectively concentrating 
research, production and marketing around non-competing specialities. 
Up until the 1960s, large numbers of combination products were marketed 
containing drugs whose patents had expired but which could be repatented 



























Source: Arabella Melville & Colin Johnson, Cured to Death, The Effects 
of Prescription Drugs, (Sevenoaks, Kent, New English Library, 
1183}, p.49 
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in combination with another drug. The combined effect of patent 
protection and the profit motive in drug research and development has 
contributed to the large number of drugs available. Market leaders 
stimulate other companies to imitate their success with 'me too' drugs, 
producing similar compounds which have been modified sufficiently to be 
patentable and with less associated risk and lower research and 
development costs. As a result, the market for branded prescription 
drugs has been described as "product-competitive" rather than "price-
competitive ".10 
Whilst some countries, such as the Communist bloc and Italy, do 
not provide patent protection, other countries which do, such as 
Britain, Canada and Sweden, can enforce compulsory licensing 
arrangements which grant a limited period of exclusive rights to the 
patent holder, after which the company must grant a licence in return 
for royalties from other companies for the remainder of the patent 
period.'''' Some of the economic and political ramifications of 
licensing of patented drugs have been illustrated in the case study of 
Valium and Librium in Britain, set out in Section 4.9.2. 
4.4 Drug Research and Development 
Most drug companies spend about 10% of their turnover on research 
and development (R & D).''^ jhe drug industry defends its high profits 
with the argument that it is a high risk industry, especially in 
research and development. However, data on market share instability and 
equity capital investments for the drug industry show that the high 
risks are more than offset by much higher profits. 
Industrial drug research has changed dramatically since its 
beginnings last century as a side-line for European dye-manufacturers. 
It^now follows the highly successful American example of large teams of 
researchers working in expensively equipped laboratories (for example, 
Upjohn employed approximately four hundred scientists in 1970 compared 
with only twelve in 1938). 
In the early 1970s, the American drug industry was spending about 
$700 million per year on drug research and had introduced several dozen 
major new drugs (as well as over one hundred 'me too' types of drug) 
during the preceding decade. Additionally, about $100 million per year 
was spent by the American government to produce about one dozen major 
new drugs. Even within the state, however, expenditure on drug R & D is 
not easily accountable. For example, of about $1.5 billion spent within 
the medical research budget of the National Institutes of Health (NIH), 
it has been estimated that a not inconsiderable portion would have 
included basic research of potential long-term benefit for the 
development of new drugs for both government and private industry.''^ 
The drug industry also funds researchers outside their 
organizations such as in academic institutions. Results from 
benzodiazepine reseach funded in this way have sometimes been the 
opposite of corporate expectations, and this was illustrated by two of 
the studies discussed in Chapter 2. Tyrer and Owen were partly funded 
by the British drug company Bristol-Myers for their study, which found 
no evidence that short-term diazepam use was effective in the treatment 
of anxiety by general practitioners.''^ The work by Shapiro and his 
colleagues, which found no evidence that long-term use of diazepam was 
effective against anxiety, was initially funded by Roche. However, the 
authors noted that this funding did not extend to most of the data 
analysis, which gave results unfavourable to Roche's major selling 
product.''^ 
Clinical trials of new drugs are also an important part of the 
contemporary drug industry research program. These are usually carried 
out by consultant doctors not employed by the drug industry but, 
nevertheless, paid a substantial fee. Criticisms have been levelled at 
the methodological shortcomings in the conduct of drug trials. Also, 
standard short-term clinical trials cannot detect a variety of unwanted 
effects which may appear years later, and negligence or even outright 
fraud are difficult to detect. This was shown in a large-scale WHO 
study of Clofibrate, an anti-cholesterol drug, which had been on the 
market for many years yet was found in this study not to be effective 
and perhaps even a danger to health. 
In Australia, it has been estimated that limitations set by the 
state on clinical trials for marketing approval of a drug have produced 
a situation in which: 
the product may have been studied in fewer than 100 subjects 
to establish efficacy and only up to 2000-3000 for assessing 
safety. Furthermore, it is uncommon to have data on long-
term safety (>1 year) in more that 500 patients. 
4.5 Drug Promotion 
Estimates vary widely on how much the drug industry spends on drug 
promotion. Nevertheless, it is widely accepted that promotion attracts 
about double the funding of R & D within the drug industry. An 
estimated 22% of sales income (totalling about $1.8 billion) was spent 
on drug promotion in 1975 in the United States. The majority was spent 
on detailing and sampling whilst about 15% went to advertising in 
professional journals. British figures are at the lower end of the 
range of estimated promotional costs. For example, promotion has been 
estimated at only 14% of sales (about 32 million pounds in 1973). 
However, there is considerable variation within this estimate, ranging 
from less than 10% up to about 40% of sales (see Table 4.4). For 
Table 4.4: Costs of promotion as a percentage of sales by size of 
company for the UK drug industry in 1969 
Sales of prescription 




Ave % of sales 
spent on promotion 
Over 8 4 9.6 
5 to 8 4 10.0 
3 to 5 9 12.1 
2 to 3 9 16.9 
1 to 2 6 23.2 
0.5 to 1 14 24.3 
below 0.5 52 40.0 
Source: Monopolies Commission Report, Chlordiazepoxide and Diazepam. A 
Report on the Supply of Chordiazepoxide and Diazepam, (London, 
HM Stationery Office, 1973), p.40 
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example, a large company such as Roche, with sales of 9 million pounds, 
would spend less than 10% of sales income to employ about 66 detailers 
whereas Berk, a much smaller company with sales of only 2-3 million 
pounds, would have had to spend almost double the proportion of its 
sales income in order to maintain an equally large team of detailersJ^ 
An increase in prescription volume has been linked with a drug 
detailer's increased visits to a doctor, although this may not be 
causative as detailers have been known to select high prescribers in 
preference, if they can gain access to this informat ion. 20 The high 
promotional expenditure on drug detailing has given unprecedented direct 
sales contact with doctors. Estimates of drug detai1er:doctor ratios 
vary from 1:20 in Britain to 1:10 for the United States and only 1:3 for 
some developing countries (Mexico, Guatemala, Brazil).^'' 
Promotional techniques tolerated for other products have been seen 
as unethical when offered by detai1er to doctor. Examples range from 
free drug samples and preprinted prescriptions to more extravagant 
incentives such as colour television sets and travel.^^ Recent 
controversy in Australia surrounded the Searle drug company's promotion 
of Lomotil, an anti-diarrhoeal, when they staged a competition with an 
overseas trip as first prize. About six thousand doctors saw no ethical 
problems in the promotion, when they sent in their entry coupons which 
incouded the following statement: 
I am a Lomotil prescriber (we'll take your world for it) and 
would like to enter your Lomotil Summer Olympics' 
competition.23 
Not so well publicized was the promotion in Australia of Capoten, an 
anti-hypertensive from Squibb, offering doctors loan of a computer, free 
of charge, in return for supplying medical data on at least five 
patients using the drug. The drug company and the doctor benefited from 
this arrangement at the expense of the state. As Capoten is an 
expensive drug and for long-term use, it represented a large cost to the 
state ($79.30 per prescription) compared with the patient contribution 
of $10.24 Many large and reputable drug companies have been criticized 
for over-selling drugs, some of which have other potentially dangerous 
effects (for example, Parke-Davis' Chloromycetin (chloramphenicol) which 
causes aplastic anaemia and other blood disorders, Merk's Indocin 
(indomethacin) which can cause peptic ulcers, and Searle's oral 
contraceptive which was found to cause dangerous and even fatal blood 
clots).25 
Claims of safety and efficacy in promotional literature rely on 
scientific authority by referencing scientific literature which, on 
closer examination, may have little or no relevance to the specific 
industry claims.26 Examples continue to surface indicating that the 
drug industry has difficulty conforming to state requirements, not only 
with its written claims of scientific support but also in the overall 
design of promotional material. For example, an employee of one British 
drug company was reported to comment on requirements imposed by the 
Department of Health and Social Security (DHSS): 
As an art director you try to hide all this away ... We have 
to incorporate all this stuff without letting it dominate the 
ad or interfere with what we are trying to do ... We are 
actually more restricted in what we can say than what we can 
show.27 
Doctors are exposed to drug advertising in most of their 
professional literature. In the United States the only medical 
publication free of drug company advertising is The Medical Letter28 (an 
equivalent situation exists in Australia with the Australian 
Prescriber). By the early 1970s, advertising of the benzodiazepines was 
coming under increasing criticism. Gaylord Nelson, the American Senator 
who successfully challenged the drug industry, attacked Sandoz for 
advertising its minor tranquillizer Serentil in medical journals as 
useful for the relief of everyday tensions and anxiety-provoking 
situations such as "the newcomer in town who can't make friends" and 
"the woman who can't get along with her new daughter-in-law".29 
Others have criticized the sexist advertising of minor 
tranquillizers (already mentioned in Chapter 3). Advertisements of 
benzodiazepines in medical journals have been seen to reinforce 
stereotypical sex roles. Doctors have been cast as the mediators when 
they prescribe long-term benzodiazepine therapy for many women 
expressing anxiety from unsuccessful attempts to conform to unrealistic 
social roles. Drug companies target stereotyped attitudes within the 
medical profession with advertisements which present the young housewife 
whose "symptoms reflect a sense of inadequacy and isolation", the female 
student whose "newly stimulated intellectual curiosity may make her more 
sensitive to and apprehensive about unstable national and world 
conditions", or the married female graduate "currently centered around 
home and children, with too little time to pursue a vocation for which 
she has spent many years in training".30 
Promotional texts and accompanying illustrations dominate the 
greater part of advertisements; side effects are presented in smaller 
and harder to read type. A useful example of promotional methods was an 
advertisement for Valium in a 1983 Australian edition of MIMS.31 The 
dominant text appealed to a doctor's professional power of prescribing 
and a male doctor was pictured as the authority and expert in the 
decision-making process. Side effects were listed on the other side of 
the page in small type together with other product information. An 
appeal to facts rather than feelings attempted to cast criticism of 
Valium and other benzodiazepines as irrational and unscientific. 
Finally, references to the scientific literature were used to support 
the use of diazepam in withdrawal from dependence on short-acting 
benzodiazepines and to deny the addiction potential of Valium. 
The Journal of the American Medical Association earns at least $7 
million per year from drug advertising. Its strengthening links with 
the drug industry, particularly its increasing economic dependence on 
advertising revenue from the mid-1950s on, have raised questions about 
its editorial independence (for example, its turn around on the subject 
of generic prescribing in 1955).32 The Medical Journal of Australia can 
similarly be seen to be in a compromising position with respect to its 
inclusion of drug advertising. 
Advertising in American journals is subject to stringent 
regulatory controls by the state in contrast to the British drug 
industry's self-regulation. American controls have progressively 
increased since the Kefauver-Harris amendments and are reflected in the 
greater space given to side effects and contraindications in the 
advertisements.33 
The standard prescription drug reference journals, controlled by 
the drug industry and widely available to the medical profession, are 
also influential promotional tools. Entries in the American PDR and 
British MI MS (also in Australia) are listed alphabetically according to 
the brand name. To find information in order to prescribe a 
benzodiazepine, the American doctor needs to know the brand name and the 
drug company name whereas the British (and Australian) doctor can refer 
to the alternate section divided according to the drug's designated 
action (for benzodiazepines these are listed in MIMS under "antianxiety 
agents", "sedatives, hypnotics" and "anticonvulsants").34 These 
publications promote brand name loyalty and are selective about the 
inclusion of products (for example, generics) and warnings of unwanted 
effects (for example, MIMS publications in different countries), and 
even within a country the product information for the different 
benzodiazepines has been found to vary more widely than expected for a 
basically similar family of drugs.^^ 
Other literature put out by the drug industry is often disguised 
as unbiassed scientific information. For example, a large 'newsletter* 
format report on an international symposium on hypnotics was recently 
distributed to Australian d o c t o r s . j h e publishing company was funded 
by Wyeth International Limited, manufacturers of Normison brand 
temazepam, one of the newer short-acting benzodiazepines. The majority 
of articles detailed positive comments on temazepam and on its 
superiority compared with nitrazepam (the established market leader in 
hypnotics but not marketed by Wyeth), and the remainder of the articles 
generally confirmed the safety and efficacy of benzodiazepines. 
Numerous medical-scientific experts were pictured and quoted, including 
Professor Karl Rickels who is a prominent advocate of benzodiazepines, 
stating that "psychotropic drugs are conservatively used and possibly 
even underused". Rickels has even gone as far as to suggest: 
(f)rom the public health point of view as well as from a 
cost/benefit point of view, wouldn't it be more sensible to 
try a psychotherapeutic drug first before entering into more 
expensive, time-consuming and not necessarily more effective 
non-drug treatments?37 
4.6 Drug Safety and Efficacy and Controls by the State 
Britain was the first Western industrialized nation to introduce 
State controls on the purity of mdnufdctured food and drugs in 1872.^^ 
The main British regulatory body is the Committee on Safety of Medicines 
(CSM), first established as the Committee on Safety of Drugs in 1964. 
From its terms of reference, it is clear that its role is an advisory 
one which emphasises drug safety. Proof of drug efficacy appears to 
require only that a drug can be shown to be better than placebo rather 
than being better than drugs already available. The CSM structure has 
been criticized because of its secrecy and lack of cohesion. In 1978 it 
was reported to rely on advice from 587 people (mainly academics and 
doctors), on thirty-two sub-committees and two jid hoc consultative 
groups with one joint sub-committee and one working party, as well as 
bureaucratic staff support. Allegations of secrecy have been levelled 
at the CSM on the grounds that the Committee refused to pass information 
on to the American Food and Drug Administration (FDA) because of fear 
that the American Freedom of Information Act would allow public access 
to it.39 
The American regulatory agency is the FDA, part of the Department 
of Health and Human Services (DHHS). Pharmaceutical drugs are covered 
by the Bureau of Drugs, within which exist numerous subdivisions 
(Division of Drug Experience, New Drug Evaluation, Division of 
Scientific Investigations, Division of Drug Advertising), each headed by 
a Director and with their own specialist staff. These subdivisions also 
invite experts from outside the FDA to join advisory committees. The 
FDA has been praised for its more effective role compared with the 
British CSM, especially with respect to its lack of secrecy and its 
greater powers to enforce compliance. On the other hand, the FDA's 
system of drug approval has been criticized because it depends on 
evidence provided by drug manufacturers rather that carrying out drug 
trials itself.40 
In the United States, proof of drug safety was first required in 
1938 following the introduction of the Food, Drug and Cosmetic Act. 
This legislation was introduced following strong public reaction to the 
tragic deaths of 107 people, most of them children, who had tried a new 
sulphur drug in liquid form, containing di-ethylene glycol which 
attacks the liver and kidneys.41 Another death, not so well publicised, 
was that of the drug company's chief chemist, who committed s u i c i d e . 
Although the Americans appear to have been slow initially in 
introducing state controls on drug production and distribution, they 
have now become world leaders in this respect despite their cultural 
stereotype of being free-market adherents. From 1962, proof of drug 
efficacy in addition to drug safety was mandatory, following the 
Kefauver-Harris Senate Bill.^^ 
The thalidomide tragedy also induced the FDA to establish a 
national registry of adverse drug reactions. More recently, state 
controls were considerably strengthened when it became compulsory in the 
United States for doctors and drug companies to report suspected 
adverse drug reactions to the Bureau of Drugs.^^ 
Nevertheless, other barriers to safe benzodiazepine use still 
exist. The doctor or other health professional must be able to 
recognize a possible adverse drug reaction (in the case of prescribing 
benzodiazepines for anxiety. Chapter 2 has already shown the problems in 
differentiating the emergence of anxiety as a withdrawal symptom from 
the re-emergence of the original anxiety). 
Secondly, time and effort have to be invested in making a report 
to the relevant state authority. It has been estimated that perhaps 
only 1% of adverse reactions are reported. An American estimate for 
1974 was that 55,000 life-threatening adverse reactions, resulting in 
30,000 deaths, occurred from the misuse of antibiotics in American 
hospitals. A more conservative American estimate in 1978 was 100,000 
adverse reactions over eleven y e a r s . A n Australian study suggested 
that there are about one million cases each year of all types of adverse 
drug reactions but that only a very small number are considered 
sufficiently serious to report to the relevant authorities.46 
Thirdly, there are the social and political problems in the 
process of risk assessment and state controls on a drug with suspected 
adverse actions. For example, in Australia, the Adverse Drug Reactions 
Advisory Committee appears to apply conflicting estimates of risk to 
women's health, as shown in the following two statements taken from 
their 1976-77 report: 
Oral contraceptive preparations were the subject of a number 
of reports suggesting that their use was associated with 
increased risks of myocardial infarction. This possibility 
was studied carefully and, while there was some evidence of 
increased risk, the Committee felt the evidence needed 
strengthening before regulatory action was justified. 
As a result of initial investigations into the risk of 
abortion or the possibility of congenital abnormalities being 
induced in the babies of pregnant women exposed to 
anaesthetic gases, a warning statement was issued to 
hospitals. Although the studies were inconclusive, it was 
felt prudent to assume that exposure to these gases and 
vapours, particularly in operating theatres and anaesthetic 
rooms, could constitute a risk in p r e g n a n c y . 
On the one hand, the Committee chose not to act on "some evidence of 
increased risk" whilst, on the other, it chose to act on "studies 
(which) were inconclusive". 
In Australia, despite some favourable r e p o r t s , t h e state 
continues to rely on a voluntary system similar to the British for 
detecting adverse drug reactions. Declining participation in this 
scheme forced the Australian Department of Health to institute 
'educational' measures, such as: providing quarterly reports to the 
drug industry on adverse drug reactions; supporting the department's 
publication Australian Prescriber (established in 1975 and containing 
articles on adverse effects of new drugs, notification forms of adverse 
drug reactions, etc.) as well as submitting articles in the Medical 
Journal of Australia;^^ and two direct mail approaches to all 
Australian doctors in mid-1982.50 jhe Health Department has even 
resorted to using drug company representatives (detailers) to collect 
information on adverse drug reactions: drug companies were required to 
supply reporting forms to doctors under a scheme which aimed to speed up 
the introduction of new drugs on to Australian markets.51 
A summary of the regulation process prior to marketing a new drug 
in Australia is summarized in Table 4.5 (some changes have occurred more 
recently, such as with the reorganization of the Health Department in 
1984-85).52 jhe marketing of a drug, such as a benzodiazepine, is 
determined by the Australian Drug Evaluation Committee (ADEC), whilst 
the Pharmaceutical Benefits Advisory Committee (PBAC) decides whether it 
is to be listed under the PBS. Both of these committees are dominated 
by medical-scientific 'experts', and the PBAC has been criticized by the 
drug industry for giving medical considerations precedence over pricing 
issues.53 Prices of drugs under the PBS are determined by the 
Pharmaceutical Benefits Pricing Authority (PBPA), comprising equal 
representation by the Department of Community Services and Health, and 
the Department of Industry, Technology and Commerce, as well as by the 
drug industry and health consumers.5^ 
Table 4.5: Process of drug regulation in Australia 
Application to market a new drug, new formulation, 
extend currently approved indications or change 
dosage regimens (supporting data provided by sponsor) 





Animal pharmacology and 
toxicology ^ 
Human clinical trial data 
Drug Evaluation Section 
Australian Drug Evaluation Committee (ADEC) 
Subcommittees: 






National Drug Information Advisory 
Vaccines 
Recommendation to Minister for Health 
Source: R.C. Hall (1982), "Drug Regulation - A Review of Australian 
Procedures", Australian Prescriber, No.1, p.14. 
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4.7 Drug Lag 
The strengthening of American state controls has lengthened the 
time for marketing new drugs (to about five years) compared with Europe, 
although still comparable with Canada and J a p a n . i n Australia, it 
was recently estimated that the average length of time for marketing a 
new drug from overseas and for it to then become widely available on the 
PBS was about 9-1/2 years.56 a comparison between Australia and eleven 
major countries of time differences in granting approval to market drugs 
between 1970 and 1983 has shown that Australia has a longer average lag 
time (about 3-1/2 years) compared with, say, Britain (about 1-3/4 years) 
and the United States (about 2-3/4 years). However, there is a lack of 
agreement on drug lag estimates because of methodological differences, 
such as choice of numbers and types of drugs. For example, other 
evidence has been presented which has suggested that most countries take 
longer than Australia to approve marketing of new drugs,57 
The increase in drug lag in the United States, following the 1962 
Kefauver-Harris amendments to the Food, Drug and Cosmetic Act, has been 
repeatedly criticized by the drug industry and its supporters. A common 
criticism and one raised by the American economist, Milton Friedman, and 
an American drug researcher, William Wardell, is that the FDA is 
preventing more people from getting help from, possibly, life-saving 
drugs which could have been available earlier. 
In his 1973 article in the widely-read Newsweek magazine, Friedman 
applied a cost-accounting analysis in accordance with his free-market 
philosophy to urge the repeal of the Kefauver-Harris amendments (as well 
as the abolition of the FDA) because "the cost of delaying a beneficial 
innovation is something like ten to 100 times the value of avoiding a 
thalidomide-type mistake". For evidence, Friedman largely relied on "a 
brilliant paper" given by another economist at a conference in which the 
author: 
uses highly imaginative techniques to assign dollar values to 
the benefit from suppressing harmful drugs and to the harm 
from suppressing or postponing the introduction of useful new 
drugs. His methods are too complex to describe here.58 
However, cost-accounting approaches can only attempt to deal with 
economic problems and certainly cannot come to grips with the full 
meaning and value of life and the effects of drugs on it. Moreover, 
Henry E. Simmons, the Director of the FDA's Bureau of Drugs, effectively 
challenged Friedman's argument by questioning his interpretation of data 
showing a fall in approval of new chemical entities. Simmons agreed 
that there had been a drop in the number of new drugs introduced on to 
the market but that this had occurred in the six years before the 
passing of the Kefauver-Harris amendment. Most importantly, the number 
of new drugs, compared with recombinations or reformulations ('me too' 
drugs), had remained stable since about 1950 at about five to seven per 
year. 
4.8 Generics 
The escalating cost of their drug bill has been seen as a serious 
problem for many nations since World War II. In the late 1960s, 
following the introduction of the Medicare and Medicaid schemes, the 
American government initiated inquiries into the high cost of 
prescription drugs (the Nelson hearings and the (HEW) Task Force on 
Prescription Drugs).60 
Generic drugs became a focus of attention in heated discussions of 
drug cost with respect to quality. Greater use of generics was made 
possible in the United States by the repeal of anti-substitution laws in 
the early 1970s, so that the dispensing pharmacist could substitute a 
cheaper generic for a more expensive brand name drug prescribed by a 
doctor. This was an important move in challenging the doctors' 
previously powerful position as the sole decision-makers in prescribing. 
However, economic benefits to the state were more long-term as, 
initially, about 75% of drugs were still patented and there were no 
equivalent generics.^'' 
4.9 Case Studies 
4.9.1 LiBlted drug lists - the British experience 
Generics continue to be important world-wide, especially with 
respect to prescription drug controls by the state. In 1985 in Britain, 
Thatcher's Conservative government aroused considerable hostility from 
both the pharmaceutical industry and medical practitioners when it 
announced a cost-cutting scheme involving generics, in an attempt to 
revise their pharmaceutical pricing policy in the National Health Scheme 
(NHS). The sequence of events over the ensuing five months provides an 
examplar of a political power struggle over control of pharmaceuticals, 
especially with respect to benzodiazepines, in an industrialised Western 
country. 
(a) The proposed plan and the final outcome 
The British government's campaign to promote the limited drug list 
was spearheaded by publicity over its intention to restrict minor 
tranquillizers.62 The preliminary list proposed by the DHSS contained 
three benzodiazepines only - diazepam, nitrazepam and temazepam63 - and 
may be favourably compared with only one benzodiazepine listed as an 
essential psychotherapeutic drug by a WHO Expert Committee.However, 
the final list presented to Parliament contained seven different 
benzodiazepines in twenty-five different forms (see Table 4.6). 
The government's initial proposal contained a total of only thirty 
Table 4.6: Benzodiazepine Sedatives and Tranquillisers included in 








5, 10 mg 
5, 10, 25 mg 





2 mg in 5 ml 
2, 5, 10 mg 





2.5 mg in 5 mi 
5, 10 mg 





10, 20 mg 
10 mg in 5 mi 
triazolam tabs 0.125, 0.25 mg 
Note: also still available were all benzodiazepines prepared for 
parenteral or rectal administration and those licensed only as 
anticonvulsants (e.g., clonazepam - 'Rivotril'). Clobazam was still 
available by special arrangement for patients with epilepsy only. 
Source: Rodney Deitch "Blows Fall on the Pharmaceutical Industry", The 
Lancet, March 2, 1985, p.533. 
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listed d r u g s 6 5 whereas there were 108 drugs included on the limited 
list approved in March 1985 by the House of Commons.66 jhe government 
achieved its primary economic objective of a reduction in the NHS drug 
bill for the state, although its intention to restrict minor 
tranquillizers failed due to concessions granted to the medical and drug 
industry lobby. 
(b) The doctors' response 
The strong reaction from British doctors against a limited list of 
NHS drugs was not so much against the government's proposal to introduce 
generic compounds, as it was to protect their professional power, 
expressed in their 'freedom to prescribe'. A preliminary short list of 
drugs prepared by the DHSS provoked 650 letters from the medical 
profess ion.67 
Scientific journals were an important medium for political 
expression by doctors presenting their case against the proposals. 
During the controversy, the two major medical-scientific journals. The 
British Medical Journal and The Lancet, carried editorials, letters and 
articles supporting the existing systems of voluntary limited 
formularies (under investigation or already introduced into individual 
general practice and hospitals).68 These voluntaristic policies were, 
of course, directly under the control of the medical profession rather 
than the state. 
Other tactics adopted by the medical profession included the 
distribution of a letter written from the British Medical Association 
(BMA) to all general practitioners in Britain; a move which brought 
censure on the BMA by government Ministers.69 
(c) Response by the drug industry 
The drug industry's campaign against the British restricted drug 
list included the following appeals to both the medical profession and 
the consumer: Roche Products Ltd. sent a circular letter to general 
practitioners which needed only to be endorsed with the surgery stamp 
and signed before posting to the local MP (a stamped envelope was also 
supplied); and full-page newspaper advertisements were placed by the 
drug industry "showing the happy pensioner who can afford her drugs and 
the sad one who will not be able to".70 
The state achieved a cut about 5%, or 74 million pounds, from the 
NHS drug bill in contrast to the preliminary target of 100 million 
pounds,71 which indicates that its concessions for a considerably 
expanded drug list did not represent a proportionate economic loss. 
Overall, however, state savings on the NHS were quite conservative 
compared with the magnitude of profits (1325 million pounds) anticipated 
by the British drug industry for that year . 
(d) The contradictory role of the state 
The state failed to significantly challenge the power of the drug 
industry interests. Despite having imposed some limits on the number of 
drugs available on the NHS, British drug pricing policy is still 
seriously hampered by structural d i f f i c u l t i e s , 7 2 arising from conflicts 
within the state. The Pharmaceutical Price Regulation Scheme (PPRS), 
introduced in 1978, gave the state two essentially conflicting roles: 
firstly, to ensure safety and efficacy of NHS drugs and, secondly, to 
enable the DHSS to promote R & D in the British drug industry. As a 
result, drug safety and efficacy must be compromised when a regulatory 
body of the state is intimately bound up with promoting the corporate 
interests of the drug industry, whilst at the same time monitoring drug 
safety and efficacy which the industry views as threatening to corporate 
profits. 
The PPRS is basically a limited system of financial control: the 
small secretariat of fourteen staff in 1985 employed only three 
accountants and no doctors. It is a voluntary scheme based on a 
'gentlemen's agreement' which allows the state to request certain 
information and actions from the drug industry. It arose initially 
from a Voluntary Price Regulation Scheme proposed by the Association of 
British Pharmaceutical Industries and set up by the British government 
in 1957.73 jhe PPRS, for example, allows the DHSS to ask the drug 
companies to aim for profit levels set by the state. It can also ask 
for annual financial statements of all large-selling British drug 
companies for the purpose of setting limits on the industry's 
expenditure on promotion and on their profits. The DHSS has authority 
to then determine the profits of drug companies from their calculated 
capital expenditure and offsetting costs. 
As a result, a company's sales of drugs to the NHS are crucial for 
calculating their allowable profit. The importance of sales figures to 
the calculations of state-determined profits has been exploited by 
transnational corporations based outside Britain, which have understated 
capital expenditure and other items. Under the PPRS, manufacturing 
costs (the largest of drug industry costs) are open to distortion by 
company transfer pricing arrangements although the state was satisfied 
this was no longer a problem after the much publicised Roche affair in 
the 1970s (see Section 4.9.2). Whilst R & D costs in the British drug 
industry rose from 82 million pounds (12% of NHS sales) in 1978 to 247 
million pounds (18% of sales) in 1983, the PPRS has not enabled the 
state to check how much of this was innovative R & D compared with 
developing 'me too' or other slightly modified chemical compounds, or 
drugs for sale overseas, over the counter or to the private sector 
rather than drugs for the NHS. Instead, the state has used the PPRS to 
focus on drug industry profits which they reduced from 25% in 1982-83 to 
15%. However, this is a notional figure open to political manipulation, 
representing an average for the whole industry which can vary from only 
4% of sales for Hoechst in 1984-85 to 33% for Fisons.74 
Furthermore, the action to curb drug industry profits arose only 
after disclosures made by the Commons Public Account Committee in 1983. 
Inadequate resources provided by the state (such as the DHSS having only 
one full time accountant to counter the combined expertise of sixty-five 
of the biggest transnational in the world) had allowed about 200 
million pounds per year to disappear in transnational transfer pricing 
arrangements by multinationals, and excess profits of about 33 million 
pounds to be siphoned off from the NHS by nine drug companies over two 
years.75 
4.9.2 Transfer Pricing & Roche 
(a) Background history of Roche 
The Swiss-based company, F. Hoffman-La Roche & Co. (Roche), 
initiator of the minor tranquillizers, has been perhaps the most 
profitable drug company of all. Founded in Basle in 1896 by Fritz 
Hoffman with the aim of using scientific research to produce brand name 
pharmaceutical products for the world market, Roche was soon successful 
in marketing a variety of drugs including a cough syrup (Sirolin), a 
heart remedy (Digalen), and a painkiller containing all the alkaloids of 
natural opium (Pantopon) (which was still on the market in 1 9 7 1 ) .76 its 
marketing of opium products implicated the company in the illegal drug 
trade. Between the two major world wars, it has been alleged that Roche 
(and other drug companies) was heavily involved in trafficking of 
morphine and heroin with illegal drug dealers in underworld centres 
including China. These activities led Sir John Campbell, chairman of 
the British delegation to the League of Nations Opium Advisory Committee 
meeting of 1927, to comment that "Hoffman La Roche and Company was not a 
firm to which a licence to deal with drugs should be given".77 its 
success between the wars with vitamin production, especially vitamins C 
and A, marked Roche's transition to synthesis of new pharmaceutical 
products. This, in turn, led to its marketing of Librium and Valium in 
the early 1960s. Dr. Adolf W. Jann, a law gradúateos and ex-banker who 
joined Roche in 1957 and has been its President and Chairman of the 
Board since 1965, has directed Roche's course since the time that 
Librium was the best-selling prescription drug in the early 1960s in the 
United States (until 1969 when Valium pushed it back to second place).^^ 
(b) Profitability of Roche 
As with other drug companies, accurate financial information on 
Roche's activities is extremely difficult to obtain. In addition, the 
protection offered to Swiss-based drug companies, together with its not 
being a publicly listed company, has supported Roche's policy of secrecy 
and enabled it to generally understate its true financial position (for 
example, its earnings for 1970 have been estimated to be more than eight 
times its reported figure). In the late 1960s, Roche's sales world-
wide were estimated to be increasing by approximately 15%, with total 
revenues for 1970 estimated at $(US)1.2 billion (almost double those of 
Merck, its nearest competitor) largely from sales of only one type of 
drug: the benzodiazepines (Librium and Valium). They accounted for 
about one half of world sales of all tranquillizers. 
Roche's financial success is epitomized by its unusual corporate 
position of being able to finance all its investments from earnings, in 
part derived from cash reserves. However, its code of secrecy began to 
break down in the early 1970s when Roche's obvious success with Valium 
sales attracted world-wide attention to the company's financial returns, 
fuelled by the wide-spread judgement that profit margins for 
prescription drugs, generally, were excessive.^'' 
(c) The benzodiazepines 
Librium and Valium profited Roche enormously because of their 
patent protection, being the first and best-known brand names of 
benzodiazepines. This is clearly illustrated in Table 4.7 which 
compares prices of Valium and Librium world-wide at a time when British 
prices were reaching a peak. 
Table 4.7 also illustrates the effect of political forces through 
the widely differing state controls on drug prices: the British had 
been hardening their attitude to their already relatively stringent 
policy of setting prices in accordance with a state-defined 
predetermined profit to the companies; high American prices were 
subject to minimal intervention by the s t a t e ; S 2 Italy did not recognise 
patent protection (hence, lower prices) and negotiated prices based 
simply on costs of raw materials and production (thus easing the 
downward pressure on prices for those companies able to convince the 
state of their high production costs); New Zealand used legal measures 
for pressuring manufacturers to lower prices (the lowest prices 
surveyed); and, in Australia, Valium escaped state scrutiny of its 
price until after it was included in the PBS scheme in December 1972, 
when it was taken off the restricted list. 
(d) Prelininary action by the state in Britain 
Although British prices were lower than in many other countries, 
the state had been involved in a long-running battle with Roche to lower 
its prices even further and to break its monopoly. From 1964 to 1971 
Table 4.7: Comparative International Prices of Librium and Valium, 1971 
(prices to pharmacists in US dollars) 





United Kingdom 2.40 2.88 100 100 
United States 6.40 8.03 267 279 
Australia^ 3.74 3.74 159 130 
Brazil 2.40 3.62 100 126 
Canada 5.45 6.01 227 209 
Ireland 2.05 2.46 85 85 
Italy 3.55 3.42 148 119 
New Zealand 1.83 2.72 76 94 
Sweden 3.11 3.71 130 129 
^For 100 X 10-mg capsules 
bpor 100 X 5-mg tablets 
^As percentages of UK price 
^Valium was not included in the Prescription Benefit Scheme (PBS) at 
this time 
Source: adapted from M. Silverman & P.R. Lee, Pills Profits & Politics, 
(California, University of California Press, 1976), pp.336,337. 
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Roche refused nine different applications for voluntary licences to 
manufacture their minor tranquillizers in Britain;^^ Japan had been the 
only country Roche issued with new product l i c e n s e s . i t was only in 
1968 that the state broke this monopoly when Roche was ordered to grant 
a compulsory licence to DDSA Pharmaceuticals to manufacture 
chlordiazepoxide (Librium) and its intermediates, and to DDSA and Berk 
Pharmaceuticals in 1971 to manufacture diazepoxide (Valium). Royalties 
payable to Roche were set, based not on sales but rather on the amount 
of drug produced, at a generous rate of 140 pounds/kg and 465 pounds/kg. 
Roche fought back strongly to prevent its competitors from gaining 
access to its own established market. As profits in the drug industry 
are most sensitive to price variation, Roche had continuously and 
strongly resisted lowering its prices. However, in order to maintain 
its monopoly Roche defended its market by immediately reducing its 
tranquillizer prices by about one-third (but keeping them still slightly 
higher than those of its competitor). When Berk was invited by the 
state to tender for a contract to supply NHS hospitals and the armed 
forces with its diazepam product (Atensine) in 1972, the company lost 
the contract to Roche who tendered a price equivalent to 480-530 
pounds/kg, only slightly above Berk's royalty fees payable to Roche and 
therefore clearly below the profitable range of its only competitor.86 
Other tactics Roche used were to supply Librium and Valium free of 
charge to British hospitals for a limited period (from July 1969 and 
July 1971 respectively to June 1972). 
Roche was forced to repay excess profits to the state, but it was 
allowed to maintain its high prices. Total repayments for excess 
profits in the two and a half years up to December 1969 were 1.6 million 
pounds.88 This compromise by the state meant that Britain played an 
important contributory role in maintaining high prices of Librium and 
Valium world-wide, as a drop in British drug prices could have been an 
effective bargaining tool for other countries to enforce a price 
reduction.®^ 
As well as profit refund deals such as these with Roche, Britain 
has caused concern for regulatory bodies such as the WHO and the 
European Committee for Proprietory Medicinal Products because of similar 
voluntary and private negotiations over drug safety between the state 
and British drug companies. The British Committee on Safety of 
Medicines can privately request drug companies to voluntarily withdraw 
drugs from sale (for example, practolol, marketed as Eraldin by ICI, and 
released in 1970, was sold to approximately 100,000 people in Britain 
before being voluntarily withdrawn in 1975 by ICI because of severe 
adverse affects).90 Because the government has not had to exercise a 
regulatory decision, legal requirements to report withdrawal of a drug 
to other regulatory bodies have not applied. Other countries do not, 
therefore, benefit from the British experiences. This has entrenched 
the individualistic approach (at a national level), preventing a truly 
international effort at networking and establishing uniformly consistent 
regulatory codes. It is interesting that Australia is one of the 
countries cooperating with WHO in setting limited standards for new drug 
applications.91 
(e) The British Monopolies Comission Inquiry into Libriua and Valiua 
The state's procrastination in taking action against Roche finally 
came to an end, apparently when it was discovered the state had lost 
considerably more than that first calculated, despite the large 
compensation payments made by Roche. According to the DHSS, in 1965 
they first suspected that Roche's transfer pricing policy was fixing the 
price of imported base ingredients from the parent company about 20% 
higher than would be reasonably expected from costs involved. However, 
when they discovered that this figure was more likely to be about 80% 
too high, and Roche was still refusing to reduce tranquillizer prices to 
the NHS (whilst having supplied hospitals free of charge), they called 
on the Department of Trade and Industry to refer the matter to the 
Monopolies Commission in 1971. In its report released in 1973, the 
Commission recommended that Roche reduce its price of Librium by at 
least 60% and Valium by at least 75% of the 1970 prices.92 jhe 
government ordered Roche to reduce prices by 40% and 60% respectively.93 
The Commission reviewed data on sales, costs and profits provided 
by Roche to confirm enormously inflated transfer prices (compared with 
prices of active ingredients set by Italian manufacturers who do not 
recognise patent protection) and inflated overheads and research costs 
(using alternative data supplied by Roche). They estimated that Roche 
had grossly understated its profits: for only one year (1970) profit on 
Librium had been 405 pounds/kg, not 1 pound/kg as stated by Roche; and 
on Valium it was 1,210 pounds/kg rather than 191 pounds/kg. As a 
result, the Commission calculated that the apparently large amount Roche 
had repaid to the DHSS since 1966 represented only a small part of the 
total 24 million pounds owing solely on Librium and Valium.94 Roche's 
understated profits from its transfer pricing policy also served to 
reduce its tax burden in foreign markets such as Britain, since the 
company paid only 40% profits tax in Switzerland in contrast with other 
countries such as 50% tax in Britain, Germany and America and 78% tax in 
India.95 
(f) Roche's response 
Undaunted, Roche played for time by launching an appeal through 
the House of Lords, which effectively deferred its final response until 
November 1975, when Roche made an out-of-court settlement to pay 3.75 
million pounds to Britain. This was light penalty indeed, since the 
state had initially sought from Roche 12 million pounds in excess 
profits from 1970 to 1973. It now agreed to repay 8.25 million pounds 
to Roche in compensation for inflation and devaluation effects on prices 
of Valium and Librium, frozen in 1973. 
In the year that Roche was negotiating a compromise solution, the 
effects of the price freeze relative to world-wide prices of Valium and 
Librium were as shown in Table 4.8. By this time, however, Roche knew 
that its monopoly on the tranquillizers was coming to an end. The 
patent on Librium had already expired and was soon to end for Valium 
(December, 1 9 7 6 ) .96 The settlement also saved the state further 
embarrassment arising from Roche's subsequent allegations of excessive 
transfer pricing arrangements by British drug companies (Beecham, a 
British company, and Bristol-Myers, its American subsidiary, had been 
overcharging for antibiotics in the United States).^7 
(g) Other attenpts to regulate Roche's activities 
Roche's success with protracted litigation in Britain was repeated 
in West Germany, where the state had followed the British lead and 
ordered Roche to reduce prices by 35% (Librium) and 40% (Valium) in late 
1974.98 In this instance, Roche was permitted to continue charging its 
usual prices during the drawn-out legal battle which was finally 
resolved six years later in the West German Supreme Court, well after 
the patents had expired (Librium in 1977 and Valium in 1978). Similar 
victories won in Denmark in 1977 and Holland in 1979 meant that Roche 
has never been successfully prosecuted for over-pricing its 
tranquillizers. 
Table 4.8: Relative Wholesale Prices of Librium and Valium, 1975 (in US 
dollars) 





United Kingdom 0.83 0.63 100 100 
United States 5.80 6.89 699 1,093 
Germany, Federal 
Republic 4.38 5.35 528 849 
Switzerland 4.75 5.44 572 908 
Mexico^ 4.42 6.03 532 957 
Costa Ricad 7.03 9.13 847 1,449 
3 For 100 X 10-mg capsules 
^ For 100 X 5-mg tablets 
c As percentages of the UK price 
d Data are for 1976 
Source: Gary Gereffi, The Pharmaceutical Industry and Dependency in the 
Third World, (Princeton, N.J., Princeton University Press, 
I W I , p.194. 
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Moreover, Roche emerged virtually unscathed from legal action 
taken against it during this time by the EEC for abusing its dominant 
position in the vitamin market. Roche was found guilty in 1976 of 
limiting competition by giving "loyalty discounts" to its twenty-two 
largest customers of its vitamins. Roche's appeal ended in the European 
Court of Justice in February 1979, which confirmed the company's guilt 
but reduced the f i n e . T h i s relatively minor setback for Roche 
involved far greater hardship for Stanley Adams who had played an 
important role in the EEC's initial inquiries when, in February 1973, he 
passed on information gained while working for Roche. 
After leaving Roche later that year to set up his own pig-farming 
business in Italy, Adams' anonymity was broken leading to his 
imprisonment for three months in Switzerland (an event which 
precipitated his wife's suicide). Adams was subsequently found guilty 
of "persistent economic espionage" and "persistently betraying trade 
secrets" and sentenced to twelve months' suspended imprisonment, ordered 
to pay costs and forfeit bail and banished from Switzerland for five 
years. 
Adams' trial highlighted the strong links between corporate and 
state interests in Switzerland forged by the economic successes of the 
Swiss-based transnational drug companies, acting in concert to 
criminalise Adams' deed as an act of treason whilst condoning Roche's 
illegal activities which Adams had exposed. Roche's political strength 
in the internal affairs of governments other than the Swiss is evidenced 
in the EEC's reticence to play the full strength of its hand in its 
negotiations with the Swiss government and in the company's apparent 
influence with the Italian government in exacerbating Adams' 
difficulties. 
High profits and their dependency on only a small number of 
products are certainly powerful inducements for companies such as Roche 
to fight hard to maintain their position as leaders in the drug 
industry. It is easy to believe Adams when he states: 
[Roche's] history over the last twenty years shows clearly 
the lengths to which they were prepared to go in order to 
suppress competition and ensure that their orofits remained 
high, even at the expense of the i n d i v i d u a l 
4.10 Conclusion 
The drug industry is an excellent example of the monopoly sector 
of capitalism in that it is organised at an international and national 
level, is not price competitive because of its highly organised sales 
markets which have been assisted by patent protection, and production is 
capital i n t e n s i v e J 0 3 its development and marketing of minor 
tranquillizers are also a clear example of the industry's pattern of 
concentration of resources on marketing in preference to R & D, and 
within R & D on 'me too' products in preference to innovative drugs 
(refer to Chapter 1). 
In Chapter 3 it was shown that health is not a finite and 
quantifiable entity which can be objectively assessed and cannot 
therefore be easily incorporated into long-range economic planning by 
the state. Decisions on medical care must be based on rationing of 
available resources according to health priorities which are set by the 
state. Increasing state intervention in Western industrial societies 
and economic crises of capitalism have recently favoured monetarist 
policies such as 'Thatcherism' and 'Reaginism' which have sought to 
restrict social welfare spending, such as on health. 
The concentration of capital in large transnational corporations, 
such as in the drug industry, and corporate interactions with the state 
have formed the basis of renewed debate on and interest in Marxist 
theoretical approaches. The evidence presented in this chapter on the 
relationship between the drug industry and the state supports the view 
that the state is deeply involved in the contradictions of capitalism. 
Following Habermas,104 the crises of late monopoly capitalism can be 
seen as the result of contradictory functions of the state which 
support, on the one hand, capital accumulation (directly for the drug 
industry, and indirectly for the national economy) and, on the other 
hand, legitimation of its social welfare role (the state must show it 
can fulfil its function of supplying basic health n e e d s ) . 
In the health area, the fiscal crisis with the British NHS drug 
bill prompted the British government to introduce a limited drug list in 
an attempt to cut back on costs by appealing to its legitimation role in 
health welfare. Here, the growing public awareness of addiction 
problems within society and, in particular, the dangers of addiction 
associated with benzodiazepines were useful ideological tools for 
proposing to cut back on unnecessary and potentially dangerous drugs. 
Whilst this was useful for one section of the national economy, the 
state was also bound by its contradictory commitment to support the 
British drug industry and its continued research and development 
program. The final political decision capitulated to the drug 
industry's market requirements of a greatly expanded NHS drug list. 
This ensured that the national economy continued to benefit from 
revenues obtained from the industry as well as obtaining greater 
legitimacy for the state in its relations with industry. The role of 
the medical profession in protecting its professional power was another 
important factor in the policy change. 
Doyal has complained of the state's reluctance to nationalise the 
British drug industry as a logical extension of its earlier 
nationalisation of health in the formation of the NHSJO^ However, the 
difficulties are considerable when compared with the struggle outlined 
above between the state and only one drug company - Roche - in Britain: 
a less ambitious, yet unsuccessful, attempt by the state to gain access 
to knowledge of corporate (transfer) pricing policies and to increase 
state control over the drug industry. The problems were reflected in 
the delay in establishing the Monopolies Commission examination of 
Valium and Librium pricing and, subsequently, in enforcing its findings 
to obtain financial compensation from Roche. The legislative tactics 
used by Roche in Britain, and successfully repeated in Europe, enabled 
it to maximise profits during the final years of patent protection on 
their two best-selling minor tranquillizers. The antagonism between the 
state and Roche in Britain was not assisted by the British state's 
refusal to punish its own domestic drug industry for transfer pricing 
deals with subsidiaries in other countries. Similarly, Roche has 
enjoyed strong protection from the state in Switzerland, its country of 
origin, and from other national and international bodies (such as the 
Italian state and the EEC), due to their mutual political and economic 
interests meshing with that of Roche. 
Turner has summarised some problems with Marxist critiques of 
health and medicine, such as their failure to identify different types 
of capitalism, and to identify different patterns of illness and health 
care and their expression within different forms of capitalism, and to 
deny the positive role of welfare s y s t e m s . D o y a l ' s political economy 
analysis of medicine, whilst well-researched as well as being moderately 
gender and culture inclusive, illustrates some of these failings. For 
example, she has strongly emphasised the repressive role of the state in 
reproducing existing capitalist relations^O^ whereas others, such as 
Frankel, have shown how the contradictory role of the state allows it to 
become an important "emancipatory f o r c e " . D o y a l also has 
inadequately explained why the British health system was nationalised 
and not the American, except to state: 
the absence of a militant labour movement in the USA must be 
seen as a major reason for the failure to develop an American 
state health serviceJ^O 
Whilst the absence of a strong radical political movement and 
unionisation in the United States is a likely component, Doyal's 
interpretation denies the importance of other social movements, such as 
the health consumer movement, in shaping American state policy. It also 
denies the comparitively stronger controls with respect to drug safety 
and efficacy exerted on the drug industry by the American state compared 
with those in Britain. Her analysis shows a tendency to be culture 
bound within the British Marxist tradition. Additional explanations for 
the different American health system point to the constitutional 
separation of powers and the consequent absence of centralised state 
activity, and to ideological causes based on American individualism.'''''' 
Further analyses of the drug industry and the state will be 
developed in Chapter 5, which examines the socio-economic forces shaping 
the Australian drug industry in an historical context. 
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5 THE SOCIO-ECONOMIC SHAPING OF MINOR TRANQUILLIZER USE IN AUSTRALIA 
5.1 Introduction 
An historical outline is presented of major factors important to 
the use of minor tranquillizers in Australia. Important state 
initiatives in medicine are described, including the setting up and 
operation of the Prescription Benefits Scheme (PBS), and various 
committees which review drug prices and evaluate new drugs for marketing 
as well as monitoring continuing drug use. 
The attempt by the Whitlam government to exert increased state 
controls on benzodiazepine sales, and the overall drug industry, is 
outlined. The drug industry's continuing call for greater financial 
assistance from the state has been met by a number of inquiries, and two 
of these are discussed in detail: the Ralph Inquiry (in the late 
1970s) and the I AC Inquiry (in the mid-1980s). The Hawke government's 
approach to the drug industry has been more conciliatory, and evidence 
is given of its attempts to encourage a greater research and development 
effort and to give the industry input into decision-making on PBS drug 
prices. At the same time, equal representation was granted to the 
health consumer movement and an outline of events within the past two 
years show it has entered a period of strong growth. 
A summary is presented of the erosion of medical power within some 
sectors of the state, whilst the profession retains an important role as 
medical-scientific 'experts' in an advisory capacity. The professions's 
significant role in prescribing minor tranquillizers has not been 
addressed in a systematic manner nor have any effective controls been 
instituted. Whilst there have been minor attempts to correct problems 
of minor tranquillizer use by reaching the consumer and addressing 
problems of addiction, as well as preliminary research on doctors' 
training and attitudes to minor tranquillizer use, no concerted action 
in state control of professional prescribing power has been initiated. 
5.2 The Prescription Benefits Scheme and the Escalating Drug Bill 
In common with the post-war trend in developed countries around 
the world, there has been increasing state intervention in medicine in 
Australia. For prescription drugs such as the benzodiazepines, an 
important arena of struggle has been the PBS, which has had a 
politically contentious history since the Labor government's first 
attempts to introduce a universal drug benefit scheme in 1944. A 
limited scheme was introduced in 1950 to provide 139 drugs free to the 
general population and in 1951 the range of drugs was extended for 
pensioners and their dependents.^ The scheme's brief was widened by the 
National Health Act of 1959 introduced in 1960.2 in 1953 the 
Pharmaceutical Benefits Advisory Committee (PBAC) was set up as a 
Ministerial committee of medical-scientific experts, whose identity was 
kept secret until 1970 when the Senate forced their disclosure.^ 
By the early 1960s, the Menzies government was under heated attack 
by the Labor Party over high drug prices. Only ten years after the PBS 
had been set up, the national drug bill was climbing at an annual rate 
of 20% to 30%.4 In 1963, following world-wide publicity of the 
discovery of the dangerous effects of thalidomide and the lead of other 
countries, and under continuing attack from its political o p p o s i t i o n , 5 
the government initiated greater state controls over both drug prices 
and drug evaluation. 
The Australian Drug Evaluation Committee (ADEC) was established to 
assess the safety of new drugs from overseas for approval for marketing 
in Australia. ADEC's range of activities was later widened to include 
drug efficacy and, subsequently, advisory subcommittees were set up.6 
The Pharmaceutical Benefits Pricing Bureau (PBPB) was established to 
assist the Department of Health in setting prices for PBS items. A 
voluntary scheme was first instituted in 1964 for doctors, chemists, 
dentists and other health professionals to report adverse drug 
reactions.7 When the PBPB negotiated a number of cuts in drug prices, 
the drug industry argued that higher charges were necessary in Australia 
because of additional costs of transport charges, higher wages and a 
greater ratio of investment in plant and equipment to the size of the 
population covered.8 
Amidst increasing pressure from the opposition, including calls 
for a Royal Commission into the Australian drug industry,^ drug prices 
for 1962-63 rose by 9 % . T h e government appeared to adopt a tough 
bargaining stance when Menzies publicly warned the industry that tougher 
controls would be e n f o r c e d . T h e then Minister for Health, Senator 
H.W. Wade, disclosed that drugs sold in Australia were up to three times 
more expensive than in Britain^^ and that six of the most frequently 
prescribed drugs in Australia were also the most expensive.13 
Nevertheless, the drug bill increase was not insignificant and the 
government statements may be interpreted more as political posturing to 
satisfy public concern about drug prices, whilst the drug industry's 
agreement to moderate price increases helped it to avoid public scrutiny 
of its finances. 
However, criticism continued into the late 1960s of the high cost 
of drugs in Australia, with further calls for a Royal Commission into 
the drug industry14 and reports from health officials that "Australia 
had become one of the world's most lucrative areas of operation for 
international drug concerns .... Australia is the laughing stock of the 
medical health authorities in Canada and the United States".15 Although 
the average cost of drugs had fallen since 1 9 6 3 , t h e rising 
prescription volume meant the total cost of drugs on the PBS had 
continued to riseJ^ A Senate committee on drugs'iS was established and 
further regulatory controls were initiated. Since 1959, when it had 
been set up, the National Biological Standards Laboratory (NBSL) had 
imposed standards on new drugs in Australia similar to British 
standards. New standards specific to Australia were set in the 
Therapeutic Goods Act (1966) covering labelling, packaging and container 
requirements. The Code of Good Manufacturing Practice was also 
established in cooperation with the States to promote drug quality.^^ 
Despite the increased state controls, the Australian drug industry 
continued to maintain high drug prices. For example, in the early 1970s 
prices for benzodiazepines were generally higher than in Britain and New 
Zealand, although lower than in the United States (refer to Chapter 4, 
Table 4.7).^® Nevertheless, in 1972 the industry launched a major 
indirect cost-cutting exercise when the largest manufacturer, the US-
owned Merck Sharp and Dohme, reduced wholesalers' margins from 20% to 
15% of the selling price. Most of the major drug companies followed 
suit within six months. Some companies, such as Burroughs Wellcome, and 
Squibb, accused the government of being partly responsible because of 
the Health Department's more stringent pricing policy for the PBS, and 
other state controls affecting their profitability. However, these 
reductions merely brought the Australian wholesaling process more into 
line with the majority of overseas countries, especially Britain and the 
United States, where the industry had already established margins of 
about 15%. Moreover, the 20% margin had clearly been excessive as many 
wholesalers had been able to offer rebates to chemists of up to 7.5%.21 
(Wholesale margins were reported to have been revised downwards again in 
1987, to 10JI» of the price charged to pharmacies. 
5.3 The Uhitlaa Goverment Initiatives 
Despite growing concern about the safety of psychotropic d r u g s , 2 3 
Roche's Valium was approved for listing under the PBS on 1 December 
1972.24 On 2 December 1972 the Whitlam Labor government was elected.25 
Within one month, prescriptions of Valium had soared to more than most 
other drugs for the entire six months ended 31 December 1972. This was 
a dramatic improvement on an already strong market performance for the 
year ended June 1972, prior to its PBS listing, when it had ranked 
fourth.26 The economic value of PBS listing to Roche was indicated by 
its agreement to a 13% price reduction and the imposition of limits on 
the number of tablets prescribed (a reduction by half to fifty tablets 
and only one repeat).27 Prescriptions, however, continued to climb, 
almost doubling in three months (Table 5.1). 
Health services became highly politicised during the 1970s, 
especially with the Whitlam government's initiatives in health insurance 
(Medibank) and in hospital and other health services.28 The medical 
profession's political activity became more visible as it came under 
attack, and the sovereignty of the Australian Medical Association (AMA) 
was challenged by conflict within the profession between groups such as 
the militant right-wing General Practitioners' Society of Australia 
(GPSA), and the left-wing Doctors' Reform Group.29 in line with a more 
open style of government, the new Minister for Health, Doug Everingham, 
reversed a long-term policy of keeping secret details of market shares 
by the different drug companies in Australia. In March 1973 the Health 
Department released a list of the top ten most prescribed drugs in 
Australia: Valium was in fourth place, just edging out Amytal, a 
barbiturate sedative.30 
Table 5.1 Number of prescriptions for Valium dispensed under the PBS 
for the three months January to March, 1973 
Valium dosage Month No prescriptions 
2mg January 86,152 
February 118,810 
March 143,707 
5mg January 102,419 
February 148,338 
March 189,478 
Source: John Larkin, "The Soma Society. Part I The Go-Slow Pill", The 
Age, 22 May 1973, p.9 
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The drug industry reacted with alarm when in February 1973 the 
Minister for Social Security, Bill Hayden, launched further state 
controls to curb drug prices. No doubt spurred on by the British 
Monopolies Commission inquiry into Valium and Librium (see Chapter 4), 
Hayden publicly criticised the high profits of the drug industry. He 
estimated a ratio for profits to funds employed within the Australian 
drug industry of over 20% compared with 13% for all Australian 
industries (the APMA reported this had dropped to about 16% by the end 
of the 1973 financial year).31 
Hayden announced an investigation into the setting up of a state-
owned drug manufacturing company in addition to, or in conjunction with, 
the Commonwealth Serum Laboratories (CSL) - which manufactured mainly 
biological pharmaceutical products such as vaccines, especially 
Australian-specific items. In reply Gibbs, the executive director of 
the APMA, quoted alternative figures on the industry's profits to sales 
ratio of 12.8% before tax and 6.7% after tax, although no comparison was 
made for the rest of Australian industry. The APMA press conference 
provided a platform for the industry to launch an emotive attack against 
the government for its 'socialist' aims and allegations that public 
money would be lost on this new government venture just as for CSL which 
had recorded a loss in the previous year because 'all socialist 
industries are inefficient'.32 jhe mutually beneficial goals of both 
the Liberal Party and the APMA against the Labor Party proposals were no 
doubt assisted by Gibbs' links with the Liberal Party as a former 
Liberal MP.33 
One month later Everingham announced that the Australian Industry 
Development Corporation (AIDC), the state-owned bank established in 1974 
to finance Australian-owned industrial development, had been asked to 
finance the purchase of a drug company which would be linked with CSL 
and that at least five different companies were interested in 
negotiating with the government.34 
Less than one month after that, in mid-April, the Australian press 
gave wide coverage to the British Monopolies Commission report and the 
high price of Valium in Australia compared with the British prices. 
Following the 40% reduction in British prices in 1972 for diazepam, the 
Health Department had tried to negotiate a similar price reduction with 
Roche in Australia, achieving reductions of only 13.3% (2mg tablets) and 
11.5% (5mg tablets). Australian wholesale prices for Valium were a 
little more than twice those in Britain.35 
Everingham reported that the Attorney-General, Lionel Murphy, was 
investigating the feasibility of breaking the patent monopoly held by 
drug companies in Australia, especially for Valium which was the most 
expensive item on the state's drug bill. Three possible options were 
considered: shorter patent lifetimes, compulsory patent licences 
granted to other companies, and price restrictions on drugs under 
patent.36 Everingham was reported to favour patent lengths of only one 
year, and that companies with a monopoly on a particular drug under 
patent should be subject to compulsory licence laws. 
The drug industry and the state were in open, angry confrontation. 
Everingham accused the drug industry of being a "mercenary, money-
grabbing bunch". The APMA's Gibbs continued the attack on the 
inefficiency of state enterprises when he retorted: 
Dr Everingham does not know what he is talking about. His 
comments are a load of pure, unadulterated rubbish. If he 
wants to run a government company at a loss to taxpayers, let 
him.37 
A report by the AIDC on the feasibility of expanding CSL's 
activities into non-biological drugs and on variation of patent rights 
was submitted to the government in early May. At that time. Everingham 
stated that an important role for the state's entry into drug 
manufacture was as a means to gain access to information on production 
costs, in order to expose hidden profits in the industry.38 He 
criticised the industry's assertion that high profits were justified in 
order to cover long-term research costs, arguing that: "investigation 
shows that only 6% of their prices is spent on research with 25% going 
into dividends and 25% into promotion", with much of research 
concentrating on developing 'me too' products.39 in other comments, 
Everingham revealed possible difficulties with some of the alternative 
options considered by the government. He rejected the Italian example, 
imposed by Mussolini, of virtually abolishing drug patents, conceding 
that this would impose undue hardship on the Australian drug industry. 
However, he maintained his determination to shorten lengths of drug 
patents, although this might involve the state in lengthy legal 
proceedings in the High Court. He also rejected the New Zealand system 
of fixing a flat rate for similar drugs under pharmaceutical benefits, 
with the user paying any differences. Overall, he favoured proceeding 
with a state venture into manufacture of non-biological drugs. 
A Cabinet decision was finally announced in May 1973 to set up an 
"Australian pharmaceutical commission" which would own and operate one 
or more drug companies, although no decision had been made on CSL's 
involvement. 
The Australian drug industry blamed Roche and its recalcitrant 
attitude towards the British government for the Australian government's 
new policies on tighter controls of drug prices, stating in its trade 
journal : 
[Roche] last month unwittingly handed the Australian Federal 
Government the public relations weapon it needs to enforce 
restrictive drug patent laws and depress drug prices ... 
Australian prices, not only of Valium but also of many other 
drugs, are sure to come down in the near future. For 
manufacturers, it means that their public relations battle 
with the new Government over drug prices and changes to 
patent laws is already lost. The only weapons they have left 
are the ultimate threats of curtailment of some Australian 
manufacturing and research activities, or even total 
withdrawal from the Australian m a r k e t . 
Twelve years later, some transnational drug companies decided that 
Australian operations were no longer sufficiently profitable and ceased 
operations here.43 
The Whitlam government continued to maintain its pressure on the 
drug industry in other ways. A Joint Parliamentary Sub-Committee heard 
evidence in June 1973 from the Health Department criticizing Roche and 
other drug companies for maintaining their prices despite an upward 
revaluation of the Australian dollar, thereby increasing their profits 
on imported products and ingredients.^^ At that time, Roche had 
declared that about half of Valium's total production, including its 
basic ingredients, was manufactured at its Dee Why plant in Australia. 
Despite their stated aims of increasing this to total production, this 
could well have been a temporary move to keep up with the surge in 
demand until the 'plateau' anticipated by R o c h e . j n June 1973 Roche's 
Basle headquarters sent Otto Nowotny to present its case to Everingham. 
Nowotny had also been assigned to convince the Swedish government to 
reject the British Monopolies Commission findings. The Australian 
negotiations were interrupted when Nowotny was sent back to Basle for 
more precise financial information, especially on contributions of 
capital, overheads and research costs to the cost of V a l i u m . 4 6 
Nowotny's return to Australia six weeks later in July signalled a 
hardening of Roche's refusal to negotiate price reductions for Valium in 
Australia. The company's resolve, however, was challenged by reports at 
that time of its attempt to maintain a monopoly of the New Guinea market 
by drastically reducing Valium prices to the New Guinea Department of 
Health. In response to New Guinea's decision to purchase a relatively 
small amount of diazepam from Hungary (where no patent protection 
applied), at a reduced cost totalling about $8,000, Roche had offered to 
sell Valium to the New Guinea government at prices up to one-third lower 
than Australian prices, and to replace the Hungarian shipment with 
Valium free of charge, provided most of the Hungarian diazepam was 
destroyed. A small amount of the Hungarian diazepam was to be released 
to Roche for testing, effectively preventing any challenge to Roche's 
allegations concerning the poor quality of its competitor's product.47 
July and August 1973 were decisive months in the tranquillizer 
stakes, with unexpected long-term repercussions, when Roche's monopoly 
of the minor tranquillizer market was broken. In July the lower priced 
benzodiazepine, Serepax, was added to the PBS.^^ Roche's Nowotny again 
visited Australia at the end of August to continue negotiations with 
Everingham on Valium prices. As political leverage, Roche appealed to 
Labor's policy of encouraging research by announcing the establishment 
of a $4 million research unit into marine pharmacology at their Dee Why 
plant, costing an estimated $1 million per year.^^ 
Nevertheless, Roche received a setback in 1974 when the state 
imposed a price freeze on V a l i u m . 5 0 a year later, further state 
controls were imposed on the drug industry in Australia. After a delay 
of two years, proposed amendments to the National Health Bill were 
introduced into Parliament, to increase the power of the Health 
Department to obtain cost and other financial information from the 
manufacturers of PBS drugs. The Health Department's strongest 
bargaining lever in price negotiations with the drug industry was the 
threat of de-listing a drug from the PBS. 
In June 1974, the government also announced its purchase of the 
Fawnmac group of companies, comprising manufacturing and marketing 
divisions for its own and other overseas companies' products, for a sum 
later disclosed in Parliament as $8.7 mi 11 ion.52 jhe purchase was 
completed in September, 1975.53 Fawnmac Industries was chosen from nine 
other drug companies investigated by the AIDC.54 About one month after 
completion of the purchase of the Fawnmac group, Everingham was able to 
inform Parliament of the company's high record of profits of around 25% 
to 30% of annual turnover.55 
The financial secrecy of the Australian drug industry was broken 
at last. Everingham announced that the new state-owned drug company 
would function separately from CSL and he anticipated that both state-
owned companies would set the pace for drug prices.56 These state 
initiatives were short-lived. Two months after the Whitlam government 
was defeated at the polls in December 1975, the new Eraser government 
decided it would sell the Fawnmac group of companies.57 
5.4 ValliH - the Falling Star 
The last half of the 1970s saw a continuing increase in sales of 
prescribed drugs in Australia: total drug sales in pharmacies and 
hospitals increased by 70% from 1975 to 1979. However, prescription 
sales in pharmacies rose most slowly (see Table 5.2). 
In 1976, under the new Eraser government, the Health Department 
responded to recommendations by the PBAC to restrict the availability of 
benzodiazepines because of their addiction potential. As a result, the 
Department removed lOmg Valium tablets from the PBS list, abolished 
Table 5.2: Ex-manufacturer values and value indexes of per capita usage 
of drugs sold by pharmacies and hospitals: Australia, 1975 
to 1979 
Drugs 1975 1976 1977 1978 1979 
Ethical drugs ($m) 188.4 195.0 215.6 228.4 255.7 
Index of per capita 
usage 100 102 112 117 130 
Proprietary drug(s) ($m) 56.6 63.5 73.4 81.0 90.5 
Index of per capita 
usage 100 111 127 138 153 
Drugs from hospitals ($m) 36.9 45.0 51.0 54.3 58.7 
Index of per capita 
usage 100 121 136 142 152 
Total drugs ($m) 281.9 303.5 340.0 363.7 404.9 
Index of per capita 
usage 100 107 118 125 137 
Source: Bureau of Industry Economics, Research report 17, Retai1 
Pharmacy in A u s t r a l i a ^ economic appraisal, p.87 
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repeats for the 5mg and 2mg tablets, and abolished special provisions 
for three months' supplies of the three benzodiazepines available at the 
time (Valium, Ducene and Serepax). In effect, a person would get only 
three weeks' supply of benzodiazepines with one p r e s c r i p t i o n . 5 8 As well 
as reducing the addiction potential for consumers of the drugs, it was 
estimated that the government would benefit financially by saving 
approximately 10% of its drugs bill.59 The chemists also reaped 
financial rewards at the consumers' expense, as it was estimated that at 
least 20% of sales of the benzodiazepines were subsequently at the 
private retail price, which gave calculated profits of between 187% and 
281% for Valium.60 
By 1978, Valium's popularity was well on its down-hill slide. 
Sales of Valium had fallen by one-third from their peak in 1972 of $6 
million (226 million 5mg tablets) to $2.3 million (112 million 5mg 
tablets) in 1978.51 Roche failed to recapture the market with a new 
brand of diazepam: Ducene, marketed in 1974 by a subsidiary company, 
Sauter.52 Diazepam had fallen out of favour well before the Valium (and 
Mogadon) patent had expired in December 1976. Nevertheless, Roche had 
intensified its marketing strategies competing against its own 
subsidiary by supplying Valium and Mogadon free to chemists, requesting 
payment only at the end of the month on stock sold, and had begun direct 
trading with chemists to avoid wholesalers' marked-up prices.53 
Two new brand names appeared on the Australian market in 1978: 
Hoechst's Lorinon (withdrawn several years later) and Protea's Pro-
Pam.54 None were able to repeat Valium's past performance. Whilst 
Valium's notoriety had spread to any diazepam, other benzodiazepines 
were ready to step in and fill the gap in the 'anti-anxiety' market. In 
Australia, ironicallyj this role was taken up by oxazepam, the 
tranquillizer introduced by the Whitlam government to break the Roche 
monopoly and cut the country's drug bill. By the end of the 1970s, 
sales of Valium had been overtaken by Serepax (oxazepam), marketed by 
the US-owned company Wyeth (see Chapter 1). Roche's other best-seller. 
Mogadon, was challenged by another nitrazepam, Protea's Dormicum, when 
the patent expired. However, in the same year, Roche attempted to 
recapture the benzodiazepine sedative/hypnotic market with a 'me too' 
product when it introduced Dalmane ( f l u r a z e p a m ) . 6 5 
By diversifying its interests, Roche had no cause for great 
concern over the growing uncertainties of the benzodiazepine market. In 
Australia in 1978 its highest turnover was in agrochemicals ($30 
million) and sales were increasing steadily (no doubt assisted by its 
takeover of the agricultural company. Lane Ltd.), whilst ethicals were 
in second place ($15 million) and static. Although recording losses in 
1977 ($2.2 million) and 1978 ($4.8 million), Roche had still been able 
to make its usual research contributions to its parent company in Basle 
($2.8 million in 1978). However, at that time the money was re-directed 
to Australia for its Research Institute of Marine Pharmacology in Dee 
Why, then employing sixty-two staff,66 as the research centre continued 
to be a useful political tool for Roche. 
5.5 The Ralph Inquiry 
Since 1970, a number of inquiries and other studies at both 
Federal and State level have examined the drug industry and the use of 
prescription drugs in Australia (Table 5.3). The first of the most 
recent inquiries directly investigating the drug industry in Australia 
is discussed below. 
Following intense lobbying by the drug industry,67 the Inquiry 
into the Pharmaceutical Manufacturing Industry was appointed by the 
Liberal government in September, 1978 and was chaired by J. T. Ralph, 
the mining industrialist and Executive Director of Conzinc Riotinto of 
Aust Ltd. In contradiction of the drug industry's calls for greater 
state assistance, the inquiry's report, tabled in Parliament in 
September 1979, recommended less state regulation and more competition 
within the drug industry.68 in response to its terms of reference 
seeking ways of encouraging an Australian-based drug industry, the Ralph 
Inquiry found no case for any special treatment over and above for 
manufacturing industry, in general, and that the dominance of existing 
large transnational drug companies precluded Australia becoming a major 
exporter of pharmaceuticals.69 
Instead, the Inquiry turned its attention to PBS pricing policies 
and the role of patents, drug lag and use of generics. The APMA had 
proposed that patent life on drugs be extended from sixteen to twenty 
years. The Association complained that drug lag gave less patent 
protection because of the shorter time of the drug on the market and 
referred to the British precedent set in 1977 when patent life was 
extended to twenty years. The Ralph Inquiry did not agree that the drug 
industry warranted special consideration over patents.^^ 
In response to the drug industry's complaints that they were 
forced to set low prices in Australia, the Inquiry found that the state 
was able to negotiate with drug manufacturers to lower drug prices in 
Australia if there were competitors able to supply cheaper generic 
versions of drugs on the PBS. However, because the state also did not 
permit significant price differentials between competing brands of the 
same drug, and because of the subsidised standard rate of payment for 
drugs on the PBS by the consumers, drug manufacturers of brand name 
drugs were cushioned from suffering adverse competition from generics. 
As a result, prices of out of patent major selling drugs sold under the 
PBS in Australia were significantly higher than in Britain. Moreover, 
this enabled brand name drugs to continue to be predominantly prescribed 
in Australia after patent expiry. This became increasingly important 
with the drop in the proportion of patented to out-of-patent drugs. 
Patented drugs fell from 55% to 30% of the market between 1972 and 1978 
for the fifty most prescribed PBS drugs. On the other hand, 
manufacturers of generics were protected also, as their listing on the 
PBS provided evidence of drug quality, ensuring sales to hospitals and 
central purchasing houses (often made by tender at lower prices). 
Nevertheless, average hospital prices were only slightly lower than the 
PBS price to wholesalers,72 although price reductions to hospitals were 
possible for some benzodiazepines, and in some cases these were 
significantly discounted. Hospital prices for diazepam and oxazepam 
were an average of 16% and 5%, respectively, less than the PBS price to 
the wholesaler. However, drug companies were able to selectively reduce 
prices much further. For example, the lowest price recorded for 
diazepam was 34% lower than the PBS price (2mg diazepam), and for 
oxazepam it was 13% (15mg oxazepam). 
As a result, the Inquiry recommended that the state set a maximum 
purchase price and that any additional costs be borne by the consumer (a 
scheme similar to that in New Zealand). It also recommended that 
monitoring of prices and profits should come under the jurisdiction of 
the Prices Justification T r i b u n a l . 7 3 
The APMA's submission to the Ralph Inquiry included the proposal 
to introduce a pharmaceutical profit monitoring scheme, similar to the 
British PPRS (see Chapter 4). The Inquiry rejected this proposal 
because it represented special assistance to the drug industry, stating: 
the scheme offers scope for a guarantee of industry-wide and 
individual company profitability, a privilege not enjoyed by 
any other industry. 
The Inquiry acknowledged that reported profitability of the drug 
industry in Australia had fallen significantly during the 1970s from 
just over 14% to around 3% or 4% (see Table 5.4). Nevertheless, despite 
a 70% to 80% drop in reported profitability, drug companies had been 
increasing their already very high outlays on promotion to almost 20% of 
sales in the PBS.75 Manufacturing costs had also increased, more than 
half being in the biggest item (imported raw materials from overseas) 
accounting for more than one third of all costs (see Table 5.5). This 
strongly suggests that the Australian drug industry was continuing to 
adjust profits with artificially high transfer pricing strategies. 
However, the Inquiry did not confront the drug industry in its financial 
reporting, merely noting that: 
tranfer prices can be set in such a way as to lower the 
profitability of the local subsidiary without affecting its 
contribution to corporate profitability or its viability.76 
Instead, a price rise of 4.4% was recommended to restore profits to a 
level consistent with the rest of Australian manufacturing industry. It 
should be noted that Ralph, who chaired the Inquiry, headed Conzinc 
Riotinto, a subsidiary of Rio-Tinto Zinc, which had been named in a 
British study as one of twenty large industrial companies which avoided 
taxes by transfer pricing adjustments between countries.77 
Neither the drug industry nor the government were happy with the 
Ralph Inquiry's recommendations. The APMA responded by calling for a 
10% price rise whilst the government made a preliminary decision to 
increase drug prices by 3.5% (plus 10 cents per prescription at 'price 
to chemist' level for the PBS maximum quantity), effective from November 
Table 5.4: Profits (as percentage of sales) reported by drug companies 
in Australia in the PBS Pharmaceuticals Sector 
Profit reported by 1972 1973 1974 1975 1976 1977 1978 
Constant group of 14.4 12.7 9.7 6.1 3.8 4.0 2.9 
companies 
(coverage: 30 (84%) 
companies surveyed) 
Maximum number of 14.4 13.0 10.3 6.7 4.6 4.7 3.9 
companies surveyed 
(coverage: 
No. of companies (31) (33) (35) (35) (37) (38) (37) 
Percentage) (85) (87) (93) (93) (93) (93) (92) 
Source: Pharmaceutical Manufacturing Industry Inquiry. Report. 
Parliamentary Paper No.256/1979, (Canberra, AGPS, 1979), p.36 
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Table 5.5: Costs (as percentage of sales) reported by drug companies in 
Australia in the PBS Pharmaceuticals Sector (1972 to 1978) 
1972 1973 1974 1975 1976 1977 197fi 
Variable Manufacturing Costs 
Materials from 














Fixed Manufacturing Costs 5.4 5.6 5.1 6.7 6.9 7.7 7.7 
Total Cost of Goods Sold 51.4 51.2 51.2 56.0 57.8 59.3 60.7 
Administration Costs 6.9 7.3 7.1 6.4 6.6 6.3 6.1 
Distribution Costs 2.8 3.2 3.7 4.2 4.1 4.0 3.8 
Selling, Marketing and 
Promotion Costs 17.1 19.4 20.6 19.7 19.5 19.8 19.4 
Research and Medical Costs 

































(excluding interest) -0.4 -1.4 0.7 0.5 1.3 -0.1 0.4 
Total Non-Manufacturing 
Costs 33.2 35.7 39.4 38.1 39.1 37.1 36.3 
Total Costs 84.6 86.9 90.6 94.1 96.9 96.4 97.0 
(Note: Information from 27 companies (73% of companies with sales in 
PBS pharmaceutical sector) 
Source: Australia. Pharmaceutical Manufacturing Industry Inquiry, 
Pharmaceutical Manufacturing Inquiry Report. ParTiamentary 
Paper No. 2 W 1 9 7 9 . (Canberra, A6PS, 1979), p.37. 
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1981. This increase was estimated to cost the government $25 million 
(which was at variance with the Ralph Inquiry's estimate of only $8 
million for a 4.4% increase).78 The APMA also criticised the Report's 
emphasis on enhancing competitiveness within the industry, pointing out 
that a majority (60%) of consumers under the PBS were subsidised 
pensioners, so that free market principles would apply to only 40% of 
the total market.79 
One year later, no significant action had been taken on the Ralph 
Inquiry proposals to alter existing PBS arrangements on drug prices. 
Aside from the political costs of increasing drug prices, two other 
issues had tested the state's ability to follow the recommendations. 
The first was that only two days after announcing its budget decision in 
favour of this recommendation, the government backed down on its 
decision to allow chemists to discount prices. Secondly, considerable 
concern arose from an independent study of the cost of the Ralph 
Inquiry's recommendations which calculated drug price increases of about 
62% (patented drugs) and 55% (unpatented drugs) and a $94 million 
increase in the PBS bill, in contrast to an increase of only 1% per year 
since 1972 under the existing scheme.80 
5.6 The Early 1980s 
In 1980 temazepam, a new benzodiazepine classified as a 
sedative/hypnotic, was added to the PBS.81 In the same year the import 
of a barbiturate sedative - Mandrax (methaqualone) - was banned. Mr. 
Justice Williams of the Australian Royal Commission into Drugs stated 
that Mandrax was the most abused prescribed drug in Australia and that 
"it had little therapeutic value", "was mainly abused by the people 
taking it medically", was habit-forming and often mixed with alcohol or 
other d r u g s . 8 2 Although similar criticisms had been made of the 
benzodiazepines, no such recommendation was made concerning their 
withdrawal. 
Less than two years later, Jean Lennane, the well-known director 
of a leading Sydney drug and alcohol treatment unit, publicised a 
significant rise in clients addicted to sedatives (from 3% in the 
previous year to 10% in April 1982). The drug most likely to be misused 
was Serapax (oxazepam), which had produced severe withdrawal effects in 
a number of her clients.83 By December 1982, Lennane was reporting an 
incidence of 25% of clients addicted to benzodiazepines.84 
Meanwhile, the Australian Consumers' Association (ACA) was 
following the lead of similar consumer organisations overseas in 
publicising unethical actions by the Australian drug industry. In 
September 1982, the Australian-owned drug company, Nicholas Pty Ltd was 
accused of dumping its compound analgesic, Vinac (containing caffeine, 
aspirin and salicylamide) on Third World countries such as Malaysia and 
African countries, including Ethiopia. Vinac was not available in 
Australia because of strict government controls on compound analgesics 
here, but was manufactured and promoted in Malaysia where legal 
restrictions were not as severe.85 
Around the same time, the APMA was given some state encouragement 
when the Liberal Health Minister, Jim Carlton, announced his support for 
the Ralph Inquiry's recommendations which were in agreement with his 
free market philosophy. He asked the APMA to submit a proposal for a 
new pricing system after having rejected their previous submission made 
soon after the release of the Ralph Report.86 However, any further 
development of these plans was interrupted by the election of the Hawke 
government. 
Lobbying of the new Hawke government became intense. In March 
1984 the APMA released a report it had commissioned which was strongly 
critical of the PBS pricing system. Once again the drug industry was 
blaming PBS pricing for its low profits and cited, as examples, the 
CIBA-Geigy (Australia) Ltd closure of its plant at Smithfield in Sydney 
and the cancellation of Boehringer Ingelheim's research project into 
heart disease at St Vincents Hospital, Sydney, worth $350,000. This 
latter move had been a retaliatory reaction by Boehringer against a 
state decision to remove one of its drugs from the PBS because it had 
refused to lower the price to that of a competitor.87 By April 1985, 
Lilly Industries had closed one of its factories and announced that it 
would withdraw completely from local manufacture by July 1985, a loss of 
ninety-six jobs in total. The loss of eighty jobs from the closure of 
CIBA-Geigy's Smithfield plant in 1984, and of 180 jobs by Merck Sharpe 
and Dohme in 1983 added up to a total loss of just under 5% of the total 
of eight thousand jobs generated by the industry. The drug industry 
also blamed the devaluation of the Australian dollar for an increase in 
the cost of materials and, thus, for a fall in profits.88 
However, the Hawke government's desire to encourage Australian 
technology and industrial development, and specifically to support an 
Australian drug industry were in obvious conflict with its desire to 
curb health costs. In the continuing struggle between the state and the 
drug industry. Health Minister Neal Blewett introduced amendments to the 
National Health Act which would allow a drug to be included within the 
PBS even when agreement had not been reached on price. A maximum state-
determined price would be set and the consumer pay the difference. This 
was approved in May 1985 together with an increase to the PBS general 
contribution rate from $4 to $5.89 Although presenting this legislation 
as being of benefit to the consumer who would otherwise be deprived of a 
necessary drug, the state had nevertheless passed on to the consumer a 
charge which it had considered unreasonable. 
Also in 1985, the ACA launched a public campaign critical of drug 
advertising and calling for greater state intervention.90. At that 
time, only State controls applied and these were limited to prohibiting 
misleading advertisements.91 The only federal controls were through a 
voluntary Code of Conduct for marketing and advertising prescription 
drugs set by the APMA. Despite a number of misleading advertisements 
having been identified by independent researchers, the APMA had never 
acted against a company for breaching its Code. In response to the ACA 
campaign, the National Therapeutic Goods Committee began to prepare 
guidelines, in consultation with consumer and other interested groups 
such as the Medical Lobby for Appropriate Marketing (MLAM)92 (an 
international organisation based in Adelaide).93 in 1986, the APMA 
revised its code of conduct to allow input from the scientific-medical 
community on an 'independent' advisory committee, with representation by 
pharmacologists and doctors.94 This recognised the doctor's role as 
consumer of the industry's promotional messages and reinforced the 
conjunction of interests between the medical profession and the 
industry. It also confirmed the industry's difficult relations with the 
health consumer movement, representing the consumer of the industry's 
product but not represented on the APMA committee. 
More recently, the ACA's criticism of Searle for unethical 
promotion of Lomotil (see Chapter 4) which drew a great deal of 
publicity,^^ brought a quick reaction from the APMA, which asked Searle 
to withdraw its advertisement as it was in breach of their voluntary 
code of conduct.96 The APMA later announced the formation of another 
committee to monitor prescription drug advertising on a regular basis as 
wel 1 3s retdining its former committee to dedl with specific 
complaints.97 Their prompt action was no doubt influenced by the 
current two-year trial period granted to the industry to establish a 
self-regulation process considered effective by the state.^^ 
5.7 The lAC Inquiry 
The final Report from this inquiry was handed to the government in 
April 1986. The drug industry continued to claim it was suffering from 
problems of low profitability with costing estimates that were 
essentially unchanged from those submitted to the Ralph Inquiry (see 
Table 5.6). Referring to the soaring drug bill (which had undergone a 
forty-fold increase in the thirty-five years since the introduction of 
the PBS - see Table 5.7), the lAC (Industries Assistance Commission) 
Inquiry repeated the Ralph Report's decision to focus on the PBS as the 
major concern for the drug industry, : 
(a)lthough industry assistance considerations have played a 
small role in the introduction of these (government) 
regulations, the existing regulatory framework has a 
pervasive influence on the structure and operations of the 
pharmaceutical industry. Thus this report differs from many 
Commission reports in that its primary focus is not upon 
tariffs nor direct financial assistance to the industry. 
Rather, the focus is on the regulatory framework and its 
impact on the industry and the community g e n e r a l l y . ^ ^ 
The I AC Report's main recommendations were that the government 
should subsidise only the cost of the cheapest drug within any group of 
therapeutically substitutable drugs, and that a concession scheme be 
introduced to cover excess costs (essentially an insurance scheme by 
which the consumer would pay an appropriate sum for the privilege of 
paying for prescription drugs at a reduced price, which would become 
free after more than fifty scripts had been dispensed in one year). The 
scheme would permit generic substitution by the chemist dispensing the 
Table 5.6: Costs (as percentage of sales) reported by drug companies in 
Australia in the PBS Pharmaceutical Sector (1983) 
PBS Total Human Use 
Pharmaceuticals 
Variable Manufacturing Costs 
Material from overseas affiliates 
Other 







Total Cost of Goods Sold 62.8 55.9 
Administration Costs 5.9 5.8 
Distribution Costs 2.9 3.2 































Financial Costs (excluding 
interest) 0.3 (0.1) 
Total Non Manufacturing Costs 32.2 32.8 
Total Costs 95.0 88.7 
Source: Australian Pharmaceutical Manufacturers' Association: 
Submission to Industries Assistance Commission Inquiry into 
the Pharmaceutical ProductTTndustry, (1985), p.3Tr 
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Table 5.7: Expenditures under the PBS (1968-69 to 1984-85) (Smill.) 
cr 




























1968-69 20.13 64.03 84.15 - - - 36.61 100.63 712 
1969-70 21.94 73.23 95.17 - - - 41.07 114.30 808 
1970-71 24.38 88.18 112.56 - - - 45.18 133.36 943 
1971-72 35.47 90.06 125.53 - - - 52.01 142.07 1,005 
1972-73 48.64 87.43 136.07 - - - 58.14 145.57 1,029 
1973-74 59.02 108.07 167.08 - - - 66.80 174.87 1,237 
1974-75 66.83 131.34 198.17 - - - 80.59 211.93 1,499 
1975-76 95.25 149.03 244.28 - - - 107.32 256.35 1,813 
1976-77 111.68 111.08 222.75 - - - 115.20 226.28 1,600 
1977-78 115.03 118.30 233.33 - - - 127.91 246.22 1,741 
1978-79 129.54 110.43 239.97 - - - 151.13 261.55 1,850 
1979-80 123.42 101.19 224.60 - - - 166.36 267.55 1,892 
1980-81 129.92 107.90 237.83 - - - 191.04 298.95 2,114 
1981-82 157.96 139.55 297.51 - - - 239.89 379.44 2,683 
1982-83 170.62 131.77 302.39 5.88 11.10 16.98 272.71 415.58 2,939 
1983-84 166.04 114.64 280.68 19.98 39.28 59.25 317.82 471.74 3,336 
1984-85 201.14 142.44 343.58 20.21 43.27 63.48 356.21 541.92 3,833 
^ Excludes payments for the provision of PBS pharmaceuticals to hospitals, bush nursing centres, the Royal 
Flying Doctor Service. 
Source: Industries Assistance Commission, Report. Pharmaceutical Products, p.30 
drug, as in the US. By this time, the majority of PBS drugs were no 
longer protected by patent (see Table 5.8). The Report also suggested 
cutting back on drug evaluation procedures by allowing drugs approved 
for marketing in other approved countries to be marketed in Australia 
immediately, with evaluation studies to follow.100 
In order to combat what they viewed as excessive drug use by 
pensioners (and benzodiazepines are a significant component of these 
drugs), the lAC recommended that pensioners pay for all drugs at the 
concessional rate of $2 each up to a maximum of fifty scripts, and that 
a pension increase (of $50 per year) be paid in compensation. 
Essentially, it would cost pensioners $50 before they could qualify for 
free prescriptions. An alternative was to offer pensioners the 'choice' 
of foregoing the pension rise and obtaining free medication if they 
would accept the cheapest drug within a therapeutically substitutable 
category.''01 
In the mid-1980s it was estimated that the federal government 
would save nearly $150 million per year if it followed the lAC 
recommendation to remove subsidies on most prescription d r u g s . ' ' 0 2 
Instead, the 1986 budget raised the Medicare levy by 0.25 percent 
(saving $175 million that year and approximately $325 million in a full 
year), and the state continued to subsidise prescription drugs but at a 
reduced level. The maximum cost to the consumer was doubled to $10 per 
prescription drug (this was estimated to represent a saving to the 
government of $67 million).103 Thus, the general users' PBS 
contribution rate had increased over thirty-five years from zero to $10 
per prescription (see Table 5.9). The lAC proposal for a concession 
scheme was rejected. However, the 1986 budget retained the concept of a 
limit beyond which prescription drugs would be available free (the 
Table 5.8: Patent Status of the Australian Pharmaceutical Market (1983) 
% of Total Sales 
Patented Products 18 
Out-of-Patent Products 
No other manufacturer sells 
the same presentation 29 
Another manufacturer(s) sells 
the same presentation ^ 82 
Total 100 
(Note: Information from APMA survey of pharmaceutical drug industry (41 
companies) in Australia in October 1984. 
Source: Australian Pharmaceutical Manufacturers' Association, 
Submission ^ Industries Assistance Commission Inquiry into the 
Pharmaceutical Products Industry, January 1985. 
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Table 5 . 9 : PBS Contribution Rate for General Users (1950-1985) 
Date Contribution Rate 
$ 
September 1950 Free 
March 1960 0.50 
November 1971 1.00 
September 1975 1.50 
March 1976 2.00 
July 1978 2 .50 
September 1979 2.75 
December 1981 3.20 
January 1983 4 .00 
July 1985 5.00 
November 1986 10.00 
Source :Australia. Industries Assistance Commission, Report. 
Pharmaceutical Products 4 April 1986, p.32; Michael Laurence, 
"Patients to get cut-price W u g s " 7 1 1 1 » ^ November, 1986, p.1 
145b 
number of scripts being set at twenty-five in any one year),104 possibly 
in an attempt to appease consumer anger with the 100% price increase. 
The 1986 budget also followed the usual recommendations made from 
time to time by the PBAC to remove from the pensioner free list some 
commonly used drugs available without prescription. These included 
analgesics (including some forms of aspirin), antihistamines, cough 
mixtures and some vitamins. This was estimated to save the government 
approximately $30 mi 11 ion.105 ¡p response to pensioner reaction against 
this decision, the head of the PBAC referred to the Committee's charter 
which set out that the PBS scheme was set up to provide "life saving and 
disease preventing" drugs and they could not recommend a drug for the 
treatment of "minor or trivial" conditions.106 in the case of aspirin, 
this is clearly untenable: although analgesics are probably used for 
many minor or trivial conditions (and probably misused), they are 
nevertheless indispensable for relief of severe pain. It is notable 
that, in the case of benzodiazepines, which, like aspirin, can hardly be 
considered life saving drugs, the PBAC did not also recommend their 
removal from the free list for pensioners (nor the more economical step 
of providing only one generic benzodiazepine). 
The state and the drug industry have been continually locked in 
battle over drug pricing policy. Using similar tactics to those against 
doctors' proposals to raise their fees beyond that which the state was 
prepared to support through Medicare, the state has refused to subsidise 
what it perceives as unreasonable drug price increases. For example, in 
mid-1986 when Parke Davis attempted to increase, by 25%, the cost of 
Dilantin (an anti-convulsive drug for which there was no other 
substitute drug), Blewett publicly criticised the company for its 
action. The drug companies complained, however, that they were being 
forced to price their products too low in Australia. 
In support of the proposed Dilantin price increase, the APMA 
released information on the cost of the top fifteen brand name drugs in 
Australia (Table 5.10). In a pre-budget newspaper article just before 
/ 
the government was to announce its response on the lAC Inquiry 
recommendations, the APMA complained about the cheap drug prices in 
Australia: according to industry information, our drugs were 38% 
cheaper than in Britain and 67% cheaper than in the United States.107 
However, these figures were not comprehensively surveyed nor easily 
comparable. 
The lAC Inquiry exposed the extreme difficulty in making price 
comparisons because of the considerable price variability between drugs 
within Australia and between Australia and overseas. For example, for 
nine of the ten most commonly prescribed drugs on the PBS in Australia, 
prices in Australia were 37% lower than in New Zealand. However, three 
of the ten most prescribed drugs in Australia were sold to New South 
Wales hospitals at 94% of the PBS price. This could perhaps be 
explained by the hospital tendering system for bulk items permitting 
some price discounting, although these same drugs were sold by a major 
drug supplier to countries in the South Pacific region at 24% of the 
Australian PBS price. Furthermore, of fourteen commonly used drugs it 
was found that 35% were cheaper in the South Pacific region than in NSW 
hospitals.108 
In their pre-budget lobbying, the APMA also blamed the lack of 
research in Australia by drug companies on the low Australian drug 
prices, claiming that "low prices have led to cancelled investments of 
$15 million, deferred investment of $40 million, the loss of 720 jobs, 
about $4 million that was not spent on research and $7.6 million not 
Table 5.10: Cost of Top Fifteen Brand Name Drugs Sold in Australia 
Under the Prescription Benefit Scheme compared with other 
Countries as at July 1986 
Price to Wholesaler 
Trade Name Company 
Aust NZ UK USA 
1. Amoxil Beecham Research 
Laboratories 2.68 
2. Modiuretic Merck Sharp & 
Dohme (Aust) 1.85 1.81 4.76 9.17 
3. Naprosyn Syntex Aust 3.69 - 10.80 27.10 
4. Septrim Wellcome Aust 
Ltd 2.48 - 3.65 7.37 
5. Ventolin Glaxo Aust 2.52 - 5.11 -
6. Serapax Wyeth Pharma-
ceuticals 1.50 32.14 
7. Lasix Hoechst Aust 2.13 - 4.53 -
8. Betaloc Astra Pharma-
ceuticals 7.34 19.44 - -
9. Clinoril Charles E. Frosst not 
(Aust) 3.72 7.24 10.10 sold 
10. Triphasil Wyeth Pharma-
ceuticals 2.55 32.62 
11. Mogadon Roche Products - 1.22 - -
12. Tenormin * ICI Aust 5.48 8.84 9.79 14.96 
13. Aldomet Merck Sharp & 
Dohme (Aust) 5.91 8.29 10.71 21.86 
14. Zyloprim Wellcome Aust 3.30 - 20.53 -
15. Indocid Merck Sharp & 
Dohme (Aust) 2.42 2.14 4.48 16.91 
* pre-March 1986 prices 
Source: Michael Laurence, "How Australians dose up at bargain prices". 
The Sydney Morning Herald", July 5, 1986, p.12 
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spent on promotion" and that, consequently, "most research done here is 
limited to improving existing d r u g s " J 
Complaints by the drug industry of being 'squeezed' by the state 
are not supported by the industry's continuing practice of importing 
most of its supplies in the unfinished state for formulation and 
packaging here (see Table 5.11). As a result, high transfer pricing 
could continue to support the industry's assertions of poor profits in 
Australia as a lever against the state pricing policies. 
5.8 The New South Wales Woaen and Prescribed Drugs Caapaign 
Most recently, the Hawke government has turned to the consumer in 
an effort to improve controls on the use, or over-use, of drugs (both 
prescription and non-prescription). A major campaign across Australia 
was initiated on the use of alcohol and other drugs - the National 
Campaign Against Drugs and Alcohol (NCADA) - launched in April 1985 as a 
combined Federal-State p r o j e c t . A total of $100 million was 
committed over a three-year period. An additional $20 million of 
Federal funds was committed for the Drug Offensive media campaign ($5 
million), research projects ($2 million), data collection ($1 million) 
and drug and alcohol services ($12 m i l l i o n ) B o t h legal and illegal 
drug use was covered. A small component of that campaign was directed 
towards reducing the use of prescribed tranquillizers. 
Political figures such as the Prime Minister, Bob Hawke, and the 
Premier of NSW, Barrie Unsworth, turned their own, or family, problems 
with drugs into favourable publicity for the parts they were playing in 
the NCADA. Political gains were sought overseas by Blewett at a world 
conference of Health Ministers when he spoke of the NCADA and described 
it as an aid for the state in reducing both the demand and supply of 
d r u g s . 1 1 2 As well as gaining international recognition, the Hawke 
Table 5.11: Composition of Human Use Pharmaceutical Sales in Australia 
(1983) 
Category 




Products imported in the fully finished 
and packaged form 
Products imported fully finished in bulk 
then packaged in Australia 
Active ingredients (or intermediates) 
imported which are then formulated as 
drugs and packaged in Australia 
Drugs, formulated from active ingredients, 








Source: Industries Assistance Commission, Report. Pharmaceutical 
Products, p.13. 
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government has also stood to gain much nationally, especially by 
promoting an image of social responsibility to the voting public through 
the Drug Offensive media campaign. The government took the risk of 
alienating voters who were also drug consumers unwilling to be 
•educated' on responsible drug use (especially regarding alcohol and 
tobacco use which were included in the NCADA) but this was offset by 
focussing on illegal drug use (a small minority of drug users) and on 
improving the image of law enforcement agencies (appealing to the 
public's need to feel safe) as well as highlighting young people's drug 
use. 
Two of the first projects launched in New South Wales were 
specifically concerned with the use of minor tranquillizers. One was 
the St Vincent's Hospital Hypnosedative Project which produced a 
'patient education program' of a video and literature for the general 
public. Although also promoted as being for health professionals, the 
main target of the project was clearly the drug user.^^^ 
The second project was aimed at women's use of minor 
tranquillizers. (Other educational campaigns on minor tranquillizer use 
by women have since been carried out in South Australia and Victoria, 
and planning is under way for one in Western Australia in 1989.)''''̂  The 
New South Wales Women and Prescribed Drugs campaign was coordinated by 
the Women's Coordination Unit of the Premier's Department and funded by 
a grant of $103,800 from the NSW Drug and Alcohol Authority.115 jhe 
campaign was launched in May 1986 to inform women of risks associated 
with benzodiazepine use and to help them obtain counselling and 
information (in English and ten other community languages), initially 
through a state-wide phone-in and with further opportunities for face-
to- face counselling involving specially trained counsellors, again 
catering for the eleven major languages. 
The campaign adopted a 'community education' approach, using TV, 
radio and printed media including women's magazines and medical and 
health journals, as well as posters and a specially prepared pamphlet in 
eleven languages mailed out to women's refuges, hospitals, health 
centres, doctors and other health professionals. Again, the primary 
target was the user. Although general practitioners received a copy of 
the poster for their waiting rooms (enclosed with the May issue of the 
Medical Practice journal) and multiple copies of the specially prepared 
leaflet for their patients (by mail), the campaign did not directly 
challenge the doctors' - nor the drug companies - role in over-
prescribing; on the contrary, women were urged to seek their doctors' 
advice. 
Secondly, long-term effects of this campaign were limited severely 
because of its 'one o f f preliminary nature. TV and radio coverage as 
well as contact with doctors and other health professionals were for 
only a short period of time. However, treatment services were better 
equipped to help people suffering from minor tranquillizer addiction 
through special training of counselling staff. Nevertheless, education 
and prevention strategies were certainly not comprehensively addressed. 
The campaign did not receive extra funding for national coverage nor 
even for additional, follow-up coverage in NSW. It essentially became a 
tokenistic effort to placate those concerned about women's health and 
tranquiliser use. It did not address the pharmaceutical industry's role 
and its profits from benzodiazepine sales in Australia, nor did it 
challenge the powerful medical lobby in NSW. 
Whilst a number of women and minor tranquillizer support groups 
and services have now been set up (for example, the Italian speaking 
self-help group sponsored by a Sydney Italian community group, and the 
Louisa Lawson House Minor Tranquillizer Clinic)J''7 the state campaign 
may be seen more as a response to political pressure from the women's 
health movement.118 Well before the state initiative, the Leichhardt 
Women's Health Centre had initiated a public awareness campaign when, in 
1983, it conducted a phone-in on tranquillizer use. The response to the 
phone-in triggered the setting up of a minor tranquillizer clinic at the 
Health Centre.119 Many women's health workers were active in assisting 
the New South Wales Women and Prescribed Drugs campaign, such as 
educating other health workers in the associated workshops.120 
5.9 Erosion of Poner of Medical Profession 
In Australia there has been an erosion of doctors' powers over 
drug regulation within the state. In 1987 four senior officers (all of 
whom were doctors) resigned from the drug evaluation section within the 
Health Department following a Public Service Board review of its 
functions. The position of one of them, as head of the section, was 
reclassified as an administrative position rather than a medical one.121 
This loss of medical dominance within the administrative functions of 
the state is also reflected in the recent decision to allow the 
Commonwealth Director General of Health to no longer be medically 
qualified.122 jhe review of the drug evaluation section was triggered 
by allegations of administrative errors concerning generics of doubtful 
bioeuivalence having been listed under the PBS, and that some drugs may 
have been mistakenly approved for PBS listing prior to marketing 
approval having been g r a n t e d . ^ 2 3 claims by one of the outgoing medical 
officers of inadequate staffing and facilities being made available by 
the Department can be added to criticisms by the drug industry that most 
delays in evaluation procedures for drugs rest with the Department 
rather than with ADEC.124 
As discussed in Chapter 3, the hospital has been a crucial site 
for testing medical professional power. The public image of the medical 
profession, which had suffered during the Medibank controversy of the 
Whitlam years, fell even further in the 1980s with the conflict between 
the procedural specialists and the state over control of services within 
public hospitals. Their falling public image was a major cause of 
dissatisfaction amongst doctors (especially general practitioners) in a 
1983 survey.''^B /\n important factor in the medical profession's loss of 
power was its fragmented political representation. Membership of the 
AMA has dropped significantly to about half of all doctors in 
Australia'i^e (more recently, significant variations were found between 
states, with New South Wales having one of the lowest rates of 
membership at 38% of all doctors compared with a maximum of 62% in 
Western A u s t r a l i a ) F o l l o w i n g a recent review of its organisation, 
the AMA decided to remove power from the different state branches and 
centralise it within the executive.'128 yhe drop in AMA membership has 
been accompanied by the formation of alternative medical lobby groups 
such as the General Practitioners' Society of Australia (GPSA)''29 and 
the Doctors' Reform Society (DRS) in the 1970s (see Section 5.3), and 
the National Council of Procedural Specialists, the Private Doctors' 
Association, the Public Hospital Staff for the Protection of Medicare, 
and Doctors for Patients),'•^O as ^ell as the resignation from the AMA of 
the Australian College of Surgeons. Other factors contributing to the 
profession's loss of power in Australia are the popular challenges to 
the biomedical model and the rise of alternative medicine in the 1970s 
and the oversupply of doctors, especially in New South Wales.''31 
5.10 Strengthening of Health ConsiMer Movement 
The health consumer movement in Australia has strengthened its 
voice during the Hawke government's term. Following lobbying by a 
coalition of consumer groups in 1985, the Consumer Health Forum (CHF) 
was established at the end of 1986. Partly funded by the Department of 
Community Services and Health (formerly the Health Department), it 
comprises sixteen community health groups representing interests of 
different consumers such as, women, ethnic communities, aboriginal 
communities, pensioners and aged people, youth, disabled people, and 
others.''32 
An important role of the CHF is to improve consumer representation 
within the state. The newly formed PBPA (see Chapter 4) includes a 
consumer representative selected by the CHF. Other state health bodies 
for which the CHF provides consumer representation include: various 
committees of the National Health & Medical Research Council (NH&MRC), 
Australian Institute of Health, HEAPS (a national database of health 
promotion programs and resources), and other committees examining dental 
health, organ transplants, and a publication on tuberculosis.^^^ It 
also provides a small grants program for research in the health field 
(70 grant applications, totalling $450,000, were received for an 
available amount of only $60,000).'•34 
The CHF has recently put out a discussion paper on "rational" drug 
policy. Whilst acknowledging the role of the drug industry, doctor, 
consumer and the state and the political, rather than technical, nature 
of drug use the authors contradict themselves in their reliance on 
rationality and objectivity, apparently mediated by greater state 
intervention, which denies the political and irrational elements 
permeating the process of drug use. For example, they point to a "need 
to identify drugs that are essential to meet therapeutic n e e d s " j p 
the light of the British experience with limited drug lists, outlined in 
Chapter 5, the political process for implementation of a technically 
rational policy cannot ensure the expected outcome. More attention is 
required to identify and modify the political processes involved in 
order to implement technically rational objectives. 
Nevertheless, the contemporary health consumer movement is 
challenging the power of the drug industry and those it supports. The 
formation and organisation of the CHF has been bitterly attacked by the 
Australian Association of National Advertisers (AANA) as "a precedent 
which must be arrested, if government policy is to reflect the balanced 
views of competing interests within a free-enterprise s y s t e m " . T h e 
strength of the attack illustrates the advertising industry's fear of 
the consumer movement as well as the strong influence of the drug 
industry within the AANA. 
As mentioned in Chapter 3, increased consumer representation 
within the state carries with it potential dangers that the consumer 
movement will become professionalized and adopt strategies which it has 
criticized in the medical profession (such as objectification of the 
client or p a t i e n t ) . ' ' ^ 7 jh-js warning by Freidson is relevant to the 
Australian health consumer movement which, under the present Labor 
government, has been strengthened nationally by state funding of the 
CHF, and which has gained greater access to advisory and decision-making 
bodies within the state. Consumer groups in Australia now have greater 
scope for activity but also run the risk of losing power through greater 
economic and political ties with the state. 
Freidson has also proposed consumer power could be increased by 
providing greater choice of medical services for consumers and a system 
of regularly monitoring consumer satisfaction which will effectively act 
in order to translate individual choice into political p o w e r J 3 8 
Although he did not outline how consumers could effect these changes, an 
excellent example comes from the women's health movement in Australia. 
In 1973 political pressure from the women's movement'^^Q ŷ as favourably 
received by the Whitlam government and led to the establishment of the 
first women's health centre in Australia at Leichhardt in 1974. Other 
centres quickly appeared in Liverpool (Sydney), Newcastle, Melbourne, 
Brisbane, Adelaide and Perth. The centres were funded through the 
Community Health Program, a new initiative to expand community health 
services which also included the setting up of women's refuges and rape 
crisis c e n t r e s . A l t h o u g h state policy intended funding over a 
limited period of ten years with services to then be integrated in 
general community health services, the increased political strength of 
women's services has ensured their continued separate existence. 
A discussion paper on national policy on women's health under 
consideration by the Hawke government this year proposed to continue 
women's health services "to operate alongside and complement mainstream 
health services". Acceptance of this draft policy will consolidate 
the political strength of women's services. However, the advisory 
committee within the state (the Australian Health Ministers' Advisory 
Council Subcommittee on Women and Health) is dominated by state 
bureaucrats: six representing Federal health services and nine from 
State health services. Only two of these are members of the medical 
profession. There are three organisations representing women health 
consumers: the CHF, the Australian Women's Health Network, and the 
ACTU.I^^ Nevertheless, the strategy taken up by the committee of 
extensive consultation with women around Australia concerning the draft 
policy represents a useful example of Freidson's suggested "method of 
monitoring consumer satisfaction", and should help overcome some of the 
difficulties of adequate representation of all women's interests, rather 
than a professional elite within the state. 
5.11 Conclusion 
For the Australian drug industry, development and marketing of 
drug technology, such as for the benzodiazepines, has been strongly 
dependent on the PBS which has been an important arena of conflict 
between the industry, the state, the medical profession and health 
consumers since the Labor government's first attempts in 1944 to 
introduce a universal drug benefit scheme. 
The state has a special relationship with the drug industry, 
exercising control both as its major client and by imposing regulatory 
controls on the industry. The soaring cost of the PBS saw government 
cost-cutting projects intensify from the early 1970s, fuelling strong 
reaction from the drug industry, whose political lobbying for greater 
government support instigated a major inquiry into the Australian drug 
industry in the late 1970s (the Ralph Inquiry). When the resultant 
report neither favoured the drug industry nor the state, a further major 
inquiry was held in the mid-1980s (the lAC Inquiry). Again, the 
government was urged to take the electorally unfavourable step of 
passing on more of the PBS costs to the consumer (especially the 
pensioner component) as well as cutting costs by reducing drug 
regulatory controls. 
Political conflict over the availability of prescribed drugs in 
Australia has exposed differences within the Australian Labor Party 
during its current and previous terms of government. For example, the 
Australian drug industry has benefited by the Hawke government's strong 
support of industry generally, by special programs to support industrial 
R & and by -¡ts reluctance to attack the industry directly on the 
high sales volume and consequent cost of tranquillizers and other drugs. 
Instead, it has acted indirectly at what Blewett has described as the 
"demand" side, through treatment and prevention of drug addiction in the 
consumer under the NCADA. This may be seen as a strong political 
strategy to promote a socially responsible image for the government. 
This approach contrasts strongly with that of the previous Labor 
government under Whitlam, which assumed an aggressively anti-drug 
industry stance. Initiatives important to minor tranquillizer sales in 
Australia included: launching a concerted public campaign against 
excessive profits in the drug industry; establishing a state-owned drug 
company; proposing significant cuts in patent life of pharmaceutical 
drugs; and initiating increased legislative powers of the Istate to 
obtain financial information from drug companies. 
Secondly, prescribed drug use has exposed inter- and intra-
departmental conflict within the state. On the one hand, the Department 
of Community Services and Health attempts to balance its fiscal 
responsibilities over minimizing the drug bill with its social 
responsibilities for providing appropriate medication for all citizens; 
on the other hand, the Department of Industry, Technology and Commerce 
strives to encourage the drug industry for its national economic, 
employment and technological benefits without granting special 
concessions which would adversely affect the rest of Australian 
manufacturing industry. 
The Australian government's continuing difficulties with managing 
the Australian PBS expose the economic, social and political forces 
which may be seen to impose contradictory functions on the state of 
supporting capital accumulation (directly, for the drug industry and, 
indirectly, for the national economy) and legitimation of its social 
welfare role (the state must show it can fulfil its function of 
supplying basic health needs). Both the Whitlam and Hawke strategies 
may be seen as political forces enabling the state to further support 
capitalism in response to the legitimation crisis of contemporary 
democracy brought on by a persistent economic crisis within capitalism. 
With an escalating drug bill and tighter restrictions on available funds 
for health care, the Hawke era has favoured the former function of the 
state whilst the Whitlam era favoured the latter. However, a dichotomy 
between capital accumulation and legitimation may be too simplistic a 
view and this is explored with respect to an analysis of the state and 
health care put forward by Navarro. 
A dominant voice within the Marxist school has been Navarro 
who, in the mid-1970s, provided an in-depth political economy analysis 
of medicine, concentrating on the role of class relations and the state 
in health care''^^. Because of the importance recently given by 
Turner''^^ to Navarro's theories on the negative and positive modes of 
state intervention in health care, these are explored using some of the 
evidence presented in Chapters 4 and 5. 
An example of Navarro's proposed ideological negative selection 
mechanism of state intervention, which "systematically and continually 
excludes those strategies that conflict with the class nature of the 
capitalist society"''^^, could be applied to benzodiazepine use. Using 
Navarro's example of an individualistic ideology being bound up in 
capitalism, it could be stated that the state favours individualistic 
solutions for health problems involving anxiety or sleep difficulties, 
thereby attempting to 'cure' the problems by a prescription, through the 
PBS scheme, in contrast to 'preventing' the problem by economic and 
legislative changes such as supporting greater childcare facilities, 
less stressful working conditions, more equitable access to education, 
etc. In addition, the Hawke government's excursion into direct 
preventative measures against the over-use of benzodiazepines may be 
seen as individualistic as it has supported an "education" program aimed 
at changing the behaviour of the individual user rather than restricting 
the role of doctors or the drug industry. 
However, Navarro's assertion of the class basis of the 
individualistic ideology within capitalism masks his gender bias. The 
ideology of individualism could also be described as a male ideology. 
Women in the paid workforce within capitalism may well appear to conform 
to a similar ideology but this conflicts with the concrete reality of 
their other social responsibilities, involving their far greater 
participation in maintaining the family unit through the care of 
children and other family members, as well as their greater 
representation in 'caring' rather than 'competitive' professions. This 
strongly suggests that women's greater role in promoting social 
cooperation and cohesiveness would weaken the case for a 'dominant' 
ideology of individualism. Giddens has also questioned the key role 
claimed for legitimation in maintaining capitalist societies, stating 
that: 
"both Left and Right have greatly exaggerated the degree to which 
there is an ideological consensus among the majority of people in 
different classes. ... It is particularly important to be 
cautious about the thesis that crises of legitimation are the main 
sources of tension which threaten the stability of Western 
capitalist societies. Such a view presumes - in company with 
Parsons and Althusser - that social order rests upon normative 
consensus"147. 
Giddens' cautions could also be applied to assumptions of consensus 
across differences such as gender and race. 
Navarro's proposed negative selection mechanisms in decision 
making can be seen in the composition of state bodies such as the PBAC 
and the ADEC which are overwhelmingly dominated by doctors. They would 
undoubtedly belong to Navarro's "capitalist" class. However, once 
again, they are also predominantly male, white and Anglo-Saxon and this 
is not adequately dealt with. According to Navarro, decision-making 
mechanisms favour the corporate and upper-middle classes who are 
dominant on the decision-making state bodies to the detriment of lower-
middle and working classes. However, his class analysis is too crude a 
measurement and fails to deal with the conflicts between different 
members of the upper-middle class. In Australia, examples are the loss 
of medical dominance within the drug evaluation section of the 
Department of Community Services and Health, but its retention in the 
ADEC as a committee of medical-scientific 'experts'. 
Positive selection mechanisms, divided by Navarro according to 
Offe's theory of the capitalist state into allocative and productive 
intervention policies, are defined in terms of laws and regulations of 
the state controlling allocation of resources already produced (such as 
laws requiring doctors to notify contagious disease and regulations 
covering ADEC's role in the evaluation of new drugs for release on the 
market or voluntary notification of adverse drug reactions) and policies 
which allow the state to be directly involved in production (for 
example, nationalized drug industries, state-funded medical education 
and the public hospital system). 
Navarro contends that there has been a post-War shift from 
allocative to productive policies. However, the Australian experience 
provides a number of exceptions to this trend. For example, the PBS 
scheme is very much an allocative function of the state and has 
continued for nearly forty years; the Whitlam attempt to introduce a 
state-controlled drug corporation dealing in non-biological 
pharmaceuticals, in order to challenge the capital accumulation in that 
industry, was a productive intervention policy which failed; whilst the 
Hawke government has been satisfied to maintain allocative intervention 
policies favouring the Australian drug industry. This is offset by the 
change from an allocative policy in the early 1970s of voluntary health 
insurance to the productive intervention policy of Medibank and Medicare 
(although, these schemes have important differences regarding the amount 
of support they have offered to overall capital accumulation). 
Navarro has concluded that capital accumulation becomes the 
primary goal for the state, so that it is therefore dependent on the 
successful development of capitalism and, thus, the capitalist class is 
dominant over the state'l^S, He defines the second characteristic of a 
capitalist state (such as in Australia) by the fact that most of the 
powerful members of the state belong to the capitalist class "either by 
origin, asociation, or the sharing of b e l i e f s " ' ' ^ ^ . Thirdly, the 
ideology of the state supports the private sector and, fourthly, the 
capitalist state is responsible for the implementation of policy and is 
separate from the elected government executive and legislature which 
decides and formulates policy. Navarro states that these four factors 
affect the health sector because state intervention reproduces: the 
class structure, ideology and alienation of capitalism. 
Most importantly, a crucial problem with Navarro's analysis (as 
for other strongly Marxist analyses) is his adherence to the primacy of 
class structure and the reproduction of power of the dominant class, 
which forces him to deny the importance of other power structures such 
as organized occupations (for example, professions) as well as, on a 
wider basis, those based on differences such as gender and race. In his 
early major work on medicine he makes tokenistic reference to gender and 
race but, despite his positivist assertion that his arguments are 
strongly based on evidence, this is clearly not so in his decision to 
impose prime importance on class hierarchies. This has been confirmed 
more recently, when he attacked the "new pluralist view" which gives 
more equal attention to class, race and gender issues of power: 
"Medicine (is) the interplay of power conflicts that operate 
within a matrix of social power categories (class, race, gender, 
and others), of which class is the organizer of how those 
conflicts, including the professional-patient conflict, take 
place. ... Racism and sexism in medicine, for example, are 
functional to the reproduction of power of not only the white male 
professions but, far more important, of the dominant c l a s s " ' ' 5 0 
Again, he provides no evidence to support his assertions on the primacy 
of class over other power conflicts. 
The erosion of power held by the medical profession within the 
state illustrates Johnson's theoretical analysis of professional power 
and the mediative role of the state. Johnson has defined mediation as 
arising when: 
the state attempts to remove from the producer or the 
consumer the authority to determine the content and subjects 
of practice. 
In the case of the PBS, the state is increasingly intervening in the 
relationship between the doctor and the patient in determining which 
drugs are available and at what cost to the patient. Initially, the 
power of the medical profession may have appeared to have been 
maintained, with the location of doctors in positions of power within 
the state administrative hierarchies. However, this bureaucratization 
of the medical profession has proved to weaken medical dominance. 
Doctors employed in administrative positions, such as those in the drug 
evaluation section of the Health Department, although in relatively 
powerful positions, have had their performance subject to review by 
those outside the medical profession and have seen their authority 
decline in recent years with the loss of the requirement of medical 
qualifications for key decision-making positions, even for the Director 
General of Health. Economic and managerial knowledge and skills have 
gained the ascendancy within the administrative bureaucracy of the 
state. 
In Australia, medical dominance has been weakened also as a result 
of the medical profession's political fragmentation from the 1970s, 
together with the contemporary challenge to the biomedical model and the 
rise of alternative medicine. Nevertheless, the professional power of 
the doctor continues in the role of medical-scientific 'expert' - drug 
evaluations for marketing and inclusion under the PBS are still seen 
largely as 'medical' issues. Medical dominance continues to exert power 
over women's use of minor tranquillizers. In New South Wales, the 
effectiveness of the Women and Prescribed Drugs campaign was adversely 
affected by the decision not to directly challenge the doctors' role in 
over-prescribing; in fact, women were urged to seek their doctors' 
advice. 
The political power of Australia health consumers has strengthened 
considerably in recent years. Through the ACA, health consumers have 
strengthened their voice nationally on such issues as unethical drug 
advertising and marketing by the pharmaceutical drug industry. State 
support of the CHF and the opening up of decision-making on health 
issues within the state have enabled consumers to participate more in 
decisions such as those on drug pricing and drug policy. Dangers 
associated with these new developments include professionalization of 
the consumer movement and erosion of its representative role. The 
women's liberation movement has been important in the contemporary 
health consumer challenge to the power of the drug industry and to 
medical dominance. In Australia, this has been reflected in a 
strengthening of public awareness of women's use of minor 
tranquillizers, and in campaigns to reduce consumption and support women 
during their withdrawal. Nevertheless, these preliminary initiatives 
have comprised 'one off campaigns run in individual Australian states: 
a national and continuing education campaign has not yet been realised. 
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6 CONauSION 
This study has reviewed society's dependence on minor 
tranquillizers in terms of a shifting power struggle over control of 
drug technology, between four major groups: the consumer, doctor, drug 
industry and the state. 
Whilst alcohol has long been used as a tranquillizer. Western 
scientific medicine has pursued the search for its own equivalent 'magic 
bullet'. Sontag has described the popularization of the military 
metaphor in medicine late last century, with the elaboration of the germ 
theory. Subsequent examples include Ehrlich's successful development of 
chemotherapy (the so-called 'magic bullet' treatment of syphilis with an 
arsenic derivative), contemporary descriptions of cancer, both the 
clinical course of the disease and society's attempts to treat and cure 
the disease,1 and the use of Eisenhower's term 'military-industrial 
complex' to refer to a 'medical-industrial c o m p l e x ' 2 , indirectly 
associating the medical profession with military organisation and 
indicating its close links with industry interests. Within these terms, 
the medicalization of the tranquillizer 'arms race' empowered doctors' 
'front line' control of the technology, through their monopoly over the 
power of prescribing, backed by the state as 'general', in its 
regulatory role, and the pharmaceutical industry as the 'arms dealers' 
and 'stockpilers'. To continue the analogy to war, the consumers of 
tranquillizers may be compared to civilians caught in the cross-fire, 
becoming the major casualties in a battle waged by the 'medical-
industrial complex' for their 'liberation'. 
This study has summarized evidence showing benzodiazepines are a 
form of medical drug technology whose application has spread widely and 
rapidly throughout the world, although information on their use has been 
collected predominantly in Western industrialized societies. The gender 
imbalance is the most pronounced aspect of benzodiazepine use, and in 
the early 1970s the emergent women's movement, together with the health 
consumer movement, in the United States placed benzodiazepines in sharp 
public focus and expanded the debate on minor tranquillizer use from a 
medically dominated perspective, to include socio-economic factors. 
This was complemented by a changing public awareness of addiction which 
served to stress the dangers of addiction associated with 
benzodiazepines. The resultant fall in Valium sales world-wide was 
heralded as a downward trend to more conservative benzodiazepine use. 
However, Australian data has been presented which indicates that upward 
pressures on benzodiazepine sales continue, primarily through marketing 
of 'me too' benzodiazepines, and that the medical profession and the 
state have made no significant progress in curbing the pharmaceutical 
industry's control over the development and application of drug 
technology. 
The medical-scientific debate on benzodiazepine efficacy and 
safety has been shown to capture the dilemma facing contemporary 
medicine's attempts to identify and treat illnesses of the mind and to 
seek technical solutions in drug therapies, using a biomedical model 
based on a mind-body split and successfully developed from the treatment 
of various illnesses identified as being of a physical nature. The 
medical profession's conversion of anxiety from what may be seen as a 
natural result of, perhaps, socio-economic difficulties, or even as a 
positive force for implementing change, to a medical illness is best 
understood as an outcome of this process. This study has traced the 
uncovering of problems of benzodiazepine addiction (just as for the 
earlier tranquillizers) which led to initial confidence and enthusiasm 
for the benzodiazepines eventually being replaced by caution and, in 
some cases, condemnation. The process has beefi shown to be marked by 
unresolved conflict, not an accumulation of disinterested knowledge of 
the risks of the benzodiazepines. That is to say, it does not lend 
itself to the conventional interpretation of the relentless progress of 
medical science. Within the context of the scientific and medical 
journals, the debate has become polarized between those who urge their 
colleagues to stop prescribing benzodiazepines altogether and those who 
argue that they should be freely available without prescription because 
they are safer than all other tranquillizers, especially alcohol. 
From extensive studies of the doctor-patient interaction in the 
consultation process, a summary has been presented of the five most 
commonly presented models to describe doctors' prescribing of 
benzodiazepines mainly to women, who also predominate amongst the aged, 
the chronically ill and the institutionalized (the other categories of 
high users of benzodiazepines). Whilst some models are mutually 
exclusive, others can complement each other so that no one model 
predominates, lending understanding to the complexity of factors 
influencing benzodiazepine use. Added to this, the mediative role of 
the doctor has been also traced to medical education (sexism built into 
the education process, and afterwards in the division of labour with 
specialization of medical practice and influences on prescribing 
practices) and the professionalization of medicine. The medical-
scientific debate over benzodiazepine efficacy and safety may be seen as 
vital to the maintenance of the medical profession's position of power. 
Whilst Johnson has emphasized the importance of indétermination of 
medical knowledge as a vital factor in sustaining the power relations of 
the medical profession, this study, instead, supports Turner's proposal 
that it is more appropriate to consider the profession's dominance over 
interpretation of medical knowledge as important to maintenance of its 
power^. The medical profession has zealously guarded its authority to 
evaluate the indications and effects of the benzodiazepines, and this 
has been crucial to the perpetuation of benzodiazepine use. 
Benzodiazepine use may be understood, also, as a consequence of various 
professional strategies such as doctors' insistence on retaining 
authority to prescribe, their monopolistic role as consumer with respect 
to drug advertising and their medical dominance over other health 
professionals. These are all crucial to a doctor's control over medical 
knowledge. That is to say, professionalization reinforces and maintains 
the cognitive authority of the medical profession. 
The Australian experience illustrates the role of the state in 
maintaining medical dominance, by defining drug regulation processes 
(such as approval for marketing of new drugs from overseas and their 
listing under the PBS) as medical issues, to be decided upon by medical-
scientific 'experts'. The open-ended nature of health and illness and 
the limitations on state health budgets have led to competition for the 
health dollar, and inevitably to conflict in decision-making within the 
state. With respect to fiscal responsibilities over a national drug 
bill, the state has been shown to apply opportunistic policies with no 
comprehensive plan for addressing major social problems, reflecting the 
contradictory nature of capitalism. State-subsidised schemes for the 
provision of benzodiazepines and other drugs have exposed fundamental 
conflicts within the state. A case study has been presented of the 
British attempt to implement a limited drug list, illustrating the 
intra-departmental conflict within the state because of the dual role of 
the DHSS in monitoring profits of the drug industry in order to curb the 
state's rising drug bill and in promoting drug R & D and general profit-
raising activities of the drug industry. In Australia, inter-
departmental conflict over this dual role of the state has been 
described with respect to the current government's activities. This 
study has examined the Hawke government's efforts to change drug 
consumers' behaviour, where (like the British government's focus on 
benzodiazepines in promoting the limited drug list) it has discovered 
the usefulness of creating an image of socially responsible government 
confronting the dangers of addiction. The present government's 
conciliatory approach to the drug industry has also been contrasted with 
the previous Labor government's confrontation with the drug industry in 
the 1970s. 
The industry's ruthless strategies, at great cost to the 
individual and to the nation, have been described in Roche's overall 
successful battle to extract the maximum economic rewards from its best-
selling product, Valium, whilst holding patent monopoly control in 
Britain and other European countries, as well as Australia. This study 
has described the importance of patents and promotion to the drug 
industry and of their vital role in Roche's financial success story with 
Valium and Librium. Whilst the drug industry continually refers to the 
high cost of R & D as justification for high prices, this study of 
benzodiazepines has clearly illustrated that the initial high outlays on 
R & D have generated almost thirty years of enormous profits for the 
drug industry - in particular, for Roche, whose benzodiazepines have 
been one of only a few concentrated pharmaceutical products manufactured 
by the company. 
World-wide, the drug Industry has been the target of health 
consumer groups, which have been an important force in checking the 
meteoric rise in benzodiazepine consumption. Consumer interest groups, 
in particular the women's health movement, have played a crucial role in 
changing public attitudes towards the benzodiazepines. Whilst this has 
severely damaged Valium sales, overall benzodiazepine use has not been 
adversely affected, reflecting the drug industry's remarkable 
resilience. Other modified versions of benzodiazepines - the 'me too' 
drugs - have filled the 'Valium gap', and there are many others waiting 
in line (for example, other types of mood-changing drugs, such as the 
major tranquillizers and anti-depressants, and possibly other classes of 
drugs, such as analgesics). 
Consumers have also exercised their power through the litigation 
process, such as the Australian case successfully brought against a 
psychiatrist, but this has targeted the doctor rather than the drug 
industry. In Australia, it has been shown that the health consumer 
movement has strengthened its links with the state and made significant 
gains in recent years in gaining access to policy-making, such as in 
determining prices of PBS drugs. Moreover, a strong women's liberation 
movement in Australia has generated considerable interest in curbing 
benzodiazepine use. 
Nevertheless, any long-term solution for reducing society's 
dependence on minor tranquillizers must address fundamental questions in 
a number of key areas. Firstly, ideological changes are necessary. For 
example, social and environmental parameters need to replace 
individualistic descriptions of illness; and the search for a 
technological solution - the 'quick fix' - could be replaced by a 
longer-term and broader 'holistic ' view of the world in which nature is 
no longer subjugated to the intellect. Secondly, pressure groups of 
citizens from such areas as the consumer health and women's movements 
need to be strengthened further. Whilst significant gains have been 
made in consumer participation within state decision-making, the health 
consumer movement must continue to strengthen its non-governmental links 
in order to avoid an overdeveloped reliance on state patronage, and the 
dangers of professionalization and bureaucratization. Furthermore, the 
health consumer movement needs to identify the limits of legislative 
controls and to question fundamental assumptions that consumers will 
necessarily be adequately protected by increased state intervention, 
such as in the call for patient package inserts and mandatory state 
controls over drug advertising. Thirdly, whilst drug efficacy and 
safety remain as high priorities, the excessive profits of the drug 
industry must be checked . For example, as public opinion turns against 
the benzodiazepines in the industrialised nations, new markets may be 
created for 'disorders in the Third World'. In Australia, which has a 
world-wide reputation for stringent drug regulation and where the state 
is the major customer and regulatory agent, state controls on drug 
prices, whilst strict, have not challenged the hidden profits of the 
drug industry. Finally, the power of the medical profession needs to be 
addressed, such as in its role as medical 'expert' in the drug 
regulation process. Doctors' prescribing habits also need to be 
changed, and this would require extensive changes in medical education 
and promotional activities by drug companies. 
In conclusion, women's special role as the major consumers of 
benzodiazepines and other mood-modifying drugs has been shown to reflect 
how medical science, medical practice, the drug industry and the state 
all contribute to the medicalization of women's social problems, which 
are exacerbated by age, poverty and chronic ill-health. The wave of 
literature on women and minor tranquillizers, which has flowed on from 
the initial work of the women's and consumer movements, has reinforced 
general awareness of many of the issues but, unfortunately, often 
focuses on the addiction problems and offers individualistic solutions 
to what is better understood as a significant and widespread social 
problem. Other analysts have given tokenistic attention to the gender 
differences whilst accentuating the economic or technological problems. 
This study has, instead, explained minor tranquillizer use in terms of a 
complex struggle over control of this particular drug technology. The 
nature of any effective long-term change in minor tranquillizer use must 
be similarly complex. 
FOOTNOTES 
1. Susan Sontag, IHnes as Metaphor, (New York, Vintage Books, 1979), 
pp,63-65 
2. For example, Bryan S. Turner, Medical Power and Social Knowledge, 
(London, SAGE Publications, 1987), pp.188-193 
3. Ibid, p.140 
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